Antibodies that bind to folr1 and methods of use

HK40137525APending Publication Date: 2026-09-11F HOFFMANN LA ROCHE & CO AG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026127050
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-12-14
Filing Date
2026-08-04
Publication Date
2026-09-11

Smart Images

  • Figure 00000186_0000
    Figure 00000186_0000
  • Figure 00000186_0001
    Figure 00000186_0001
  • Figure 00000187_0000
    Figure 00000187_0000
Patent Text Reader

Abstract

The present invention provides antibodies that bind to FolR1, in particular pH-responsive anti-FolR1 antibodies; and methods of using the same.
Need to check novelty before this filing date? Find Prior Art

Description

(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202480078598.8 (22) Application Date 2024.12.12 (30) Priority Data 23216593.6 2023.12.14 EP (85) PCT International Application Entering National Phase Date 2026.06.11 (86) PCT International Application Application Data PCT / EP2024 / 085813 2024.12.12 (87) PCT International Application Publication Data WO2025 / 125386 EN 2025.06.19 (71) Applicant: Hofmeister AG, Address: Basel, Switzerland (72) Inventors: N. Bolin, L. Deau, C.R. Gassner, X. Grippier, A. Hugh Genmat, C. Klein, G. Lassara, S.G.A. Leclerc, F. Mende, E. Menietti, E. Mosner, M. Pincha, P. Umania Fernandez (74) Patent Agency: Beijing Kunrui Law Firm, 11494, Patent Attorney: Feng Xinqin (51) Int.Cl. C07K 16 / 28 (2006.01) A61K 47 / 68 (2017.01) A61K 39 / 395 (2006.01) A61P 35 / 00 (2006.01) C12N 15 / 13 (2006.01) (54) Title of Invention Antibody that Binds to FolR1 and Method of Use Thereof (57) Abstract This invention provides an antibody that binds to FolR1, particularly a pH-responsive anti-FolR1 antibody; and a method of using the same. Claims 9 pages Description 112 pages Sequence Listing (electronic publication) Drawings 78 pages CN 122459340 A 2026.07.24 CN 1 22 45 93 40 A 1. An antibody that binds to FolR1, wherein the antibody binds to FolR1 at a first KD at neutral pH and at a second KD at acidic pH, wherein the first KD is greater than the second KD, and the first KD and the second KD are measured by surface plasmon resonance (SPR) at 25°C. 2. The antibody of claim 1, wherein the acidic pH is in the range of 6.0 to 6.6 and the neutral pH is in the range of 7.0 to 7.4, particularly wherein the acidic pH is 6.5 or 6.1 and the neutral pH is 7.0 or 7.4, more particularly wherein the acidic pH is 6.5 and the neutral pH is 7.4. 3. The antibody of claim 1 or 2.The antibody of claim 3, wherein the first KD is at least 2, at least 5, at least 8, at least 10, at least 11, at least 13, at least 16, at least 23, at least 31, at least 40, at least 60, at least 74, or at least 195 or more times the second KD. 4. The antibody of claim 3, wherein the second KD is equal to or less than 47 nM at pH 6.5, and equal to or greater than 46 nM at pH 7.4. 5. The antibody of any one of claims 1 to 4, wherein the first KD is 2 to 195 times or 5 to 195 times the second KD. 6. The antibody of any one of claims 1 to 5, wherein the antibody is a monoclonal antibody. 7. The antibody of any one of claims 1 to 6, wherein the antibody is a human antibody. 8. The antibody according to any one of claims 1 to 7, wherein the antibody comprises: a heavy chain variable domain (VH) comprising: (a) a CDR-H1 comprising the amino acid sequence X2YYX3H SEQ ID NO:88, (b) a CDR-H2 comprising the amino acid sequence X4INPX5X6GX7TX8YAQKFQG (SEQ ID NO:89), and (c) a CDR-H3 comprising the amino acid sequence GDX9X10X11LDY (SEQ ID NO:90); and a light chain variable domain (VL) comprising: (d) a CDR-L1 comprising the amino acid sequence RSSQSLLHX12NGYX13YLD (SEQ ID NO:86), (e) a CDR-L2 comprising the amino acid sequence LGSNRAS (SEQ ID NO:24), and (f) a CDR-L2 comprising MQALQGX14X15X16T. The CDR-L3 of the amino acid sequence of (SEQ ID NO:87), wherein X2 is S, T, or E; X3 is M or I; X4 is I or V; X5 is S or R; X6 is D or G; X7 is R, S, or N; X8 is S, R, N, or T; X9 is F or Y; X10 is D or E; X11 is A, G, or S; X12 is A or S; X13 is N or H; X14 is P or L; X15 is Y or A; and X16 is N or D, optionally wherein when X15 is Y, X16 is N, and when X15 is A...When X16 is D. 9. The antibody according to any one of claims 1 to 8, wherein the antibody comprises: a heavy chain variable domain (VH) comprising: (a) a CDR-H1 comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 19, 44, 49, 54 and 58; (b) a CDR-H2 comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 20, 45, 50, 55, 59, 62 and 66; and (c) a CDR-H3 comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 21, 46, 51, 60, 63, 78, 81 and 84; and a light chain variable domain (VL) comprising: (d) a CDR-L1 comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 23, 36 and 40; (e) a CDR-L2 comprising an amino acid sequence of LGSNRAS (SEQ ID NO: 24); and (f) a CDR-H3 comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 23, 36 and 40; and (f) a light chain variable domain comprising: (a) a CDR-H1 comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 24; and (c) a CDR-H2 comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 23, 36 and 40; and (d) a CDR-L2 comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 23, 36 and 40; and (e) a CDR-L2 comprising an amino acid sequence of LGSNRAS (SEQ ID NO: 24); and (f) a CDR-H2 comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 23, 36 and 40; and (c) a CDR-H3 comprising an amino acid sequence selected from the group consisting of CDR-L3 of the amino acid sequence of the group consisting of NO: 25, 37 and 41. 10. The antibody according to any one of claims 1 to 9, wherein the antibody comprises: A) a heavy chain variable domain (VH) comprising: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:19, (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:20, and (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:21; and a light chain variable domain (VL) comprising: (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:23, (e) a CDR-L2 comprising the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:25; B) a heavy chain variable domain (VH) comprising: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:44; H1, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:45, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:46; and a light chain variable domain (VL) comprising: (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:23, (e) CDR-L2 comprising the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) CDR-H3 comprising the amino acid sequence of SEQ ID NO:46.C) CDR-L3 of the amino acid sequence of SEQ ID NO:25; C) Heavy chain variable domain (VH) comprising: (a) CDR-H1 of the amino acid sequence of SEQ ID NO:19, (b) CDR-H2 of the amino acid sequence of SEQ ID NO:58, and (c) CDR-H3 of the amino acid sequence of SEQ ID NO:59; and light chain variable domain (VL) comprising: (d) CDR-L1 of the amino acid sequence of SEQ ID NO:23, (e) CDR-L2 of the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) CDR-L3 of the amino acid sequence of SEQ ID NO:25; D) Heavy chain variable domain (VH) comprising: (a) CDR-H1 of the amino acid sequence of SEQ ID NO:44, (b) CDR-H2 of the amino acid sequence of SEQ ID NO:45, (c) CDR-H3 of the amino acid sequence of SEQ ID NO:45, (d) CDR-L1 of the amino acid sequence of SEQ ID NO:44, (e) CDR-L2 of the amino acid sequence of SEQ ID NO:45, and (f) CDR-L3 of the amino acid sequence of SEQ ID NO:45. The amino acid sequence of (c) contains the CDR-H2 of SEQ ID NO: 78; and the light chain variable domain (VL) contains: (d) the amino acid sequence of SEQ ID NO: 36, (e) the amino acid sequence of LGSNRAS (SEQ ID NO: 24), and (f) the amino acid sequence of SEQ ID NO: 37; and the heavy chain variable domain (VH) contains: (a) the amino acid sequence of SEQ ID NO: 19, (b) the amino acid sequence of SEQ ID NO: 20, and (c) the amino acid sequence of SEQ ID NO: 21; and the light chain variable domain (VL) contains: (d) the amino acid sequence of SEQ ID NO: 36, (e) the amino acid sequence of SEQ ID NO: 36, (f) the amino acid sequence of SEQ ID NO: 24, (c) the amino acid sequence of SEQ ID NO: 21, (d) the amino acid sequence of SEQ ID NO: 36, (e) the amino acid sequence of SEQ ID NO: 37, (f) the amino acid sequence of SEQ ID NO: 21, (c) the amino acid sequence of SEQ ID NO: 21, (d) the amino acid sequence of SEQ ID NO: 36, (f) the amino acid sequence of SEQ ID NO: 24, (c ...4, (c) the amino acid sequence of SEQ ID NO: 21, (c) the amino acid sequence of SEQ ID NO: 24, (c) the amino acid sequence of SEQ ID NO: 24, (c) the amino acid sequence of SEQ ID NO: 24, (c CDR-L2 comprising the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:37; G) a heavy chain variable domain (VH) comprising: (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:49, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:50, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:51; and a light chain variable domain (VL) comprising: (d) an amino acid sequence of SEQ ID NO:23.(a) CDR-L1 containing the amino acid sequence of SEQ ID NO:24, (e) CDR-L2 containing the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) CDR-L3 containing the amino acid sequence of SEQ ID NO:25; (h) Heavy chain variable domain (VH) comprising: (a) CDR-H1 containing the amino acid sequence of SEQ ID NO:44, (b) CDR-H2 containing the amino acid sequence of SEQ ID NO:45, and (c) CDR-H3 containing the amino acid sequence of SEQ ID NO:46; and light chain variable domain (VL) comprising: (d) CDR-L1 containing the amino acid sequence of SEQ ID NO:36, (e) CDR-L2 containing the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) CDR-L3 containing the amino acid sequence of SEQ ID NO:37; (i) The heavy chain variable domain (VH) comprises: (a) CDR-H1 containing the amino acid sequence of SEQ ID NO:54, (b) CDR-H2 containing the amino acid sequence of SEQ ID NO:55, and (c) CDR-H3 containing the amino acid sequence of SEQ ID NO:21; and the light chain variable domain (VL) comprises: (d) CDR-L1 containing the amino acid sequence of SEQ ID NO:23, (e) CDR-L2 containing the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) CDR-L3 containing the amino acid sequence of SEQ ID NO:25; J) the heavy chain variable domain (VH) comprises: (a) CDR-H1 containing the amino acid sequence of (SEQ ID NO:19), (b) CDR-H2 containing the amino acid sequence of SEQ ID NO:62, and (c) CDR-H3 containing the amino acid sequence of SEQ ID NO:63. The amino acid sequence of the claim is CDR-H3; and the light chain variable domain (VL) comprising: (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:23, (e) CDR-L2 comprising the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:25; and (k) heavy chain variable domain (VH) comprising: (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:19, (b) CDR-H3 comprising the amino acid sequence of SEQ ID NO:25.CDR-H2 comprising the amino acid sequence of SEQ ID NO:66, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:21; and light chain variable domain (VL) comprising: (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:23, (e) CDR-L2 comprising the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:25; L) heavy chain variable domain (VH) comprising: (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:44, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:45, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:21; and light chain variable domain (VL) comprising: (d) CDR-H2 comprising the amino acid sequence of SEQ ID NO:36 (a) CDR-L1 containing the amino acid sequence of SEQ ID NO:24, (e) CDR-L2 containing the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) CDR-L3 containing the amino acid sequence of SEQ ID NO:37; M) Heavy chain variable domain (VH) comprising: (a) CDR-H1 containing the amino acid sequence of SEQ ID NO:44, (b) CDR-H2 containing the amino acid sequence of SEQ ID NO:45, and (c) CDR-H3 containing the amino acid sequence of SEQ ID NO:81; and light chain variable domain (VL) comprising: (d) CDR-L1 containing the amino acid sequence of SEQ ID NO:36, (e) CDR-L2 containing the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) CDR-L3 containing the amino acid sequence of SEQ ID NO:37; or N) The heavy chain variable domain (VH) comprises: (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:44, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:45, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:84; and the light chain variable domain (VL) comprises: (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:36, (e) CDR-L2 comprising the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:37.11. An antibody that binds to FolR1, wherein the antibody comprises A) a heavy chain variable domain (VH) comprising: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:19, (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:20, and (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:21; and a light chain variable domain (VL) comprising: (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:23, (e) a CDR-L2 comprising the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:25; B) a heavy chain variable domain (VH) comprising: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:44, (b) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:45. The following are examples of amino acid sequences: (a) CDR-H2 containing the amino acid sequence of SEQ ID NO: 23, (b) CDR-H3 containing the amino acid sequence of SEQ ID NO: 24, and (c) CDR-H3 containing the amino acid sequence of SEQ ID NO: 25; and a light chain variable domain (VL) comprising: (d) CDR-L1 containing the amino acid sequence of SEQ ID NO: 23, (e) CDR-L2 containing the amino acid sequence of SEQ ID NO: 24, and (f) CDR-L3 containing the amino acid sequence of SEQ ID NO: 25; and a heavy chain variable domain (VH) comprising: (a) CDR-H1 containing the amino acid sequence of SEQ ID NO: 19, (b) CDR-H2 containing the amino acid sequence of SEQ ID NO: 58, and (c) CDR-H3 containing the amino acid sequence of SEQ ID NO: 59; and a light chain variable domain (VL) comprising: (d) CDR-L1 containing the amino acid sequence of SEQ ID NO: 23, (e) CDR-H3 containing the amino acid sequence of SEQ ID NO: 23, (e) CDR-H2 containing the amino acid sequence of SEQ ID NO: 24, and (f) CDR-L3 containing the amino acid sequence of SEQ ID NO: 25. CDR-L2 comprising the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:25; (Claims 3 / 9, page 4, CN 122459340 AD) Heavy chain variable domain (VH) comprising: (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:44, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:45, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:78; and light chain variable domain.(VL), comprising: (d) CDR-L1 containing the amino acid sequence of SEQ ID NO:36, (e) CDR-L2 containing the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) CDR-L3 containing the amino acid sequence of SEQ ID NO:37; E) Heavy chain variable domain (VH), comprising: (a) CDR-H1 containing the amino acid sequence of SEQ ID NO:19, (b) CDR-H2 containing the amino acid sequence of SEQ ID NO:20, and (c) CDR-H3 containing the amino acid sequence of SEQ ID NO:21; and light chain variable domain (VL), comprising: (d) CDR-L1 containing the amino acid sequence of SEQ ID NO:36, (e) CDR-L2 containing the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) CDR-L3 containing the amino acid sequence of SEQ ID NO:37. G) A heavy chain variable domain (VH) comprising: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:49, (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:50, and (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:51; and a light chain variable domain (VL) comprising: (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:23, (e) a CDR-L2 comprising the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:25; H) a heavy chain variable domain (VH) comprising: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:44, (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:45, and (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:45. The CDR-H3 comprises the amino acid sequence of SEQ ID NO:46; and a light chain variable domain (VL) comprising: (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:36, (e) a CDR-L2 comprising the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:37; I) a heavy chain variable domain (VH) comprising: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:54, (b) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:46;CDR-H2 comprising the amino acid sequence of SEQ ID NO:55, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:21; and a light chain variable domain (VL) comprising: (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:23, (e) CDR-L2 comprising the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:25; J) a heavy chain variable domain (VH) comprising: (a) CDR-H1 comprising the amino acid sequence of (SEQ ID NO:19), (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:62, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:63; and a light chain variable domain (VL) comprising: (d) CDR-H2 comprising the amino acid sequence of SEQ ID NO:23; The CDR-L1 comprising the amino acid sequence of SEQ ID NO:24, (e) the CDR-L2 comprising the amino acid sequence of SEQ ID NO:25, and (f) the CDR-L3 comprising the amino acid sequence of SEQ ID NO:25; K) a heavy chain variable domain (VH) comprising: (a) the CDR-L1 comprising the amino acid sequence of SEQ ID NO:19, (b) the CDR-L2 comprising the amino acid sequence of SEQ ID NO:66, and (c) the CDR-L3 comprising the amino acid sequence of SEQ ID NO:21; and a light chain variable domain (VL) comprising: (d) the CDR-L1 comprising the amino acid sequence of SEQ ID NO:23, (e) the CDR-L2 comprising the amino acid sequence of SEQ ID NO:24, and (f) the CDR-L3 comprising the amino acid sequence of SEQ ID NO:25; L) Heavy chain variable domain (VH) comprising: (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:44, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:45, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:21; and light chain variable domain (VL) comprising: (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:36, (e) CDR-L2 comprising the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) ... (Claims 4 / 9, page 5, CN 122459340 A)M) A heavy chain variable domain (VH) comprising: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:44, (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:45, and (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:81; and a light chain variable domain (VL) comprising: (d) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:36, (e) a CDR-H2 comprising the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:37; or N) a heavy chain variable domain (VH) comprising: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:44, (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:45, and (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:45. The amino acid sequence of CDR-H2 is (c) the amino acid sequence of SEQ ID NO:84; and the light chain variable domain (VL) comprises: (d) the amino acid sequence of SEQ ID NO:36, (e) the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) the amino acid sequence of SEQ ID NO:37. 12. The antibody according to any one of claims 8 to 11, further comprising: the light chain variable domain framework FR1 sequence of SEQ ID NO:91, the light chain variable domain framework FR2 sequence of SEQ ID NO:92, the light chain variable domain framework FR3 sequence of SEQ ID NO:93, the light chain variable domain framework FR4 sequence of SEQ ID NO:94; and / or the heavy chain variable domain framework FR1 sequence of SEQ ID NO:95 or SEQ ID NO:96, the heavy chain variable domain framework FR2 sequence of SEQ ID NO:97, the heavy chain variable domain framework FR3 sequence of SEQ ID NO:98, and the heavy chain variable domain framework FR4 sequence of SEQ ID NO:99. 13. The antibody according to any one of claims 1 to 12, wherein the antibody comprises QVQLVQSG AEVKKPGASVKVSCKASGYTFX17X2YYX3HWVRQAPGQGLEWMGX4INPX5X6GX7TX8YAQKFQGRVTMTRDTSThe VH of the amino acid sequence TSTVYMELSSLRSEDTAVYYCARGDX9X10X11LDYWGQGTLVTVSS (SEQ ID NO: 107), and / or the VL of the amino acid sequence DIVMTQSPLSLPVTPGEPASISCRSSQSLLHX12NGYX13YLDWYLQKPGQSPQLLIYLG SNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQGX14X15X16TFGQGTKVEIK (SEQ ID NO: 108), wherein X2 is S, T, or E; X3 is M or I; X4 is I or V; X5 is S or R; X6 is D or G; X7 is R, S, or N; X8 is S, R, N, or T; X9 is F or Y; and X10 is D or E. X11 is A, G, or S; X12 is A or S; X13 is N or H; X14 is P or L; X15 is Y or A; X16 is N or D; and X17 is T or S, optionally X16 is N when X15 is Y, and X16 is D when X15 is A. 14. The antibody according to any one of claims 1 to 13, wherein the antibody comprises: A) VH, comprising at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO: 22; and / or VL, comprising at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO: 26; B) VH, comprising at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO: 47; and / or VL, comprising at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO: 26; C) VH, comprising at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO: 60 The amino acid sequence of the form is at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to that of the form; and / or VL, which contains at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 26.A) VH, comprising at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical amino acid sequence to the amino acid sequence of SEQ ID NO: 79; and / or VL, comprising at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical amino acid sequence to the amino acid sequence of SEQ ID NO: 38; B) VH, comprising at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical amino acid sequence to the amino acid sequence of SEQ ID NO: 38; C) VH, comprising at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical amino acid sequence to the amino acid sequence of SEQ ID NO: 22; D) VH, comprising at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical amino acid sequence to the amino acid sequence of SEQ ID NO: 38; D) VL, comprising at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical amino acid sequence to the amino acid sequence of SEQ ID NO: 38; E) VH, comprising at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical amino acid sequence to the amino acid sequence of SEQ ID NO: 38; G) VH, comprising at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical amino acid sequence to the amino acid sequence of SEQ ID NO: 38; VH, comprising at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO: 52; and / or VL, comprising at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO: 26; H) VH, comprising at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO: 47; and / or VL, comprising at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO: 38; I) VH, comprising at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO: 56. The same amino acid sequence; and / or VL, which contains at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the same amino acid sequence as SEQ ID NO: 26; J) VH, which contains at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the same amino acid sequence as SEQ ID NO: 64; and / or VL, which contains at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the same amino acid sequence as SEQ ID NO: 64;SEQ ID NO: 26 contains at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical amino acid sequences; K) VH, which contains at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical amino acid sequences to the amino acid sequence of SEQ ID NO: 67; and / or VL, which contains at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical amino acid sequences to the amino acid sequence of SEQ ID NO: 26; L) VH, which contains at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical amino acid sequences to the amino acid sequence of SEQ ID NO: 76; and / or VL, which contains at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical amino acid sequences to the amino acid sequence of SEQ ID NO: 38; M) VH, comprising at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO: 82; and / or VL, comprising at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO: 38; or N) VH, comprising at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO: 85; and / or VL, comprising at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO: 38. 15. The antibody according to any one of claims 1 to 14, wherein the antibody comprises: A) a VH containing the amino acid sequence of SEQ ID NO: 22 and / or a VL containing the amino acid sequence of SEQ ID NO: 26; B) a VH containing the amino acid sequence of SEQ ID NO: 47 and / or a VL containing the amino acid sequence of SEQ ID NO: 26; C) a VH containing the amino acid sequence of SEQ ID NO: 60 and / or a VL containing the amino acid sequence of SEQ ID NO: 26; D) a VH containing the amino acid sequence of SEQ ID NO: 79 and / or a VL containing the amino acid sequence of SEQ ID NO: 79.E) VL containing the amino acid sequence of SEQ ID NO: 38; G) VH containing the amino acid sequence of SEQ ID NO: 52 and / or VL containing the amino acid sequence of SEQ ID NO: 26; H) VH containing the amino acid sequence of SEQ ID NO: 47 and / or VL containing the amino acid sequence of SEQ ID NO: 38; I) VH containing the amino acid sequence of SEQ ID NO: 56 and / or VL containing the amino acid sequence of SEQ ID NO: 26; J) VH containing the amino acid sequence of SEQ ID NO: 64 and / or VL containing the amino acid sequence of SEQ ID NO: 26; K) VH containing the amino acid sequence of SEQ ID NO: 67. VL containing the amino acid sequence of SEQ ID NO: 26; L) VH containing the amino acid sequence of SEQ ID NO: 76 and / or VL containing the amino acid sequence of SEQ ID NO: 38; M) VH containing the amino acid sequence of SEQ ID NO: 82 and / or VL containing the amino acid sequence of SEQ ID NO: 38; or N) VH containing the amino acid sequence of SEQ ID NO: 85 and / or VL containing the amino acid sequence of SEQ ID NO: 38. 16. An antibody that binds to FolR1, wherein the antibody comprises A) a VH containing the amino acid sequence of SEQ ID NO: 22 and / or a VL containing the amino acid sequence of SEQ ID NO: 26; B) a VH containing the amino acid sequence of SEQ ID NO: 47 and / or a VL containing the amino acid sequence of SEQ ID NO: 26; C) a VH containing the amino acid sequence of SEQ ID NO: 60 and / or a VL containing the amino acid sequence of SEQ ID NO: 26; D) a VH containing the amino acid sequence of SEQ ID NO: 79 and / or a VL containing the amino acid sequence of SEQ ID NO: 38; E) a VH containing the amino acid sequence of SEQ ID NO: 22 and / or a VL containing the amino acid sequence of SEQ ID NO: 38; G) a VH containing the amino acid sequence of SEQ ID NO: 22 and / or a VL containing the amino acid sequence of SEQ ID NO: 38;VH containing the amino acid sequence of SEQ ID NO: 52 and / or VL containing the amino acid sequence of SEQ ID NO: 26; H) VH containing the amino acid sequence of SEQ ID NO: 47 and / or VL containing the amino acid sequence of SEQ ID NO: 38; I) VH containing the amino acid sequence of SEQ ID NO: 56 and / or VL containing the amino acid sequence of SEQ ID NO: 26; J) VH containing the amino acid sequence of SEQ ID NO: 64 and / or VL containing the amino acid sequence of SEQ ID NO: 26; K) VH containing the amino acid sequence of SEQ ID NO: 67 and / or VL containing the amino acid sequence of SEQ ID NO: 26; L) VH containing the amino acid sequence of SEQ ID NO: 76 and / or VL containing the amino acid sequence of SEQ ID NO: 38; M) VH containing the amino acid sequence of SEQ ID NO: 82 and / or VL containing the amino acid sequence of SEQ ID NO: 38; or N) VH containing the amino acid sequence of SEQ ID NO: 85 and / or VL containing the amino acid sequence of SEQ ID NO: 38. 17. The antibody according to any one of claims 1 to 16, wherein the antibody is an antibody fragment binding to FolR1. 18. The antibody according to any one of claims 1 to 17, wherein the antibody fragment is a Fab molecule. 19. The antibody according to any one of claims 1 to 16, wherein the antibody is a full-length IgG1 antibody. 20. The antibody according to any one of claims 1 to 19, comprising an Fc domain consisting of a first subunit and a second subunit. 21. The antibody according to any one of claims 1 to 20, wherein the antibody is multispecific. 22. The antibody according to any one of claims 1 to 21, wherein the antibody is a bispecific antibody comprising at least one CD3-binding domain and at least one FolR1-binding domain. 23. The antibody of claim 22, wherein the CD3-binding domain is a Fab molecule, wherein the variable domains VL and VH of the Fab light chain and the Fab heavy chain, or the constant domains CL and CH1, particularly the variable domains VL and VH are interchanged. 24. The antibody of claim 22 or 23, wherein the CD3-binding domain is...The FolR1-binding domain is a Fab molecule, wherein in the constant domain CL, the amino acid at position 124 is independently substituted with lysine (K), arginine (R), or histidine (H) (according to Kabat numbering), and the amino acid at position 123 is independently substituted with lysine (K), arginine (R), or histidine (H) (according to Kabat numbering); and in the constant domain CH1, the amino acid at position 147 is independently substituted with glutamic acid (E) or aspartic acid (D) (according to Kabat EU index numbering), and the amino acid at position 213 is independently substituted with glutamic acid (E) or aspartic acid (D) (according to Kabat EU index numbering). 25. The antibody according to any one of claims 18, 23, or 24, wherein the Fab molecule is a conventional Fab molecule. 26. The antibody according to any one of claims 22 to 25, wherein the CD3-binding domain and the FolR1-binding domain are fused together, optionally fused together via a peptide linker. 27. The antibody according to any one of claims 1 to 26, comprising a CD3-binding domain and a FolR1-binding domain, wherein the CD3-binding domain and the FolR1-binding domain are each Fab molecules, and (i) the FolR1-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the CD3-binding domain, or (ii) the CD3-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the FolR1-binding domain. 28. The antibody according to any one of claims 1 to 27, comprising a CD3-binding domain and a first domain binding to FolR1, optionally comprising a second domain binding to FolR1, wherein the CD3-binding domain and the FolR1-binding domain are each Fab molecules, and the antibody comprises an Fc domain composed of a first subunit and a second subunit; and wherein (i) the first domain binding to FolR1 is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the CD3-binding domain, and the CD3-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain, or (ii) the CD3-binding domain is fused at the C-terminus of the FolR1-binding domain to the FolR1-binding domain.Seeking book page 8 / 9, CN 122459340 A. The first domain of the Fc domain is fused to the N-terminus of the Fab heavy chain, and the first domain binding to FolR1 is fused to the N-terminus of the first subunit of the Fc domain at the C-terminus of the Fab heavy chain; and the second domain binding to FolR1, when present, is fused to the N-terminus of the second subunit of the Fc domain at the C-terminus of the Fab heavy chain. 29. The antibody according to claim 20 or 28, wherein the Fc domain is an IgG Fc domain, particularly an IgG1 Fc domain, and more particularly a human IgG1 Fc domain. 30. The antibody according to any one of claims 20, 28, or 29, wherein the Fc domain is a human Fc domain. 31. The antibody according to any one of claims 20 or 28 to 30, wherein the Fc domain comprises a modification that promotes association between the first and second subunits of the Fc domain. 32. The antibody of any one of claims 20 or 28 to 31, wherein the Fc domain comprises one or more amino acid substitutions that reduce binding to the Fc receptor and / or effector function. 33. The antibody of any one of claims 20 or 28 to 32, wherein the antibody comprises an Fc region derived from human IgG1 and comprises an Fc region substituted with L234A, L235A, and P329G (LALA-PG). 34. An immunoconjugate comprising: an antibody of any one of claims 1 to 33, and a cytotoxic agent. 35. An isolated nucleic acid encoding an antibody of any one of claims 1 to 34. 36. A host cell comprising the nucleic acid of claim 35. 37. A method for producing an antibody that binds to FolR1, the method comprising culturing the host cell of claim 36 under conditions suitable for the expression of the antibody. 38. The method of claim 37, further comprising recovering the antibody from the host cell. 39. An antibody produced by the method according to claim 37 or 38. 40. A pharmaceutical composition comprising: an antibody according to any one of claims 1 to 33; and a pharmaceutically acceptable carrier. 41. An antibody according to any one of claims 1 to 33 or 39, or a pharmaceutical composition according to claim 40, for use as a pharmaceutical remedy. 42. An antibody according to any one of claims 1 to 33 or 39, or a pharmaceutical composition according to claim 40.43. Use of the antibody of any one of claims 1 to 33 or 39 or the pharmaceutical composition of claim 40 in the manufacture of a medicament for treating cancer. 44. Use of the antibody of any one of claims 1 to 33 or 39 or the pharmaceutical composition of claim 40 in the manufacture of a medicament for pH-dependent T cell redirection and pH-dependent T cell-mediated killing of cancer cells. 45. A method of treating an individual with cancer, the method comprising administering to the individual an effective amount of the antibody of any one of claims 1 to 33 or 39 or the pharmaceutical composition of claim 40. 46. A method of performing pH-dependent T cell redirection and T cell-mediated killing of cancer cells in an individual, the method comprising administering to the individual an effective amount of the antibody of any one of claims 1 to 33 or 39 or the pharmaceutical composition of claim 40 to redirect T cells in a pH-dependent manner and mediate T cell killing of cancer cells. Claims 9 / 9 pages 10 CN 122459340 A Antibodies Binding to FolR1 and Methods of Using The Technical Field

[0001] The present invention relates to antibodies binding to FolR1, particularly pH-responsive antibodies binding to FolR1, pH-responsive T cell bispecific antibodies (TCBs) containing pH-responsive antibodies binding to FolR1, and methods of using them, which, for example, preferentially bind to folate receptor 1 (FolR1) at acidic pH compared to neutral pH and / or preferentially activate T cells at acidic pH compared to neutral pH. Furthermore, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells containing such polynucleotides. The present invention further relates to methods for generating said antibodies, and to methods for using said antibodies in the treatment of diseases. Background Art

[0002] FolR1 is expressed on epithelial tumor cells from various sources (e.g., ovarian cancer, lung cancer, breast cancer, kidney cancer, colorectal cancer, and endometrial cancer). Several therapeutic antibodies, such as farletuzumab, antibody-drug conjugates, or adoptive T-cell therapies targeting FolR1, have been described for tumor imaging (Kandalaft et al., J Transl Med. 2012 Aug 3;10:157. doi: 10.1186 / 1479-5876-10-157; van Dam et al., Nat Med. 2011 Sep).18th;17(10):1315-9. doi: 10.1038 / nm .2472; Clifton et al., Hum Vaccin . Feb 2011;7(2):183-90. Epub Feb 1 2011; Kelemen et al., Int J Cancer . 15 July 2006;119(2):243-50; Vaitilingam et al., J Nucl Med . 2012 Jul;53(7); Teng et al., Aug 2012;9(8):901-8 . doi: 10.1517 / 17425247.2012.694863.Epub 5 June 2012). Several attempts have been made to target folate receptor-positive tumors with constructs targeting folate receptors and CD3 (Kranz et al., Proc Natl Acad Sci USA. Sep 26, 1995; 92(20): 9057–9061; Roy et al., Adv Drug Deliv Rev. Apr 29, 2004; 56(8):1219-31; Huiting Cui et al., Biol Chem. Aug 17, 2012; 287(34): 28206–28214; Lamers et al., Int. J. Cancer. 60(4):450 (1995); Thompson et al., MAbs. Jul-Aug 2009; 1(4):348-56. Epub July 19, 2009; Mezzanzanca et al., Int. J. Cancer, 41, 609–615 (1988)).

[0003] CD3 has been extensively explored as a drug target. Monoclonal antibodies targeting CD3 have been used as immunosuppressive therapy for autoimmune diseases such as type 1 diabetes, or in the treatment of transplant rejection. In 1985, the CD3 antibody muromonab-CD3 (OKT3) became the first monoclonal antibody approved for human clinical use.

[0004] WO2016 / 079076 describes a bispecific antigen-binding molecule targeting CD3 and FolR1, thus binding to CD3 on one hand and to tumor cell antigen on the other. The simultaneous binding of this antibody to its two targets will force a temporary interaction between the target cell and the T cell, resulting in any cytotoxic T cell.Activation and subsequent lysis of target cells.

[0005] To date, the approach taken against CD3 bispecific antibodies has many drawbacks, such as lack of tumor specificity, resulting in targeted detumescent toxicity, limited T cell infiltration in the tumor microenvironment, and impact on T cell effector function levels (doi: 10.3390 / cancers13020287).

[0006] Maximizing tumor specificity is a primary goal of cancer therapy. One approach to achieving this is to utilize the acidic tumor cell surface and the acidic tumor microenvironment. (Warburg, O., Posener, K. and Neglein, E. (1924) Ü Specification 1 / 112 pages 11 CN 122459340 A ber den Stoffwechsel der Carcinomzelle .Naturwissenschaften , 12(50) , 1131- 1137). (Krähling, H. et al. The glycocalyx maintains a cell surface pH nanoenvironment crucial for integrin-mediated migration of human melanoma cells. 2009; doi.org / 10.1007 / s00424-009-0694-7).

[0007] Given the great therapeutic potential of pH-responsive antibodies (especially bispecific antibodies for activating T cells), there is a need for pH-responsive FolR1 and pH-responsive bispecific CD3 / FolR1 antibodies.

[0008] Furthermore, pH-responsive antibodies are also valuable tools for imaging purposes and acidification measurements. Rohani et al. used labeled pH-responsive peptides to label acidic regions within tumors (doi: 10.1158 / 0008-5472.CAN-18-1604). Methods such as PET, MRI, or optical methods have been attempted to accurately determine extracellular pH (pHe). A review by Zhang et al. (Zhang 2010; doi:10.2967 / jnumed.109.068981).

[0009] Reshetnyak et al. combined pH-sensitive folding and transmembrane insertion of pH (low) intercalation peptides (pHLIPs) with pH-sensitive dyes to measure local pH on the surface of tumor cells. They concluded that the pH measured at the surface of highly metastatic cells within tumors was approximately 6.1 to 6.4, while the pH in non-metastatic tumors was 6.7 to 6.9.(doi / 10.1073 / pnas.1608247113).

[0010] Several methods have been attempted to utilize the acidic tumor microenvironment for therapeutic applications.

[0011] Sulea et al. applied a dual-pH histidine scanning mutagenesis method for pH selectivity optimization (Sulea et al. doi.org / 10.1080 / 19420862.2019.1682866). The binding selectivity to acidic pH was increased by 25-fold relative to the parental anti-Her2 antibody, but the overall affinity was reduced. In fact, pH engineering of antibodies often results in a loss of affinity. Therefore, maintaining the initial affinity or obtaining a higher affinity binding agent under the desired acidic pH conditions while reducing binding at neutral pH levels is a huge engineering effort and challenge. Summary of the Invention

[0012] The present invention provides antibodies that bind to FolR1, including multispecific (e.g., bispecific) antibodies, and methods of using them. The antibody according to the invention binds to FolR1 in a pH-dependent manner. Therefore, the provided (multispecific) antibody can increase tumor specificity.

[0013] In one aspect, the invention provides an antibody that binds to FolR1, wherein the antibody binds to FolR1 at a first KD at neutral pH and at a second KD at acidic pH, wherein the first KD is greater than the second KD, and the first KD and the second KD are measured by surface plasmon resonance (SPR) at 25°C.

[0014] In one aspect, the acidic pH is in the range of 6.0 to 6.6 and the neutral pH is in the range of 7.0 to 7.4, particularly, the acidic pH is 6.5 or 6.1 and the neutral pH is 7.0 or 7.4, more particularly, the acidic pH is 6.5 and the neutral pH is 7.4.

[0015] In one aspect, the first KD is at least 2 times, at least 5 times, at least 8 times, at least 10 times, at least 11 times, at least 13 times, at least 16 times, at least 23 times, at least 31 times, at least 40 times, at least 60 times, at least 74 times, or at least 195 times or more of the second KD.

[0016] In one aspect, the first KD is at least 2 times, at least 5 times, at least 8 times, at least 10 times, at least 11 times, at least 13 times, at least 16 times, at least 23 times, at least 31 times, at least 40 times, at least 60 times, at least 74 times, or at least 195 times or more of the second KD, and the second KD is equal to 47 nM at pH 6.5.Or lower, and the first KD is equal to 46 nM or higher at pH 7.4. Specification 2 / 112 pages 12 CN 122459340 A

[0017] In one aspect, the first KD is 2 to 195 times, particularly 5 to 195 times, of the second KD.

[0018] In one aspect, the antibody is a monoclonal antibody.

[0019] In one aspect, the antibody is a human antibody.

[0020] In one aspect, the antibody comprises: a heavy chain variable domain (VH) comprising: (a) a CDR-H1 comprising the amino acid sequence X2YYX3H SEQ ID NO:88, (b) a CDR-H2 comprising the amino acid sequence X4INPX5X6GX7TX8YAQKFQG (SEQ ID NO:89), and (c) a CDR-H3 comprising the amino acid sequence GDX9X10X11LDY (SEQ ID NO:90); and a light chain variable domain (VL) comprising: (d) a CDR-L1 comprising the amino acid sequence RSSQSLLHX12NGYX13YLD (SEQ ID NO:86), (e) a CDR-L2 comprising the amino acid sequence LGSNRAS (SEQ ID NO:24), and (f) a CDR-L2 comprising MQALQGX14X15X16T (SEQ ID NO:87). The amino acid sequence of CDR-L3, wherein X2 is S, T, or E, X3 is M or I, X4 is I or V, X5 is S or R, X6 is D or G, X7 is R, S, or N, X8 is S, R, N, or T, X9 is F or Y, X10 is D or E, X11 is A, G, or S, X12 is A or S, X13 is N or H, X14 is P or L, X15 is Y or A, and X16 is N or D, optionally wherein when X15 is Y, X16 is N, and when X15 is A, X16 is D.

[0021] In one aspect, the antibody comprises: a heavy chain variable domain (VH) comprising: (a) a CDR-H1 comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 19, 44, 49, 54 and 58; (b) a CDR-H2 comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 20, 45, 50, 55, 59, 62 and 66; and (c) a CDR-H3 comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 21, 46, 51, 60, 63, 78, 81 and 84; and a light chain variable domain.(VL), comprising: (d) CDR-L1 comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 23, 36 and 40, (e) CDR-L2 comprising an amino acid sequence consisting of LGSNRAS (SEQ ID NO: 24), and (f) CDR-L3 comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 25, 37 and 41.

[0022] In one aspect, the antibody comprises:

[0023] A) a heavy chain variable domain (VH) comprising: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:19, (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:20, and (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:21; and a light chain variable domain (VL) comprising: (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:23, (e) a CDR-L2 comprising the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:25;

[0024] B) a heavy chain variable domain (VH) comprising: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:44, (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:45, and (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:45. The amino acid sequence of (c) CDR-H2, and (c) CDR-H3 containing the amino acid sequence of SEQ ID NO:46; and light chain variable domain (VL) comprising: (d) CDR-L1 containing the amino acid sequence of SEQ ID NO:23, (e) CDR-L2 containing the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) CDR-L3 containing the amino acid sequence of SEQ ID NO:25;

[0025] C) Heavy chain variable domain (VH) comprising: (a) CDR-H1 containing the amino acid sequence of SEQ ID NO:19, (b) CDR-H2 containing the amino acid sequence of SEQ ID NO:58, and (c) CDR-H3 containing the amino acid sequence of SEQ ID NO:59; and light chain variable domain (VL) comprising: (d) CDR-H2 containing the amino acid sequence of SEQ ID NO:23, (e) CDR-L2 containing the amino acid sequence of SEQ ID NO:24, and (f) CDR-L3 containing the amino acid sequence of SEQ ID NO:25; (e) CDR-L1 containing the amino acid sequence of SEQ ID NO:24, and (f) CDR-L3 containing the amino acid sequence of SEQ ID NO:25;

[0026] D) Heavy chain variable domain (VH), comprising: (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:44, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:45, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:78; and light chain variable domain (VL), comprising: (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:36, (e) CDR-L2 comprising the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:37;

[0027] E) Heavy chain variable domain (VH), comprising: (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:19, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:45, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:78; CDR-H2 comprising the amino acid sequence of SEQ ID NO:20, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:21; and a light chain variable domain (VL) comprising: (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:36, (e) CDR-L2 comprising the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:37;

[0028] G) a heavy chain variable domain (VH) comprising: (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:49, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:50, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:51; and a light chain variable domain (VL) comprising: (d) CDR-H2 comprising the amino acid sequence of SEQ ID NO:23 The amino acid sequence comprising CDR-L1, (e) the amino acid sequence comprising LGSNRAS (SEQ ID NO:24), and (f) the amino acid sequence comprising CDR-L3;

[0029] H) a heavy chain variable domain (VH) comprising: (a) the amino acid sequence comprising SEQ ID NO:44, (b) the amino acid sequence comprising SEQ ID NO:45, and (c) the amino acid sequence comprising SEQ ID NO:46; and a light chain variable domain (VL) comprising: (d) the amino acid sequence comprising(a) CDR-L1 containing the amino acid sequence of SEQ ID NO:36, (e) CDR-L2 containing the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) CDR-L3 containing the amino acid sequence of SEQ ID NO:37;

[0030] I) Heavy chain variable domain (VH) comprising: (a) CDR-H1 containing the amino acid sequence of SEQ ID NO:54, (b) CDR-H2 containing the amino acid sequence of SEQ ID NO:55, and (c) CDR-H3 containing the amino acid sequence of SEQ ID NO:21; and light chain variable domain (VL) comprising: (d) CDR-L1 containing the amino acid sequence of SEQ ID NO:23, (e) CDR-L2 containing the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) CDR-L3 containing the amino acid sequence of SEQ ID NO:25;

[0031] J) Heavy chain variable domain (VH), comprising: (a) CDR-H1 containing the amino acid sequence of (SEQ ID NO:19), (b) CDR-H2 containing the amino acid sequence of SEQ ID NO:62, and (c) CDR-H3 containing the amino acid sequence of SEQ ID NO:63; and light chain variable domain (VL), comprising: (d) CDR-L1 containing the amino acid sequence of SEQ ID NO:23, (e) CDR-L2 containing the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) CDR-L3 containing the amino acid sequence of SEQ ID NO:25;

[0032] K) Heavy chain variable domain (VH), comprising: (a) CDR-H1 containing the amino acid sequence of SEQ ID NO:19, (b) CDR-H2 containing the amino acid sequence of SEQ ID NO:66, and (c) CDR-H3 containing the amino acid sequence of SEQ ID NO:66. The amino acid sequence of (c) CDR-H2, and (d) CDR-H3 containing the amino acid sequence of SEQ ID NO:21; and light chain variable domain (VL) comprising: (d) CDR-L1 containing the amino acid sequence of SEQ ID NO:23, (e) CDR-L2 containing the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) CDR-L3 containing the amino acid sequence of SEQ ID NO:25;

[0033] L) heavy chain variable domain (VH) comprising: (a) CDR-H1 containing the amino acid sequence of SEQ ID NO:44, (b) containing(c) CDR-H2 comprising the amino acid sequence of SEQ ID NO:45, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:21; and a light chain variable domain (VL) comprising: (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:36, (e) CDR-L2 comprising the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:37;

[0034] M) a heavy chain variable domain (VH) comprising: (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:44, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:45, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:81. (Specification 4 / 112 pages 14 CN 122459340 A) The amino acid sequence of the CDR-H3; and the light chain variable domain (VL) comprising: (d) the amino acid sequence of SEQ ID NO:36, (e) the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) the amino acid sequence of SEQ ID NO:37; or

[0035] N) the heavy chain variable domain (VH) comprising: (a) the amino acid sequence of SEQ ID NO:44, (b) the amino acid sequence of SEQ ID NO:45, and (c) the amino acid sequence of SEQ ID NO:84; and the light chain variable domain (VL) comprising: (d) the amino acid sequence of SEQ ID NO:36, (e) the amino acid sequence of LGSNRAS (SEQ ID NO:24). (a) CDR-H1 containing the amino acid sequence of SEQ ID NO:19, (b) CDR-H2 containing the amino acid sequence of SEQ ID NO:20, and (c) CDR-H3 containing the amino acid sequence of SEQ ID NO:21; and a light chain variable domain (VL) containing: (d) CDR-H2 containing the amino acid sequence of SEQ ID NO:23.

[0036] In one aspect, the present invention provides an antibody that binds to FolR1, wherein the antibody comprises:

[0037] A) a heavy chain variable domain (VH) comprising: (a) CDR-H1 containing the amino acid sequence of SEQ ID NO:19, (b) CDR-H2 containing the amino acid sequence of SEQ ID NO:20, and (c) CDR-H3 containing the amino acid sequence of SEQ ID NO:21; and a light chain variable domain (VL) comprising: (d) CDR-H2 containing the amino acid sequence of SEQ ID NO:23.(a) CDR-L1 containing the amino acid sequence of SEQ ID NO:24, (e) CDR-L2 containing the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) CDR-L3 containing the amino acid sequence of SEQ ID NO:25;

[0038] B) Heavy chain variable domain (VH) comprising: (a) CDR-H1 containing the amino acid sequence of SEQ ID NO:44, (b) CDR-H2 containing the amino acid sequence of SEQ ID NO:45, and (c) CDR-H3 containing the amino acid sequence of SEQ ID NO:46; and light chain variable domain (VL) comprising: (d) CDR-L1 containing the amino acid sequence of SEQ ID NO:23, (e) CDR-L2 containing the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) CDR-L3 containing the amino acid sequence of SEQ ID NO:25;

[0039] C) The heavy chain variable domain (VH) comprises: (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:19, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:58, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:59; and the light chain variable domain (VL) comprises: (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:23, (e) CDR-L2 comprising the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:25;

[0040] D) The heavy chain variable domain (VH) comprises: (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:44, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:45, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:78. The CDR-H3 comprising the amino acid sequence of SEQ ID NO:36; and a light chain variable domain (VL) comprising: (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:36, (e) a CDR-L2 comprising the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:37;

[0041] E) a heavy chain variable domain (VH) comprising: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:19, (b) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:20The amino acid sequence of (c) CDR-H2, and (c) CDR-H3 containing the amino acid sequence of SEQ ID NO:21; and light chain variable domain (VL) comprising: (d) CDR-L1 containing the amino acid sequence of SEQ ID NO:36, (e) CDR-L2 containing the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) CDR-L3 containing the amino acid sequence of SEQ ID NO:37;

[0042] G) heavy chain variable domain (VH) comprising: (a) CDR-H1 containing the amino acid sequence of SEQ ID NO:49, (b) CDR-H2 containing the amino acid sequence of SEQ ID NO:50, and (c) CDR-H3 containing the amino acid sequence of SEQ ID NO:51; and light chain variable domain (VL) comprising: (d) CDR-H2 containing the amino acid sequence of SEQ ID NO:23 The amino acid sequence of CDR-L1, (e) the amino acid sequence of CDR-L2 containing LGSNRAS (SEQ ID NO:24), and (f) the amino acid sequence of CDR-L3 containing SEQ ID NO:25; Specification 5 / 112 pages 15 CN 122459340 A

[0043] H) Heavy chain variable domain (VH) comprising: (a) CDR-H1 containing the amino acid sequence of SEQ ID NO:44, (b) CDR-H2 containing the amino acid sequence of SEQ ID NO:45, and (c) CDR-H3 containing the amino acid sequence of SEQ ID NO:46; and light chain variable domain (VL) comprising: (d) CDR-L1 containing the amino acid sequence of SEQ ID NO:36, (e) CDR-L2 containing the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) CDR-L3 containing the amino acid sequence of SEQ ID NO:25. CDR-L3 of the amino acid sequence NO:37;

[0044] I) Heavy chain variable domain (VH) comprising: (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:54, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:55, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:21; and light chain variable domain (VL) comprising: (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:23, (e) CDR-L3 comprising the amino acid sequence of LGSNRAS (SEQ ID NO:24).CDR-L2, and (f) CDR-L3 containing the amino acid sequence of SEQ ID NO:25;

[0045] J) Heavy chain variable domain (VH) comprising: (a) CDR-H1 containing the amino acid sequence of SEQ ID NO:19, (b) CDR-H2 containing the amino acid sequence of SEQ ID NO:62, and (c) CDR-H3 containing the amino acid sequence of SEQ ID NO:63; and light chain variable domain (VL) comprising: (d) CDR-L1 containing the amino acid sequence of SEQ ID NO:23, (e) CDR-L2 containing the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) CDR-L3 containing the amino acid sequence of SEQ ID NO:25;

[0046] K) Heavy chain variable domain (VH) comprising: (a) CDR-L1 containing the amino acid sequence of SEQ ID NO:19 The amino acid sequence of the CDR-H1, (b) the amino acid sequence of SEQ ID NO: 66, and (c) the amino acid sequence of SEQ ID NO: 21; and a light chain variable domain (VL) comprising: (d) the amino acid sequence of SEQ ID NO: 23, (e) the amino acid sequence of LGSNRAS (SEQ ID NO: 24), and (f) the amino acid sequence of SEQ ID NO: 25;

[0047] L) a heavy chain variable domain (VH) comprising: (a) the amino acid sequence of SEQ ID NO: 44, (b) the amino acid sequence of SEQ ID NO: 45, and (c) the amino acid sequence of SEQ ID NO: 21. The amino acid sequence of CDR-H3; and the light chain variable domain (VL) comprising: (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:36, (e) CDR-L2 comprising the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:37;

[0048] M) heavy chain variable domain (VH) comprising: (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:44, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:45, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:81.CDR-H3; and a light chain variable domain (VL) comprising: (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:36, (e) CDR-L2 comprising the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:37; or

[0049] N) a heavy chain variable domain (VH) comprising: (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:44, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:45, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:84; and a light chain variable domain (VL) comprising: (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:36, (e) comprising LGSNRAS (SEQ ID NO:24) (f) CDR-L2 containing the amino acid sequence of SEQ ID NO:37, and (f) CDR-L3 containing the amino acid sequence of SEQ ID NO:37.

[0050] In one aspect, the antibody further comprises: the light chain variable domain framework FR1 sequence of SEQ ID NO:91, the FR2 sequence of SEQ ID NO:92, the FR3 sequence of SEQ ID NO:93, the FR4 sequence of SEQ ID NO:94; and / or the heavy chain variable domain framework FR1 sequence of SEQ ID NO:95 or SEQ ID NO:96, the FR2 sequence of SEQ ID NO:97, the FR3 sequence of SEQ ID NO:98, and the FR4 sequence of SEQ ID NO:99. Instructions for Use, page 6 / 112, CN 122459340 A

[0051] In one aspect, the antibody comprises a VH containing the amino acid sequence QVQLVQSGAEVKKPGASVKVSCKASGYTFX17X2YYX3HWVR QAPGQGLEWMGX4INPX5X6GX7TX8YAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGDX9X10X11L DYWGQGTLVTVSS (SEQ ID NO: 107), and / or contains DIVMTQSPLSLPVTPGE PASISCRSSQSLLHX12NGYX13YLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGThe amino acid sequence VL of VYYCMQALQGX14X15X16TFGQGTKVEIK (SEQ ID NO: 108), wherein X2 is S, T, or E, X3 is M or I, X4 is I or V, X5 is S or R, X6 is D or G, X7 is R, S, or N, X8 is S, R, N, or T, X9 is F or Y, X10 is D or E, X11 is A, G, or S, X12 is A or S, X13 is N or H, X14 is P or L, X15 is Y or A, X16 is N or D, and X17 is T or S, optionally wherein when X15 is Y, X16 is N, and when X15 is A, X16 is D.

[0052] In one aspect, the antibody comprises:

[0053] A) VH, comprising at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO: 22; and / or VL, comprising at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO: 26;

[0054] B) VH, comprising at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO: 47; and / or VL, comprising at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO: 26;

[0055] C) VH, comprising at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO: 26; NO: 60 has an amino acid sequence that is at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 26; and / or VL, which contains an amino acid sequence that is at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 26;

[0056] D) VH, which contains an amino acid sequence that is at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 79; and / or VL, which contains an amino acid sequence that is at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 38.

[0057] E) VH, comprising at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the amino acid sequence identical to the amino acid sequence of SEQ ID NO: 22; and / or VL, comprising at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the amino acid sequence identical to the amino acid sequence of SEQ ID NO: 38;

[0058] G) VH, comprising at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the amino acid sequence identical to the amino acid sequence of SEQ ID NO: 52; and / or VL, comprising at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the amino acid sequence identical to the amino acid sequence of SEQ ID NO: 26;

[0059] H) VH, which contains at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO: 47; and / or VL, which contains at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO: 38;

[0060] I) VH, which contains at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO: 56; and / or VL, which contains at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO: 26;

[0061] J) VH, comprising at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO: 64; and / or VL, comprising at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO: 26;

[0062] K) VH, comprising at least 95%, at least96%, at least 97%, at least 98%, at least 99%, or 100% identical amino acid sequence to the amino acid sequence of SEQ ID NO: 26; and / or VL, which contains at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical amino acid sequence to the amino acid sequence of SEQ ID NO: 26;

[0063] L) VH, which contains at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical amino acid sequence to the amino acid sequence of SEQ ID NO: 76; and / or VL, which contains at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical amino acid sequence to the amino acid sequence of SEQ ID NO: 38;

[0064] M) VH, which contains at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical amino acid sequence to the amino acid sequence of SEQ ID NO: 82. The same amino acid sequence; and / or VL, which contains at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% of the same amino acid sequence as SEQ ID NO: 38; or

[0065] N) VH, which contains at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% of the same amino acid sequence as SEQ ID NO: 85; and / or VL, which contains at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% of the same amino acid sequence as SEQ ID NO: 38.

[0066] In one aspect, the antibody comprises:

[0067] A) a VH containing the amino acid sequence of SEQ ID NO: 22 and / or a VL containing the amino acid sequence of SEQ ID NO: 26;

[0068] B) a VH containing the amino acid sequence of SEQ ID NO: 47 and / or a VL containing the amino acid sequence of SEQ ID NO: 26;

[0069] C) a VH containing the amino acid sequence of SEQ ID NO: 60 and / or a VL containing the amino acid sequence of SEQ ID NO: 26;

[0070] D) a VH containing the amino acid sequence of SEQ ID NO: 79 and / or a VL containing the amino acid sequence of SEQ ID NO: 38;

[0071] E) a VH containing the amino acid sequence of SEQ ID NO: 22.

[0072] G) VH containing the amino acid sequence of SEQ ID NO: 52 and / or VL containing the amino acid sequence of SEQ ID NO: 26;

[0073] H) VH containing the amino acid sequence of SEQ ID NO: 47 and / or VL containing the amino acid sequence of SEQ ID NO: 38;

[0074] I) VH containing the amino acid sequence of SEQ ID NO: 56 and / or VL containing the amino acid sequence of SEQ ID NO: 26;

[0075] J) VH containing the amino acid sequence of SEQ ID NO: 64 and / or VL containing the amino acid sequence of SEQ ID NO: 26;

[0076] K) VH containing the amino acid sequence of SEQ ID NO: 67

[0077] L) VH containing the amino acid sequence of SEQ ID NO: 76 and / or VL containing the amino acid sequence of SEQ ID NO: 38;

[0078] M) VH containing the amino acid sequence of SEQ ID NO: 82 and / or VL containing the amino acid sequence of SEQ ID NO: 38; or

[0079] N) VH containing the amino acid sequence of SEQ ID NO: 85 and / or VL containing the amino acid sequence of SEQ ID NO: 38.

[0080] In one aspect, the present invention provides an antibody that binds to FolR1, wherein the antibody comprises:

[0081] A) a VH containing the amino acid sequence of SEQ ID NO: 22 and / or a VL containing the amino acid sequence of SEQ ID NO: 26;

[0082] B) a VH containing the amino acid sequence of SEQ ID NO: 47 and / or a VL containing the amino acid sequence of SEQ ID NO: 26;

[0083] C) a VH containing the amino acid sequence of SEQ ID NO: 60 and / or a VL containing the amino acid sequence of SEQ ID NO: 26;

[0084] D) a VH containing the amino acid sequence of SEQ ID NO: 79 and / or a VL containing the amino acid sequence of SEQ ID NO: 38;

[0085] E) a VH containing the amino acid sequence of SEQ ID NO: 22.

[0086] G) VH containing the amino acid sequence of SEQ ID NO: 52 and / or VL containing the amino acid sequence of SEQ ID NO: 26;

[0087] H) VH containing the amino acid sequence of SEQ ID NO: 47 and / or VL containing the amino acid sequence of SEQ ID NO: 38;

[0088] I) VH containing the amino acid sequence of SEQ ID NO: 56 and / or VL containing the amino acid sequence of SEQ ID NO: 26;

[0089] J) VH containing the amino acid sequence of SEQ ID NO: 64 and / or VL containing the amino acid sequence of SEQ ID NO: 26;

[0090] K) VH containing the amino acid sequence of SEQ ID NO: 67 and / or VL containing the amino acid sequence of SEQ ID NO: 26;

[0091] L) A VH containing the amino acid sequence of SEQ ID NO: 76 and / or a VL containing the amino acid sequence of SEQ ID NO: 38;

[0092] M) A VH containing the amino acid sequence of SEQ ID NO: 82 and / or a VL containing the amino acid sequence of SEQ ID NO: 38; or

[0093] N) A VH containing the amino acid sequence of SEQ ID NO: 85 and / or a VL containing the amino acid sequence of SEQ ID NO: 38.

[0094] In one aspect, the antibody is an antibody fragment binding to FolR1. Specification 9 / 112 pages 19 CN 122459340 A

[0095] In one aspect, the antibody fragment is a Fab molecule.

[0096] In one aspect, the antibody is a full-length IgG1 antibody.

[0097] In one aspect, the antibody comprises an Fc domain, which is composed of a first subunit and a second subunit.

[0098] In one aspect, the antibody comprises an Fc domain, which is composed of a first subunit and a second subunit, wherein the Fc domain is a human IgG1 Fc domain.

[0099] In one aspect, the antibody is multispecific.

[0100] In one aspect, the antibody is a bispecific antibody comprising at least one CD3-binding domain and at least one FolR1-binding domain.

[0101] In one aspect, the CD3-binding domain is a Fab molecule, wherein the variable domains VL and VH or constant domains of the Fab light chain and Fab heavy chain are...CL and CH1, particularly the variable domains VL and VH, are interchangeable.

[0102] In one aspect, the domain bound to FolR1 is a Fab molecule, wherein in the constant domain CL, the amino acid at position 124 is independently substituted with lysine (K), arginine (R), or histidine (H) (according to Kabat numbering), and the amino acid at position 123 is independently substituted with lysine (K), arginine (R), or histidine (H) (according to Kabat numbering), and in the constant domain CH1, the amino acid at position 147 is independently substituted with glutamic acid (E) or aspartic acid (D) (according to Kabat EU index numbering), and the amino acid at position 213 is independently substituted with glutamic acid (E) or aspartic acid (D) (according to Kabat EU index numbering).

[0103] In one aspect, the Fab molecule is a conventional Fab molecule.

[0104] In one aspect, the CD3-binding domain and the FolR1-binding domain are optionally fused to each other via a peptide linker.

[0105] In one aspect, the antibody comprises a CD3-binding domain and a FolR1-binding domain, wherein the CD3-binding domain and the FolR1-binding domain are each Fab molecules, and (i) the FolR1-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the CD3-binding domain, or (ii) the CD3-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the FolR1-binding domain.

[0106] In one aspect, the antibody comprises a CD3-binding domain and a first domain binding to FolR1, optionally a second domain binding to FolR1, wherein the CD3-binding domain and the FolR1-binding domain are each Fab molecules, and the antibody comprises an Fc domain composed of a first subunit and a second subunit; and wherein (i) the first domain binding to FolR1 is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the CD3-binding domain, and the CD3-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain, or (ii) the CD3-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first domain binding to FolR1, and the first domain binding to FolR1 is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain.The first subunit of the Fc domain is fused to the N-terminus at the end; and the second domain, which binds to FolR1, is fused to the N-terminus of the second subunit of the Fc domain at the C-terminus of the Fab heavy chain when present.

[0107] In one aspect, the Fc domain is an IgG Fc domain, particularly an IgG1 Fc domain, and more particularly a human IgG1 Fc domain.

[0108] In one aspect, the Fc domain is a human Fc domain.

[0109] In one aspect, the Fc domain includes modifications that promote association between the first and second subunits of the Fc domain.

[0110] In one aspect, the Fc domain includes one or more amino acid substitutions that reduce binding to the Fc receptor and / or effector function.

[0111] In one aspect, the antibody comprises an Fc region derived from human IgG1 and includes an Fc region substituted with L234A, L235A, and P329G (LALA-PG).

[0112] In one aspect, the present invention provides an immunoconjugate comprising an antibody and a cytotoxic agent.

[0113] In one aspect, the present invention provides an isolated nucleic acid encoding an antibody.

[0114] In one aspect, the present invention provides a host cell comprising nucleic acid.

[0115] In one aspect, the present invention provides a method for producing an antibody that binds to FolR1, the method comprising culturing the host cell under conditions suitable for expressing the antibody.

[0116] In one aspect, the method further comprises recovering the antibody from the host cell.

[0117] In one aspect, the present invention provides an antibody produced by the method according to the present invention.

[0118] In one aspect, the present invention provides a pharmaceutical composition comprising an antibody and a pharmaceutically acceptable carrier.

[0119] In one aspect, the antibody or pharmaceutical composition is used as a drug.

[0120] In one aspect, the antibody or pharmaceutical composition is used to treat cancer.

[0121] Use of the antibody or pharmaceutical composition according to the invention in the manufacture of a medicament for treating cancer is also provided.

[0122] Use of the antibody or pharmaceutical composition according to the invention in the manufacture of a medicament for pH-dependent T cell redirection and pH-dependent T cell-mediated killing of cancer cells is also provided.

[0123] The invention also provides a method of treating an individual suffering from cancer, the method comprising administering to the individual an effective amount of the antibody or pharmaceutical composition according to the invention.

[0124] The invention also provides a method of performing pH-dependent T cell redirection and T cell-mediated killing in an individual.A method for killing cancer cells, comprising administering an effective amount of an antibody or pharmaceutical composition according to the invention to the individual, thereby redirecting T cells in a pH-dependent manner and mediating T cell killing of cancer cells.

[0125] Figures 1A to 1E illustrate the binding of pH-engineered antibodies, as bivalent IgGs, to the cell surface of human FolR1 endogenously expressed on HeLa cells. As shown, all tested clones elicited dose-dependent binding to human FolR1, with pH-engineered clones (P1AF7023, P1AF7206, P1AF7015, P1AF7016) (Figures 1B to 1E) showing higher binding at acidic pH 6.5 than at neutral pH 7.4. Figure 1(A) represents the previously described FolR1 binder 16D5 (P1AD2897) (see WO2016079076A1, incorporated herein by reference), used as a non-pH-responsive control IgG. In this application, FolR1 binder 16D5 is also referred to as FolR1 ID FV000670. Technical averages from replicates are depicted, with error bars indicating standard deviation (SD).

[0126] Figures 2A through 2H relate to the binding of selected pH-engineered variants of P018.394 (P1AF7016) as a bivalent IgG assay to the cell surface of human FolR1 endogenously expressed on T47D cells. As shown, all tested clones elicited dose-dependent binding to human FolR1. The pH-responsive parental clone P018.394 (P1AF7016) (Fig. 2B) and its pH-engineered derivatives (P1AI2373, P1AH5969, P1AI2378, P1AI2380, P1AI2381, P1AH5980) (Fig. 2C to 2H) showed higher binding at acidic pH 6.5 than at neutral pH 7.4. All derived clones showed further reduced binding at pH 7.4 compared to the parental clone P018.394 (P1AF7016) (Fig. 2B). The previously described FolR1 binder 16D5 (P1AD2897) was used as a non-pH-responsive control IgG (Fig. 2A). Mean values ​​from technical replicates are depicted; error bars indicate SD. Instruction manual, pages 11 / 112, CN 122459340 A

[0127] Figures 3A to 3H relate to non-pH responsive (P1AD2897, 16D5) and pH responsive (Figures 3B to 3H) human IgG1 bound to FolR1 at different concentrations.Antibodies (containing a P329G mutation in the Fc region (P329G IgG)) (P1AI2378, P1AI2373, P1AH5861, P1AF7016, P1AH5980, P1AH5969, P1AH5963) activated anti-P329G chimeric antigen receptor Jurkat (a-P329G CAR-J) reporter cells, with HeLa cells expressing human FolR1 used as target cells. pH-engineered clones showed higher activation at acidic pH 6.5 compared to activation at neutral pH 7.4. Results showed that reporter cells emitted relative luminescence 6 hours after treatment with the FolR1-binding antibody in assay media set to pH 6.5 and 7.4. The mean of technical replicates is depicted; error bars indicate SD.

[0128] Figures 4A to 4D are schematic diagrams of the T cell bispecific (TCB) forms used in the experiments: all tested TCB antibody molecules were produced in the form of (A) "2+1 IgG CrossFab, reverse", (B) "2+1 IgG CrossFab, classic", (C) "1+1 head-to-tail (HtoT) CrossFab, reverse" or (D) "1+1 head-to-tail (HtoT) CrossFab, classic", wherein the VH (black, streaked) / VL (gray, streaked) exchange in the CD3 binder and the target human FolR1 binder CH1 XC- (dark gray) / Cl XC+ (light gray) are charged, where XC- = 147E, 213E; XC+ = 123R, 124KEE. The components of AD used to assemble TCB are: the heavy chain variable domain (black) and light chain variable domain (white) of the anti-human FolR1 Fab molecule, in which CH1 XC- (dark gray) and CL XC+ (light gray) are charged; the heavy chain (VH) variable domain (black, underlined) and light chain (VL) variable domain (gray, underlined) of the anti-human CD3 cross-Fab molecule have reversed CH1 XMab (black, dashed line) and CL XMab (gray, dashed line); the heavy chain in the Fc region has a club and PG LALA mutation (dark gray, black outline); and the heavy chain in the Fc region has a mortar and PG LALA mutation (light gray, black outline).

[0129] Figures 5A to 5F illustrate the selected pH-engineered variant of P018.394 as a 2+1 TCB (monovalent anti-human CD3 and pH-responsive bivalent anti-human FolR1) test, and its comparison with endogenously expressed human FolR1 on T47D cells.Cell surface binding. As shown in the figure, all tested clones showed dose-dependent binding to FolR1. pH-engineered clones (P1AI5834, P1AI2991, P1AI2992, P1AI2993, P1AI2994) (Figures 5B to 5F) showed higher binding at acidic pH 6.5 than at neutral pH 7.4. The previously described FolR1 binder 16D5 was used as a non-pH-responsive control 2+1 TCB (P1AD4200) (Figure 5A). Technical averages from replicates are depicted; error bars indicate SD.

[0130] Figures 6A to 6F involve selected pH-engineered variants of P018.394 as tested as 1+1 TCB (monovalent anti-human CD3 and pH-dependent monovalent anti-human FolR1) binding to the cell surface of human FolR1 endogenously expressed on T47D cells. As shown in the figures, all tested clones showed dose-dependent binding to FolR1. pH-engineered clones (P1AI3010, P1AI3011, P1AI3008, P1AI3012, P1AI5836) (Figures 6B to 6F) showed higher binding at acidic pH 6.5 than at neutral pH 7.4. The previously described FolR1 binder 16D5 was used as a non-pH-responsive control in 1+1 form (P1AI3009) (Figure 6A). Technical averages from replicates are depicted; error bars indicate SD.

[0131] Figures 7A to 7G involve activation of Jurkat NFAT reporter cells (determined by luminescence) after 6 hours of culture. The latter was induced when 2+1 TCBs bound to FolR1 were simultaneously bound to FolR1-expressing T47D tumor cells and CD3-expressing Jurkat NFAT reporter cells. As shown in the figures, the tested constructs exhibited signal-dependent dose-dependent increases, and the pH-responsive TCBs (P1AG7578, P1AI2993, P1AI2991, P1AI2992, P1AI5834, P1AA0917) binding to FolR1 resulted in higher activation at acidic pH 6.5 than at neutral pH 7.4. The control TCB (P1AF2092) with a non-pH-responsive CD3 and FolR1 binder showed equivalent activation at both acidic and neutral pH (Figure 7A), while the TCB (P1AA0917) with the non-binding target DP47 showed minimal / no activation (Figure 7G). Technical averages from replicates are plotted; error bars indicate SD. (Page 22 of 12 / 112, Specification)CN 122459340 A

[0132] Figures 8A to 8G relate to the activation (determined by luminescence) of Jurkat NFAT reporter cells after 6 hours of culture. The latter was induced when 1+1 TCBs binding to FolR1 were simultaneously bound to FolR1-expressing tumor cells T47D and CD3-expressing Jurkat NFAT reporter cells. As shown, the constructs tested exhibited signal-dependent dose-increase, and pH-responsive TCBs binding to FolR1 (P1AI3008, P1AI3010, P1AI3011, P1AI5836, P1AI3012, P1AA0917) (Figures 8B to 8G) resulted in higher activation at acidic pH 6.5 than at neutral pH 7.4. The control TCB (P1AI3009) with a non-pH-responsive CD3 and FolR1 binder showed equivalent activation at acidic and neutral pH (Fig. 8A), and the 2+1 TCB (P1AA0917) with a non-binding target DP47 showed minimal / no activation (Fig. 8G). Mean values ​​from technical replicates are depicted; error bars indicate SD.

[0133] Figs. 9A to 9F involve tumor cell killing induced by a pH-responsive 2+1 TCB that binds to FolR1 in T47D cells expressing FolR1 and the red fluorescent protein (RFP) reporter gene. As shown in the figure, pH-responsive TCBs P1AG7578, P1AI2991, P1AI2992, P1AI2993, and P1AI5834 (Figures 9B to 9F) that bind to FolR1 induce tumor killing at an acidic pH of 6.5, which is higher than that at a neutral pH of 7.4. The mean of technical replicates n = 3 is shown, and the error bars indicate the standard error of the mean by SEM.

[0134] Figures 10A to 10D involve tumor cell killing induced by a pH-responsive 1+1 TCB that binds to FolR1 in T47D cells expressing the FolR1 and RFP reporter genes. As shown in the figure, pH-responsive TCBs P1AI3008, P1AI5836, and P1AI3011 (Figures 10B to 10D) bound to FolR1 caused higher tumor killing at acidic pH 6.5 than at neutral pH 7.4. The mean of technical replicates n=3 is shown, and error bars indicate the standard error of the mean using SEM.

[0135] Figure 11 illustrates the use of FolR1-bound TCBs P1AG7640 in humanized mice.P018.394 1+1 TCB (0.38 mg / kg), 2+1 TCB (0.5 mg / kg) bound to P1AG7578 or a mediator, tumor growth inhibition curves of a breast patient-derived xenograft (PDX) BC004 model, n=10. Each point represents mean tumor volume + / - SD. Vertical lines represent treatment administration.

[0136] Figure 12 Tumor growth inhibition curves (n=13) of a breast patient-derived xenograft BC004 model involving 2+1 TCB (1.5 mg / kg) bound to FolR1 P1AI2991 or a mediator. Each point represents mean tumor volume + / - SD. Vertical lines represent treatment administration.

[0137] Figure 13 Normalized affinity of protein for FolR1 under protein stress. Compared to the untreated sample, all clones P1AF7016, P1AH5969, P1AH5963, and P1AI2378 retained at least 87% of their binding levels, except for P1AH5980, which retained only 65% ​​binding at 40°C and pH 6.0.

[0138] Figures 14A to 14C illustrate the binding of selected DG aspartate deamidation remission mutants (the P1AH5980 variant tested as IgG) to the cell surface of human FolR1 endogenously expressed on T47D cells. As shown, the two tested clones, P1AK2574 and P1AK2576 (Figures 14B and 14C), showed higher binding at acidic pH 6.5 than at neutral pH 7.4. The construct P1AD2897, having the previously described FolR1 binding agent 16D5, was used as a non-pH-responsive control IgG (Figure 14A). Technical averages from replicates are depicted; error bars indicate SD.

[0139] Figures 15A to 15Z Exemplary configurations of the (multispecific) antibodies of the present invention. (A, D) Schematic diagram of a “1+1 CrossMab” molecule. (B, E) Schematic diagram of a “2+1 IgG Crossfab” molecule, wherein the order of the Crossfab and Fab components alternates (“inverted”). (C, F) Schematic diagram of a “2+1 IgG Crossfab” molecule. (G, K) Schematic diagram of a “1+1 IgG Crossfab” molecule, wherein the order of the Crossfab and Fab components alternates (“inverted”). (H, L) Schematic diagram of a “1+1 IgG Crossfab” molecule. (I, M) Schematic diagram of a “2+1 IgG Crossfab” molecule having two CrossFabs. (J, N) has twoSchematic diagram of the “2+1 IgG Crossfab” molecule of CrossFab, wherein the Crossfab and Fab components alternate in sequence (“inverted”) as per the specification page 13 / 112, CN 122459340 A. (O, S) Schematic diagram of the “Fab-Crossfab” molecule. (P, T) Schematic diagram of the “Crossfab-Fab” molecule. (Q, U) Schematic diagram of the “(Fab)2-Crossfab” molecule. (R, V) Schematic diagram of the “Crossfab-(Fab)2” molecule. (W, Y) Schematic diagram of the “Fab-(Crossfab)2” molecule. (X, Z) Schematic diagram of the “(Crossfab)2-Fab” molecule. Black dots: Optional modifications in the Fc domain to promote heterodimerization. ++, --: Optional introduction of amino acids with opposite charges in the CH1 and CL domains. Crossfab molecules are described as containing the exchange of VH and VL regions, but can alternatively contain the exchange of CH1 and CL domains – in aspects where no charge modification is introduced in the CH1 and CL domains.

[0140] Figures 16A to 16G are schematic diagrams of the reverse (A) or classic (B) forms of 2+1 TCB and their respective chains (CG). (A) “2+1 IgG CrossFab, reverse” and (B) “2+1 IgG CrossFab, classic”, which are used with charge modifications in the VH (black, underlined) / VL (gray, underlined) exchange (Xmab) and CH1 XC- (dark gray) / Cl XC+ (light gray), where XC- = 147E, 213E; XC+ = 123R, 124KEE. (CG) Components used to assemble TCB: heavy chain variable domain (black) and light chain variable domain (white) of anti-human FolR1 Fab molecule, wherein CH1 XC- (dark gray) and CL XC+ (light gray) are charged modified; heavy chain (VH) variable domain (black, underlined) and light chain (VL) variable domain (gray, underlined) of anti-human CD3 cross-Fab molecule have reversed CH1 XMab (black, dashed line) and CL XMab (gray, dashed line); heavy chain in Fc region has mortise and PG LALA mutation (dark gray, black outline) and heavy chain in Fc region has mortise and PG LALA mutation (light gray, black outline). (C) Chain A. (D) Chain B. (E) Chain H. (F) Chain K, reversed. (G) Chain K, classic.

[0141] Figures 17A to 17G 1+1 TCB reversed (A) or classic form(B) Schematic diagram of its respective chain (CG)

[0142] (A) "1+1 head-to-tail (HtoT) CrossFab, reverse" or (B) "1+1 head-to-tail (HtoT) CrossFab, classic" form, which is used with charge modifications in VH (black, underlined) / VL (gray, underlined) exchange (Xmab) and CH1 XC- (dark gray) / Cl XC+ (light gray), where XC- = 147E, 213E; XC+ = 123R, 124K EE. (CG) Components used to assemble TCB: Heavy chain variable domains (black) and light chain variable domains (white) of the anti-human FolR1 Fab molecule, with charge modifications in CH1 XC- (dark gray) and CL XC+ (light gray); Heavy chain (VH) variable domains (black, underlined) and light chain (VL) variable domains (gray, underlined) of the anti-human CD3 cross-linked Fab molecule with reverse CH1 XMab (black, dashed line) and CL XMab (gray, dashed line); Heavy chains in the Fc region with mortar and PG LALA mutations (dark gray, black outline); and Heavy chains in the Fc region with mortar and PG LALA mutations (light gray, black outline). (C) Chain A. (D) Chain B. (E) Chain H. (F) Chain K, reverse. (G) Chain K, classical. Detailed Description

[0143] I. Definitions

[0144] Unless otherwise defined below, the terminology used herein is generally as used in the art.

[0145] Unless explicitly stated otherwise, the use of the terms “first” or “second” is not intended to assign a particular order or direction to the parts.

[0146] The terms “anti-CD3 antibody” and “CD3-binding antibody” refer to an antibody that is capable of binding CD3 with sufficient affinity, such that the antibody can be used as a diagnostic and / or therapeutic agent targeting CD3. In one aspect, the anti-CD3 antibody binds to unrelated non-CD3 proteins to less than 10% of the antibody’s binding to CD3, for example, by surface plasmon resonance (SPR) at 25°C. In some aspects, the CD3-binding antibody has a dissociation constant (KD) of ≤ 1 μM, ≤ 500 nM, ≤ 200 nM, or ≤ 100 nM. When the KD of an antibody is 1 μM or less (e.g., measured by SPR at 25°C), the antibody is said to "specifically bind" to CD3. In some respects, anti-CD3 antibodies bind to epitopes of CD3 conserved in CD3 from different species, as described on pages 14 / 112 of the specification, CN 122459340 A.

[0147] “Affinity” refers to the strength of the sum of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless otherwise indicated, as used herein, “binding affinity” refers to intrinsic binding affinity, which reflects a 1:1 interaction between members of a binding pair (e.g., antibody and antigen). The affinity of molecule X for its partner Y can generally be represented by the dissociation constant (KD). Affinity can be measured by conventional methods known in the art, including those described herein. Specific illustrative and exemplary methods for measuring binding affinity are described below.

[0148] An “affinity-mature” antibody is an antibody having one or more alterations in one or more complementarity-determining regions (CDRs) that result in an improved affinity of the antibody for the antigen compared to a parent antibody without such alterations.

[0149] “Reduced binding” (e.g., reduced binding to an Fc receptor) refers to a reduced affinity for the corresponding interaction, as measured, for example, by SPR. For clarity, the term also includes reducing affinity to zero (or below the detection limit of the analytical method), i.e., the interaction is completely eliminated. Conversely, "increased binding" refers to an increase in the binding affinity of the respective interactions (a lower absolute value for KD measurements).

[0150] The terms "anti-FolR1 antibody" and "antibody that binds to FolR1" refer to antibodies that are capable of binding to FolR1 with sufficient affinity, such that the antibody can be used as a diagnostic and / or therapeutic agent targeting FolR1. The terms "anti-FolR1 antibody" and "antibody that binds to FolR1" include pH-responsive antibodies. As used in this application, the term "pH-responsive antibody" refers to an antibody that preferentially binds at acidic pH compared to neutral pH. "Acidic pH" refers to a pH below 7.0, particularly in the range of 6.0 to 6.6, and more particularly, acidic pH refers to pH 6.1 and / or pH 6.5. “Neutral pH” refers to a pH range of 7.0 to 7.4, particularly pH 7.4. When an antibody binds to FolR1 at neutral pH 7.4 with a first KD and at acidic pH 6.5 with a second KD, where the first KD is greater than the second KD, as measured by SPR at 25°C, the antibody is said to “preferentially bind” to FolR1 at acidic pH compared to neutral pH. In some respects, the first KD at pH 7.4 is at least twice the second KD at pH 6.5, as measured by SPR at 25°C. In a further respect, at pH…The first KD at pH 7.4 is at least 2, at least 5, at least 8, at least 10, at least 11, at least 13, at least 16, at least 23, at least 31, at least 40, at least 60, at least 74, or at least 195 or more times greater than the second KD at pH 6.5, as measured by SPR at 25°C, particularly wherein the second KD at pH 6.5 is equal to 47 nM or less, and the first KD at pH 7.4 is equal to 46 nM or more, as measured by SPR at 25°C. In one aspect, the antibody binding to FolR1 binds to unrelated, non-FolR1 proteins to less than about 10% of the antibody binding to FolR1, as measured, for example, by surface plasmon resonance (SPR) at 25°C. When an antibody has a KD of 1 μM or less at pH 6.5, as measured by SPR at 25°C, it is said that the antibody is “specifically bound” to FolR1. In some respects, antibodies bound to FolR1 bind to epitopes of FolR1 that are conserved in FolR1 from different species.

[0151] The term “antibody” is used herein in the broadest sense and includes a variety of antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments, as long as they exhibit the desired antigen-binding activity.

[0152] An “antibody fragment” is a molecule other than a complete antibody that contains a portion of the complete antibody and binds the antigen bound by the complete antibody. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2; bispecific antibodies; linear antibodies; single-chain antibody molecules (e.g., scFv and scFab); single-domain antibodies (dAb); and multispecific antibodies formed from fragments from the antibody specification page 15 / 112, 25 CN 122459340 A. For a review of certain antibody fragments, see Holliger and Hudson, Nature Biotechnology 23:1126-1136 (2005).

[0153] The term “chimeric” antibody refers to an antibody in which a portion of the heavy chain and / or light chain is derived from a particular source or species, while the remainder of the heavy chain and / or light chain is derived from a different source or species.

[0154] The term “immunoglobulin molecule” as used herein refers to a protein having the structure of a naturally occurring antibody. For example, IgG immunoglobulins are heterotetrameric glycoproteins of about 150,000 Daltons, which consist of two molecules linked by disulfide bonds.Each heavy chain consists of one light chain and two heavy chains. From the N-terminus to the C-terminus, each heavy chain has a variable domain (VH) (also called the variable heavy chain domain or heavy chain variable region), followed by three constant domains (CH1, CH2, and CH3) (also called the heavy chain constant region). Similarly, from the N-terminus to the C-terminus, each light chain has a variable domain (VL) (also called the variable light chain domain or light chain variable region), followed by a constant light chain (CL) domain (also called the light chain constant region). Immunoglobulin heavy chains can be classified into one of five types: α (IgA), δ (IgD), ε (IgE), γ (IgG), or μ (IgM), some of which can be further subdivided into subtypes such as γ1 (IgG1), γ2 (IgG2), γ3 (IgG3), γ4 (IgG4), α1 (IgA1), and α2 (IgA2). The light chains of immunoglobulins can be classified into one of two types based on the amino acid sequence of their constant domains: called kappa (κ) and lambda (λ). Immunoglobulins are essentially composed of two Fab molecules linked by an immunoglobulin hinge region and an Fc domain.

[0155] The “class” of an antibody refers to the type of constant domain or constant region possessed by the heavy chain of the antibody. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and some of these antibodies can be further subdivided into subclasses (isotypes), such as IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. In some respects, the antibody is the IgG1 isotype. In some respects, the antibody is the IgG1 isotype with P329G, L234A, and L235A mutations that reduce the function of the Fc region effector. In other respects, the antibody is the IgG2 isotype. In some respects, antibodies are IgG4 isotypes with an S228P mutation in the hinge region to improve the stability of IgG4 antibodies. The constant domains of the heavy chain corresponding to different classes of immunoglobulins are called α, δ, ε, γ, and μ, respectively. The light chain of an antibody, based on the amino acid sequence of its constant domain, can be classified into one of two types, called Kappa (κ) and Lambda (λ).

[0156] A “Fab molecule” refers to a protein composed of the VH and CH1 domains of the heavy chain (“Fab heavy chain”) and the VL and CL domains of the light chain (“Fab light chain”).

[0157] The term “cross-Fab” (also called “Crossfab”) refers to a Fab molecule in which the variable or constant domains of the Fab heavy chain and light chain are exchanged (i.e., replaced by each other), i.e., a cross-Fab molecule comprises: a light chainPeptide chains consisting of a variable domain VL and a heavy chain constant domain 1 CH1 (VL-CH1, in the N-terminal to C-terminal direction), and peptide chains consisting of a heavy chain variable domain VH and a light chain constant domain CL (VH-CL, in the N-terminal to C-terminal direction). For clarity, in cross-Fab molecules where the variable domains of the Fab light chain and the Fab heavy chain are exchanged, the peptide chain containing the heavy chain constant domain 1 CH1 is referred to herein as the "heavy chain" of the (cross-Fab) molecule. Conversely, in cross-Fab molecules where the constant domains of the Fab light chain and the Fab heavy chain are exchanged, the peptide chain containing the heavy chain variable domain VH is referred to herein as the "heavy chain" of the (cross-Fab) molecule.

[0158] In contrast, the term "conventional" Fab molecule refers to a Fab molecule in its native form, i.e., containing a heavy chain (VH-CH1, in the N-terminal to C-terminal direction) consisting of a heavy chain variable domain and a constant domain, and a light chain (VL-CL, in the N-terminal to C-terminal direction) consisting of a light chain variable domain and a constant domain.

[0159] The term "Fc domain" or "Fc region" herein is used to define the C-terminal region of an immunoglobulin heavy chain containing at least a portion of the constant region. The term includes native sequence Fc regions and variant Fc regions. In one aspect, the specification 16 / 112 pages 26 CN 122459340 A human IgG heavy chain Fc region extends from Cys226 or from Pro230 to the carboxyl terminus of the heavy chain. However, antibodies produced by host cells can undergo post-translational cleavage of one or more (particularly one or two) amino acids from the C-terminus of the heavy chain. Therefore, antibodies produced by host cells by expressing a specific nucleic acid molecule encoding the full-length heavy chain can comprise the full-length heavy chain, or said antibodies can comprise cleaved variants of the full-length heavy chain. This could be the case where the last two C-terminal amino acids of the heavy chain are glycine (G446) and lysine (K447, according to the Kabat EU index number). Therefore, the C-terminal lysine (Lys447) or C-terminal glycine (Gly446) and lysine (Lys447) of the Fc region may or may not be present. Unless otherwise specified, the amino acid sequence of a heavy chain containing the Fc region (or a subunit of the Fc domain as defined herein) is represented herein as a heavy chain without a C-terminal glycine-lysine dipeptide. In one aspect, a heavy chain comprising the Fc region (subunit) as specified herein is included in the antibody according to the invention, the heavy chain comprising an additional C-terminal glycine-lysine dipeptide (G446 and...)K447 (according to the Kabat EU Index number). In one aspect, a heavy chain comprising an Fc region (subunit) as specified herein is included in an antibody according to the invention, said heavy chain comprising an additional C-terminal glycine residue (G446, according to the Kabat EU Index number). Unless otherwise specified herein, the amino acid residues in the Fc region or constant region are numbered according to the EU numbering system (also known as the EU Index), as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th edition, Public Health Service, National Institutes of Health, Bethesda, MD, 1991 (see also above). As used herein, “subunit” of the Fc domain refers to one of two polypeptides forming a dimer Fc domain, namely a polypeptide comprising the C-terminal constant region of an immunoglobulin heavy chain that is stably self-associating. For example, the subunit of the IgG Fc domain comprises the IgG CH2 and IgG CH3 constant domains.

[0160] The term "fusion" means that the components (e.g., Fab molecules and Fc domain subunits) are linked directly or via one or more peptide linkers by peptide bonds.

[0161] The term "multispecific" means that the antibody is capable of specifically binding to at least two different antigenic determinants. A multispecific antibody can be, for example, a bispecific antibody. Typically, a bispecific antibody contains two antigen-binding sites, each of which is specific for a different antigenic determinant. In some respects, the multispecific (e.g., bispecific) antibody is capable of binding to two antigenic determinants simultaneously, particularly two antigenic determinants expressed on two different cells.

[0162] The term "valence" as used herein indicates the presence of a specified number of antigen-binding sites in an antigen-binding molecule. Thus, the term "monovalent binding to antigen" means the presence of one (and no more than one) antigen-binding site in an antigen-binding molecule that is specific to the antigen.

[0163] An "antigen-binding site" refers to a site of an antigen-binding molecule that provides an interaction with an antigen, i.e., one or more amino acid residues. For example, the antigen-binding site of an antibody contains amino acid residues from the complementarity determining region (CDR). Natural immunoglobulin molecules typically have two antigen-binding sites, while Fab molecules typically have a single antigen-binding site.

[0164] As used herein, the terms "antigen determinant" or "antigen" refer to a polypeptide macromolecule that binds to an antigen-binding domain.Sites on the surface of the antigen that form a complex (e.g., a continuous extension of amino acids or a conformational configuration consisting of different regions of non-continuous amino acids). Useful antigenic determinants can be found, for example, on the surface of tumor cells, on the surface of virus-infected cells, on the surface of other diseased cells, on the surface of immune cells, in serum, and / or in the extracellular matrix (ECM). In a preferred aspect, the antigen is a human protein.

[0165] Unless otherwise specified, “CD3” means any naturally occurring CD3 from any vertebrate source, including mammals such as primates (e.g., humans), non-human primates (e.g., cynomolgus monkeys), and rodents (e.g., mice and rats). The term covers “full-length”, unprocessed CD3, as well as any form of CD3 produced by intracellular processing. The term also covers naturally occurring variants of CD3, such as splice variants or allelic variants. In one aspect, CD3 is human CD3, and in particular the ε subunit of human CD3 (CD3ε). The amino acid sequence of human CD3ε is shown in SEQ ID NO: 102 (no signal peptide). See also UniProt (www.uniprot.org) accession number P07766 (version 209), or NCBI (www.ncbi.nlm.nih.gov / ) RefSeq NP_000724.1. In another aspect, CD3 is cynomolgus monkey (Macaca fascicularis) CD3, particularly cynomolgus monkey CD3ɛ. The amino acid sequence of cynomolgus monkey CD3ε is shown in SEQ ID NO: 101 (no signal peptide). See also NCBI GenBank number BAB71849.1. In some aspects, the antibodies of the present invention bind to epitopes of CD3 (particularly human and cynomolgus monkey CD3) that are conserved in CD3 antigens from different species. In a preferred aspect, the antibody binds to human CD3.

[0166] As used herein, “target cell antigen” refers to an antigenic determinant present on the surface of a target cell, such as a cell in a tumor (e.g., a cancer cell or a cell in the tumor stroma) (in this case, “tumor cell antigen”). Preferably, the target cell antigen is not CD3, and / or is expressed on cells different from CD3. According to the invention, the target cell antigen is FolR1, particularly human FolR1.

[0167] The terms “constant region derived from human origin” or “human constant region” as used herein refer to the constant heavy chain region and / or constant light chain κ or λ region of human antibodies of subclasses IgG1, IgG2, IgG3, or IgG4. Such constant regions are currently...It is well known in the art and described, for example, by the following description: Kabat, E.A. et al., Sequences of Proteins of Immunological Interest, 5th edition, Public Health Service, National Institutes of Health, Bethesda, MD (1991) (see also, for example, Johnson, G. and Wu, TT, Nucleic Acids Res. 28 (2000) 214-218; Kabat, E.A. et al., Proc. Natl. Acad. Sci. USA 72 (1975) 2785-2788). Unless otherwise specified herein, the amino acid residues in the constant region are numbered according to the EU numbering system, also known as Kabat's EU index, as described in Kabat, E.A. et al., Sequences of Proteins of Immunological Interest, 5th edition, Public Health Service, National Institutes of Health, Bethesda, MD (1991), NIH Publication 91-3242.

[0168] "Effective function" refers to those biological activities attributable to the Fc region of an antibody that vary with antibody isotype. Examples of antibody effector functions include: C1q binding and complement-dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; downregulation of cell surface receptors (e.g., B cell receptors); and B cell activation.

[0169] An “effective amount” of a pharmaceutical agent (e.g., a pharmaceutical composition) means an amount that can effectively achieve the desired therapeutic or preventative outcome at the necessary dose for the necessary period of time.

[0170] The term “Fc region” used herein is used to define the C-terminal region of an immunoglobulin heavy chain that comprises at least a portion of a constant region. The term includes native sequence Fc regions and variant Fc regions. In one aspect, the human IgG heavy chain Fc region extends from Cys226 or from Pro230 to the carboxyl terminus of the heavy chain. However, antibodies produced by host cells may undergo post-translational cleavage of one or more (particularly one or two) amino acids from the C-terminus of the heavy chain. Therefore, antibodies produced by host cells by expressing a specific nucleic acid molecule encoding the full-length heavy chain may include the full-length heavy chain, or the...Antibodies may comprise cleaved variants of the full-length heavy chain. This could be the case where the last two C-terminal amino acids of the heavy chain are glycine (G446) and lysine (K447, EU numbering system). Therefore, the C-terminal lysine (Lys447) or C-terminal glycine (Gly446) and lysine (Lys447) in the Fc region may or may not be present. Unless otherwise specified, the amino acid sequence of the heavy chain containing the Fc region is represented herein as lacking a C-terminal glycine-lysine dipeptide. In one aspect, a heavy chain comprising the Fc region as specified herein is included in an antibody according to the invention, said heavy chain (details 18 / 112, page 28, CN 122459340 A) comprising additional C-terminal glycine-lysine dipeptides (G446 and K447, EU numbering system). In one aspect, a heavy chain comprising the Fc region as specified herein is included in the antibody according to the invention, said heavy chain comprising an additional C-terminal glycine residue (G446, according to the EU index number). Unless otherwise specified herein, the amino acid residues in the Fc region or constant region are numbered according to the EU numbering system, also known as the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th edition, Public Health Service, National Institutes of Health, Bethesda, MD, 1991.

[0171] “Frame” or “FR” refers to the variable domain residues other than the complementarity-determining region (CDR). The FR of a variable domain typically consists of four FR domains: FR1, FR2, FR3, and FR4. Therefore, the CDR and FR sequences typically appear in VH (or VL) as follows: FR1-CDR-H1(CDR-L1)-FR2-CDR-H2(CDR-L2)-FR3-CDR-H3(CDR-L3)-FR4.

[0172] The terms “full-length antibody,” “intact antibody,” and “all antibody” are used interchangeably herein to refer to an antibody having a structure substantially similar to that of a natural antibody or having a heavy chain containing an Fc region as defined herein.

[0173] The terms “host cell,” “host cell line,” and “host cell culture” are used interchangeably and refer to cells in which exogenous nucleic acids have been introduced, including progeny of such cells. Host cells include “transformations” and “transformed cells,” which include primary transformed cells and progeny derived from those primary transformed cells, regardless of passage number. Progeny may not be related to the parent.The nucleic acid contents of the cells are completely identical, but may contain mutations. This includes mutant progeny with the same function or biological activity, as screened or selected in the original transformed cells.

[0174] A “human antibody” is an antibody having an amino acid sequence corresponding to the amino acid sequence of an antibody derived from a non-human source, produced by human or human cells or derived from an antibody-encoded synthetic library initiated using a human antibody lineage or other lineages. This definition of a human antibody specifically excludes humanized antibodies containing non-human antigen-binding residues.

[0175] The term “binding domain” refers to a portion of an antibody that contains a region that binds to and is complementary to an antigen, in part or in whole. The antigen-binding domain may be provided, for example, by one or more antibody variable domains (also called antibody variable regions). In a preferred aspect, the antigen-binding domain (e.g., FolR1 or CD3) comprises an antibody light chain variable domain (VL) and an antibody heavy chain variable domain (VH).

[0176] A “human common framework” is a framework that represents the amino acid residues most frequently present in the selection of human immunoglobulin VL or VH framework sequences. Generally, the selection of human immunoglobulin VL or VH sequences is derived from a subgroup of variable domain sequences. Generally, the subgroups of sequences are those described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Edition, NIH Publication 91-3242, Bethesda MD (1991), Volumes 1-3. In one aspect, for VL, the subgroup is subgroup κ II (hIGKV2-28-01), as described above by Kabat et al. In another aspect, for VH, the subgroups are subgroups I and III (hIGHV1-46-01, hIGHV1-46-02, hIGHV3-23-05), as described above by Kabat et al.

[0177] A “humanized” antibody refers to a chimeric antibody that comprises amino acid residues from a non-human CDR and amino acid residues from a human FR. In some respects, a humanized antibody will substantially comprise at least one, typically both, variable domains, wherein all or substantially all CDRs correspond to the CDRs of the non-human antibody, and all or substantially all FRs correspond to the FRs of the human antibody. A humanized antibody may optionally comprise at least a portion of the antibody constant region derived from a human antibody. An antibody in a “humanized form,” such as a non-human antibody, refers to an antibody that has undergone humanization.

[0178] The terms “variable region” or “variable domain” refer to the domain of the antibody heavy or light chain involved in antibody-antigen binding. The variable domains of the heavy and light chains of a natural antibody (VH and VH, respectively)VL domains typically have similar structures, with each domain containing four conserved frame regions (FRs) and complementarity-determining regions (CDRs). See, for example, Kindt et al., specification 19 / 112 pages 29 CN 122459340 A Kuby Immunology, 6th edition, WH Freeman & Co., page 91 (2007). A single VH or VL domain may be sufficient to confer antigen-binding specificity. Furthermore, antibodies binding to a specific antigen can be isolated using either the VH or VL domain from the antibody binding that antigen to screen libraries containing complementary VL or VH domains. See, for example, Portolano et al., J. Immunol. 150:880-887 (1993); Clarkson et al., Nature 352:624-628 (1991). As used herein, the “Kabat number” associated with the variable region sequence refers to the numbering system proposed by Kabat et al., Sequences of Proteins of Immunological Interest, 5th edition, Public Health Service, National Institutes of Health, Bethesda, MD (1991).

[0179] Glutamine or glutamate residues at the N-terminus of the antibody heavy or light chain can spontaneously convert to pyroglutamic acid (see, for example, Liu et al., Journal of Pharmaceutical Sciences 97, 2426-2447 (2008); Rehder et al., Journal of Chromatography A 1102, 164-175 (2006); Chelius et al., Anal Chem 78, 2370-2376 (2006)). Therefore, the variable regions or variable domains disclosed herein that contain glutamine (Q) or glutamate (E) amino acid residues at the N-terminus of the antibody heavy or light chain may contain an N-terminal pyroglutamic acid (pyroE) residue instead of an N-terminal Q or E residue. Similarly, the antibody heavy or light chains disclosed herein that contain glutamine (Q) or glutamate (E) amino acid residues at the N-terminus may contain an N-terminal pyroglutamic acid (pyroE) residue instead of an N-terminal Q or E residue. Therefore, for each antibody heavy chain, light chain, or variable domain or region sequence disclosed herein containing an N-terminal Q or E residue, the corresponding N-terminal pyroE residue is also covered.Sequence.

[0180] As used herein, the amino acid positions of all constant regions and constant domains of the heavy and light chains are numbered according to the Kabat numbering system described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th edition, Public Health Service, National Institutes of Health, Bethesda, MD (1991), and are referred to herein as “according to Kabat numbering” or “Kabat numbering”. Specifically, the Kabat numbering system (see Kabat et al., Sequences of Proteins of Immunological Interest, 5th edition, Public Health Service, National Institutes of Health, Bethesda, MD (1991), pp. 647–660) is used for the light chain constant domain CL of the κ and λ isotypes, and the Kabat EU index numbering system (see pp. 661–723) is used for the heavy chain constant domains (CH1, hinge, CH2, and CH3), which is further clarified herein by referring to it as “according to Kabat EU index numbering” or “Kabat EU index numbering” in this context.

[0181] The term “hypervariant region” or “HVR” as used herein refers to the individual regions in the antibody variable domain that are sequence-hypervariant and determine antigen-binding specificity, such as “complementarity-determining regions” (“CDRs”).

[0182] Typically, the antibody contains six CDRs: three in VH (CDR-H1, CDR-H2, CDR-H3) and three in VL (CDR-L1, CDR-L2, CDR-L3). Exemplary CDRs in this article include:

[0183] (a) hypervariable rings appearing at amino acid residues 26-32 (L1), 50-52 (L2), 91-96 (L3), 26-32 (H1), 53-55 (H2), and 96-101 (H3) (Chothia and Lesk, J. Mol. Biol. 196:901-917 (1987));

[0184] (b) CDRs appearing at amino acid residues 24-34 (L1), 50-56 (L2), 89-97 (L3), 31-35b (H1), 50-65 (H2), and 95-102 (H3) (Kabat et al.,Sequences of Proteins of Immunological Interest, 5th Edition Public Health Service, National Institutes of Health, Bethesda, MD (1991)); and

[0185] (c) antigenic contact sites appearing at amino acid residues 27c-36 (L1), 46-55 (L2), 89-96 (L3), 30-35b (H1), 47-58 (H2), and 93-101 (H3) (MacCallum et al., J. Mol. Biol. 262: 732-745 (1996)).

[0186] Unless otherwise stated, the CDR is determined according to Kabat et al. (ibid.). Those skilled in the art will understand that the CDR name may also be determined according to Chothia (ibid.), McCallum (ibid.), or any other scientifically accepted nomenclature system.

[0187] An “immunoconjugate” is an antibody conjugated to one or more heterologous molecules (including, but not limited to, cytotoxic agents).

[0188] An “individual” or “subject” is a mammal. Mammals include, but are not limited to, domesticated animals (e.g., cattle, sheep, cats, dogs, and horses), primates (e.g., human and non-human primates, such as monkeys), rabbits, and rodents (e.g., mice and rats). In some respects, the individual or subject is a human.

[0189] An “isolated” antibody is an antibody that has been isolated from components of its natural environment. In some respects, the antibody is purified to a purity greater than 95% or 99%, as determined by, for example, electrophoresis (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatography (e.g., ion exchange or reversed-phase HPLC). For a review of methods for assessing antibody purity, see, for example, Flatman et al., J. Chromatogr. B 848:79-87 (2007).

[0190] The terms “nucleic acid molecule” or “polynucleotide” include any compound and / or substance comprising a nucleotide polymer. Each nucleotide is composed of a base, specifically a purine or pyrimidine base (i.e., cytosine (C), guanine (G), adenine (A), thymine (T), or uracil (U)), a sugar (i.e., deoxyribose or ribose), and a phosphate ester group. Typically, nucleic acid molecules are described by a base sequence, wherein the bases represent the primary structure (linear structure) of the nucleic acid molecule. The base sequence is typically represented from 5' to 3'. In this document, the term nucleic acid molecule encompasses deoxyribonucleic acid.Nucleic acid molecules include (DNA) (including, for example, complementary DNA (cDNA) and genomic DNA), ribonucleic acid (RNA) (especially messenger RNA (mRNA)), synthetic forms of DNA or RNA, and mixed polymers containing two or more of these molecules. Nucleic acid molecules can be linear or circular. Furthermore, the term nucleic acid molecule includes both sense and antisense strands, as well as single-stranded and double-stranded forms. Additionally, the nucleic acid molecules described herein may contain naturally occurring or non-naturally occurring nucleotides. Examples of non-naturally occurring nucleotides include modified nucleotide bases having derivatized sugar or phosphate backbone bonds or chemically modified residues. Nucleic acid molecules also encompass DNA and RNA molecules suitable as vectors for direct in vitro and / or in vivo (e.g., in a host or patient) expression of antibodies used in this invention. Such DNA (e.g., cDNA) or RNA (e.g., mRNA) vectors can be unmodified or modified. For example, mRNA can be chemically modified to enhance the stability of the RNA vector and / or the expression of the encoding molecule, so that the mRNA can be injected into a subject to produce antibodies in vivo (see, for example, Stadler et al., Nature Medicine 2017, published online June 12, 2017, doi:10.1038 / nm.4356 or EP 2 101 823 B1).

[0191] "Isolated" nucleic acid means a nucleic acid molecule that has been isolated from components of its natural environment. Isolated nucleic acid includes nucleic acid molecules that are contained in cells that normally contain nucleic acid molecules, but which are present outside the chromosome or at a chromosomal location different from their natural chromosomal location.

[0192] "Isolated nucleic acid encoding an antibody that binds to FolR1" means one or more nucleic acid molecules encoding the heavy and light chains (or fragments thereof) of an anti-FolR1 antibody, including such nucleic acid molecules in a single vector or a single vector, and such nucleic acid molecules are present at one or more locations in the host cell.

[0193] As used herein, the term "monoclonal antibody" refers to an antibody obtained from a substantially homogeneous group of antibodies, i.e., individual antibodies comprising this group are identical and / or bind to the same epitopes, except for possible variant antibodies (e.g., those containing naturally occurring mutations or generated during the production of the monoclonal antibody formulation, such variants typically exist in small quantities). In contrast to polyclonal antibody formulations, which typically comprise different antibodies targeting different determinants (epitaxes), each monoclonal antibody in a monoclonal antibody formulation targets a single determinant on the antigen. Therefore, the modifier "monoclonal" indicates the characteristic of the antibody.These are obtained from a substantially homogeneous population of antibodies and should not be construed as requiring the production of antibodies by any particular method. For example, monoclonal antibodies according to the invention can be prepared by a variety of techniques, including but not limited to hybridoma methods, recombinant DNA methods, phage display methods, and methods using transgenic animals containing all or part of the human immunoglobulin loci. Such methods and other exemplary methods for preparing monoclonal antibodies are described herein.

[0194] A “naked antibody” is an antibody that is not conjugated to a heterologous moiety (e.g., a cytotoxic moiety) or a radiolabel. Naked antibodies may be present in pharmaceutical compositions.

[0195] A “natural antibody” is a naturally occurring immunoglobulin molecule with a different structure. For example, a natural IgG antibody is a heterotetrameric glycoprotein of about 150,000 Daltons, consisting of two identical light chains and two identical heavy chains bound by disulfides. Each heavy chain has a variable domain (VH), also called a variable heavy chain domain or heavy chain variable region, from the N-terminus to the C-terminus, followed by three constant heavy chain domains (CH1, CH2, and CH3). Similarly, each light chain has a variable domain (VL), also called a variable light chain domain or light chain variable region, from the N-terminus to the C-terminus, followed by a constant light chain (CL) domain.

[0196] The term “packaging insert” is used to refer to the instruction manual typically included in the commercial packaging of a therapeutic product, which contains information relating to the indications, usage, dosage, administration, combination therapy, contraindications, and / or warnings of such therapeutic products.

[0197] The “percentage of amino acid sequence identity (%)” relative to a reference polypeptide sequence is defined as the percentage of amino acid residues in the candidate sequence that are identical to those in the reference polypeptide sequence after aligning the candidate sequence with the reference polypeptide sequence and introducing vacancies (if necessary) to achieve the maximum percentage of sequence identity, and for alignment purposes without considering any conservation substitutions as part of sequence identity. The alignment used to determine the percentage of amino acid sequence identity can be performed in various ways within the scope of the art, such as using publicly available computer software, such as BLAST, BLAST-2, Clustal W, Megalign (DNASTAR) software, or the FASTA package. Those skilled in the art can determine the appropriate parameters for aligning the sequences, including any algorithms required to achieve maximum alignment across the full length of the sequences being compared. Alternatively, the sequence comparison computer program ALIGN-2 can be used to generate the identity percentage values. The ALIGN-2 sequence comparison computer program was developed by Genentech, and the source code has been submitted with user documentation to the US Copyright Office, Washington DC.20559, which is registered under U.S. Copyright Registry No. TXU510087 and described in WO 2001 / 007611.

[0198] Unless otherwise stated, for the purposes of this document, the ggsearch program of FASTA package version 36.3.8c or later was used to generate the percentage values ​​of amino acid sequence identity using the BLOSUM50 comparison matrix. The FASTA package was created by W. R. Pearson and D. J. Lipman (1988), “Improved Tools for Biological Sequence Analysis”, PNAS 85:2444-2448; WR Pearson (1996) “Effective protein sequence comparison” Meth. Enzymol. 266:227-258; and Pearson et al. (1997) Genomics 46:24-36 and is publicly available at www.fasta.bioch.virginia.edu / fasta_www2 / fasta_down.shtml or www.ebi.ac.uk / Tools / sss / fasta. Alternatively, sequences can be compared using a public server accessible via fasta.bioch.virginia.edu / fasta_www2 / index.cgi, using the ggsearch (global protein:protein) program and default options (BLOSUM50; open: -10; ext: -2; Ktup = 2) to ensure a global rather than local alignment. The percentage of amino acid identity is given in the output alignment header.

[0199] The terms “pharmaceutical composition” or “pharmaceutical formulation” refer to a formulation in which the active ingredient permitted to be contained is in a biologically effective form and does not contain any of the components listed in the supplementary instructions 22 / 112 pages 32 CN 122459340 A that would have unacceptable toxicity to a subject to be administered the pharmaceutical composition.

[0200] “Pharmaceutically acceptable carrier” refers to a component in a pharmaceutical composition or formulation other than the active ingredient that is non-toxic to a subject. Pharmaceutically acceptable carriers include, but are not limited to, buffers, excipients, stabilizers, or preservatives.

[0201] Unless otherwise specified, the term “FolR1” as used herein refers to any naturally occurring FolR1 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., animals).(e.g., mice and rats). The term includes “full-length” unprocessed FolR1, as well as any form of FolR1 produced through cellular processing. The term also covers naturally occurring variants of FolR1, such as splice variants or allelic variants. In a preferred aspect, FolR1 is human FolR1. An exemplary amino acid sequence of human FolR1 is shown in SEQ ID NO: 100. See also UniProt accession number P15328.

[0202] As used herein, “treatment” (and its grammatical variations such as treat or treating) refers to an attempt to alter the natural course of a disease in the treated individual and can be performed for prevention or may be performed during a clinicopathological process. The desired effects of treatment include, but are not limited to, preventing the onset or recurrence of disease, alleviating symptoms, attenuating any direct or indirect pathological consequences of the disease, preventing metastasis, reducing the rate of disease progression, improving or alleviating the disease state, and mitigating or improving prognosis. In some aspects, the antibodies of the present invention are used to delay the development of disease or slow the progression of disease.

[0203] As used herein, “T cell activation” refers to one or more cellular responses of T lymphocytes (particularly cytotoxic T lymphocytes), selected from: proliferation, differentiation, cytokine secretion, release of cytotoxic effector molecules, cytotoxic activity, and expression of activation markers. Suitable assays for measuring T cell activation are known in the art and described herein.

[0204] “Modification that promotes association of the first and second subunits of the Fc domain” is manipulation of the peptide backbone or post-translational modification of the Fc domain subunits that reduces or prevents the association of a polypeptide containing an Fc domain subunit with the same polypeptide to form a homodimer. As used herein, “modification that promotes association” preferably includes individual modification of each of the two Fc domain subunits (i.e., the first and second subunits of the Fc domain) to which association is desired, wherein said modification is complementary to each other to promote association of the two Fc domain subunits. For example, association-promoting modifications can alter the structure or charge of one or both of the Fc domain subunits to make their association sterically or electrostatically favorable, respectively. Thus, (hybrid)dimerization occurs between a polypeptide containing a first Fc domain subunit and a polypeptide containing a second Fc domain subunit, which may differ in relation to other components fused to each subunit (e.g., the domain that binds to an antigen (e.g., FolR1 or CD3)). In some aspects, modifications promoting association of the first and second Fc domain subunits include amino acid mutations in the Fc domain, specifically amino acid substitutions. In a preferred aspect, the modifications promoting association of the first and second Fc domain subunits are in the Fc domain...Each of the two subunits of the domain contains a single amino acid mutation, particularly an amino acid substitution.

[0205] The term "effective function" refers to those biological activities attributable to the Fc region of the antibody that vary with antibody isotype. Examples of antibody effector functions include: C1q binding and complement-dependent cytotoxicity (CDC), Fc receptor binding, antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent phagocytosis (ADCP), cytokine secretion, antigen uptake by immune complex-mediated antigen-presenting cells, downregulation of cell surface receptors (e.g., B cell receptors), and B cell activation.

[0206] An "activating Fc receptor" is an Fc receptor that, upon binding to the Fc domain of an antibody, triggers a signal transduction event that stimulates the cell carrying the receptor to perform an effector function. Human activating Fc receptors include FcγRIIIIa (CD16a), FcγRI (CD64), FcγRIIIa (CD32), and FcαRI (CD89).

[0207] Antibody-dependent cell-mediated cytotoxicity (ADCC) is an immune mechanism that leads to the lysis of antibody-coated target cells by immune effector cells. Target cells are cells containing an Fc region, which typically binds specifically to the Fc region via a protein portion that is the N-terminus. As used herein, the term “reduced ADCC” is defined as a reduction in the number of target cells lysed by the ADCC mechanism defined above at a given antibody concentration in the culture medium surrounding the target cells over a given time, and / or an increase in the antibody concentration necessary to achieve lysis of a given number of target cells by the ADCC mechanism in the culture medium surrounding the target cells over a given time. ADCC reduction is relative to ADCC mediated by the same antibody produced from the same type of host cells but not engineered, using the same standard production, purification, formulation, and storage methods (such methods are known to those skilled in the art). For example, ADCC reduction mediated by an antibody containing an amino acid substitution that reduces ADCC in the Fc domain is relative to ADCC mediated by the same antibody without that amino acid substitution in the Fc domain. Suitable assays for measuring ADCC are well known in the art (see, for example, PCT Publication No. WO 2006 / 082515 or PCT Publication No. WO 2012 / 130831).

[0208] As used herein, the terms “engineering,” “engineered,” and “modified” are considered to include any manipulation of the peptide backbone or post-translational modification of a naturally occurring or recombinant polypeptide or fragment thereof. Engineering includes modifications to the amino acid sequence, sugar…Modification of side chain groups of amino acids, either by stylation patterns or individual amino acids, and combinations of these methods.

[0209] The term “amino acid mutation” as used herein encompasses amino acid substitution, deletion, insertion, and modification. Any combination of substitution, deletion, insertion, and modification can be performed to obtain the final construct, provided that the final construct has the desired characteristics, such as reduced binding to the Fc receptor or increased association with another peptide. Amino acid sequence deletions and insertions include deletions and insertions of the amino-terminus and / or carboxyl-terminus of amino acids. Preferred amino acid mutations are amino acid substitutions. Non-conservative amino acid substitutions, i.e., replacing an amino acid with another amino acid having a different structure and / or chemical properties, are particularly preferred for the purpose of altering, for example, the binding characteristics of the Fc region. Amino acid substitutions include substitution with non-naturally occurring amino acids or with naturally occurring amino acid derivatives of the twenty standard amino acids (e.g., 4-hydroxyproline, 3-methylhistidine, ornithine, homoserine, 5-hydroxylysine). Amino acid mutations can be generated using genetic or chemical methods well known in the art. Genetic methods may include site-directed mutagenesis, PCR, gene synthesis, etc. It is also useful to consider methods other than genetic engineering (such as chemical modification) to alter amino acid side chain groups. Various names may be used herein to indicate the same amino acid mutation. For example, replacing proline at position 329 of the Fc domain with glycine can be represented as 329G, G329, G329, P329G, or Pro329Gly.

[0210] As used herein, the term “vector” refers to a nucleic acid molecule capable of carrying another nucleic acid linked thereto. This term includes vectors as self-replicating nucleic acid structures, as well as vectors incorporated into the genome of a host cell into which they have been introduced. Some vectors are capable of directing the expression of nucleic acids operatively linked thereto. Such vectors are referred to herein as “expression vectors.”

[0211] II. Compositions and Methods

[0212] In one aspect, the present invention is based in part on an antibody that preferentially binds FolR1 at acidic pH compared to neutral pH. In some respects, an antibody binding to FolR1 is provided, wherein the antibody binds to FolR1 at a first KD at neutral pH 7.4 and at a second KD at acidic pH 6.5, wherein the first KD is greater than the second KD, and the first KD and the second KD are measured by surface plasmon resonance (SPR) at 25°C. The antibody exhibits preferential binding at acidic pH compared to neutral pH. This preferential binding at acidic pH compared to neutral pH is an advantageous property for therapeutic applications (such as in cancer), for example, in terms of safety and efficacy. The antibody of the present invention can be used, for example, for the diagnosis or treatment of diseases such as cancer.

[0213] A. WithExemplary pH-responsive antibody binding to FolR1

[0214] In one aspect, the present invention provides an antibody that binds to FolR1, wherein the antibody binds to FolR1 at a first KD at neutral pH 7.4 and at a second KD at acidic pH 6.5, wherein the first KD is greater than the second KD, and the first KD and the second KD are measured by surface plasmon resonance (SPR) at 25°C. In one aspect, a separated antibody binding to FolR1 is provided, wherein the antibody binds to FolR1 at a first KD at neutral pH 7.4 and at a second KD at acidic pH 6.5, wherein the first KD is greater than the second KD, and the first KD and the second KD are measured by surface plasmon resonance (SPR) at 25°C. In another aspect, the invention provides an antibody specifically binding to FolR1, wherein the antibody binds to FolR1 at a first KD at neutral pH 7.4 and at a second KD at acidic pH 6.5, wherein the first KD is greater than the second KD, and the first KD and the second KD are measured by surface plasmon resonance (SPR) at 25°C. In some aspects, the antibody binding to FolR1 preferentially binds to FolR1 at acidic pH compared to neutral pH. In some respects, antibodies binding to FolR1 have a dissociation constant (KD) of ≤ 47 nM (e.g., 47 x 10⁻⁹ M or less) at acidic pH 6.5, as measured by SPR at 25 °C. In particular, antibodies binding to FolR1 also have a dissociation constant (KD) of ≥ 46 nM (e.g., 46 x 10⁻⁹ M or higher) at neutral pH 7.4, as measured by SPR at 25 °C. Wherein, if the KD at neutral pH 7.4 is 46 nM or higher, as measured by surface plasmon resonance (SPR) at 25 °C, then the KD at neutral pH 7.4 is at least 2, at least 5, at least 8, at least 10, at least 11, at least 13, or at least 16 times greater than the KD at acidic pH 6.5. At least 23 times, at least 31 times, at least 40 times, at least 60 times, at least 74 times, or at least 195 times, as measured by SPR at 25°C.

[0215] In one aspect, withThe FolR1-binding antibody comprises the CDR-H1, CDR-H2, and CDR-H3 amino acid sequences of the VH domain of SEQ ID NO: 22 and the CDR-L1, CDR-L2, and CDR-L3 amino acid sequences of the VL domain of SEQ ID NO: 26.

[0216] In one aspect, the FolR1-binding antibody comprises: the three heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO: 22; and a frame having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the frame amino acid sequence of the VH domain of SEQ ID NO: 22. In one aspect, the antibody binding to FolR1 comprises: the three heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO:22; and a frame having at least 95% sequence identity with the frame amino acid sequence of the VH domain of SEQ ID NO:22. In another aspect, the antibody binding to FolR1 comprises: the three heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO:22; and a frame having at least 98% sequence identity with the frame amino acid sequence of the VH domain of SEQ ID NO:22.

[0217] In one aspect, the antibody binding to FolR1 comprises: three light chain CDR amino acid sequences of the VL domain of SEQ ID NO:26; and a frame having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the frame amino acid sequence of the VL domain of SEQ ID NO:26. In one aspect, the antibody binding to FolR1 comprises: three light chain CDR amino acid sequences of the VL domain of SEQ ID NO:26; and a frame having at least 95% sequence identity with the frame amino acid sequence of the VL domain of SEQ ID NO:26. On the other hand, the antibody binding to FolR1 comprises: a three-light chain CDR amino acid sequence of the VL domain of SEQ ID NO:26; and a framework that is identical to SEQ ID NO:26.The framework amino acid sequence of the VL domain has at least 98% sequence identity.

[0218] In a further aspect, the antibody binding to FolR1 comprises the CDR-H1, CDR-H2 and CDR-H3 amino acid sequences of the VH domain of SEQ ID NO:47 and the CDR-L1, CDR-L2 and CDR-L3 amino acid sequences of the VL domain of SEQ ID NO:26.

[0219] In one aspect, the antibody binding to FolR1 comprises: three heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO:47; and a frame having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the frame amino acid sequence of the VH domain of SEQ ID NO:47. In one aspect, the antibody binding to FolR1 comprises: three heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO:47; and a frame having at least 95% sequence identity with the frame amino acid sequence of the VH domain of SEQ ID NO:47. On the other hand, the antibody binding to FolR1 comprises: three heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO:47; and a frame having at least 98% sequence identity with the frame amino acid sequence of the VH domain of SEQ ID NO:47.

[0220] In one aspect, the antibody binding to FolR1 comprises: three light chain CDR amino acid sequences of the VL domain of SEQ ID NO:26; and a frame having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the frame amino acid sequence of the VL domain of SEQ ID NO:26. In one aspect, the antibody binding to FolR1 comprises: a three-light chain CDR amino acid sequence of the VL domain of SEQ ID NO:26; and a framework having at least 95% of the framework amino acid sequence of the VL domain of SEQ ID NO:26.Sequence identity. In another aspect, the antibody binding to FolR1 comprises: the three light chain CDR amino acid sequences of the VL domain of SEQ ID NO:26; and a framework having at least 98% sequence identity with the framework amino acid sequence of the VL domain of SEQ ID NO:26.

[0221] In a further aspect, the antibody binding to FolR1 comprises the CDR-H1, CDR-H2 and CDR-H3 amino acid sequences of the VH domain of SEQ ID NO:60 and the CDR-L1, CDR-L2 and CDR-L3 amino acid sequences of the VL domain of SEQ ID NO:26.

[0222] In one aspect, the antibody binding to FolR1 comprises: three heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO:60; and a frame having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 98%, at least 99%, or 100% sequence identity with the frame amino acid sequence of the VH domain of SEQ ID NO:60. In one aspect, the antibody binding to FolR1 comprises: three heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO:60; and a frame having at least 95% sequence identity with the frame amino acid sequence of the VH domain of SEQ ID NO:60. On the other hand, the antibody binding to FolR1 comprises: three heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO:60; and a frame having at least 98% sequence identity with the frame amino acid sequence of the VH domain of SEQ ID NO:60.

[0223] In one aspect, the antibody binding to FolR1 comprises: three light chain CDR amino acid sequences of the VL domain of SEQ ID NO:26; and a frame having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the frame amino acid sequence of the VL domain of SEQ ID NO:26. In one aspect, the antibody binding to FolR1 comprises: three light chain CDR amino acid sequences of the VL domain of SEQ ID NO:26.The amino acid sequence; and a frame having at least 95% sequence identity with the frame amino acid sequence of the VL domain of SEQ ID NO:26. In another aspect, the antibody binding to FolR1 comprises: three light chain CDR amino acid sequences of the VL domain of SEQ ID NO:26; and a frame having at least 98% sequence identity with the frame amino acid sequence of the VL domain of SEQ ID NO:26.

[0224] In a further aspect, the antibody binding to FolR1 comprises the CDR-H1, CDR-H2, and CDR-H3 amino acid sequences of the VH domain of SEQ ID NO:79 and the CDR-L1, CDR-L2, and CDR-L3 amino acid sequences of the VL domain of SEQ ID NO:38.

[0225] In one aspect, the antibody binding to FolR1 comprises: three heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO:79; and a frame having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the frame amino acid sequence of the VH domain of SEQ ID NO:79. In one aspect, the antibody binding to FolR1 comprises: three heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO:79; and a frame having at least 95% sequence identity with the frame amino acid sequence of the VH domain of SEQ ID NO:79. On the other hand, the antibody binding to FolR1 comprises: the three heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO:79; and a frame having at least 98% sequence identity with the frame amino acid sequence of the VH domain of SEQ ID NO:79.

[0226] In one aspect, the antibody binding to FolR1 comprises: the three light chain CDR amino acid sequences of the VL domain of SEQ ID NO:38; and a frame having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 96% sequence identity with the frame amino acid sequence of the VL domain of SEQ ID NO:38.97%, at least 98%, at least 99%, or 100% sequence identity. In one aspect, the antibody binding to FolR1 comprises: three light chain CDR amino acid sequences of the VL domain of SEQ ID NO:38; and a frame having at least 95% sequence identity with the frame amino acid sequence of the VL domain of SEQ ID NO:38. In another aspect, the antibody binding to FolR1 comprises: three light chain CDR amino acid sequences of the VL domain of SEQ ID NO:38; and a frame having at least 98% sequence identity with the frame amino acid sequence of the VL domain of SEQ ID NO:38.

[0227] In a further aspect, the antibody binding to FolR1 comprises the CDR-H1, CDR-H2, and CDR-H3 amino acid sequences of the VH domain of SEQ ID NO:22 and the CDR-L1, CDR-L2, and CDR-L3 amino acid sequences of the VL domain of SEQ ID NO:38.

[0228] In one aspect, the antibody binding to FolR1 comprises: the three heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO:22; and a frame having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the frame amino acid sequence of the VH domain of SEQ ID NO:22. In one aspect, the antibody binding to FolR1 comprises: three heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO:22; and a frame having at least 95% sequence identity with the frame amino acid sequence of the VH domain of SEQ ID NO:22. In another aspect, the antibody binding to FolR1 comprises: three heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO:22; and a frame having at least 98% sequence identity with the frame amino acid sequence of the VH domain of SEQ ID NO:22.

[0229] In one aspect, the antibody binding to FolR1 comprises: three light chain CDR amino acid sequences of the VL domain of SEQ ID NO:38; and a frame having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, and at least90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity. In one aspect, the antibody binding to FolR1 comprises: the three light chain CDR amino acid sequences of the VL domain of SEQ ID NO:38; and a frame having at least 95% sequence identity with the frame amino acid sequence of the VL domain of SEQ ID NO:38. In another aspect, the antibody binding to FolR1 comprises: the three light chain CDR amino acid sequences of the VL domain of SEQ ID NO:38; and a frame having at least 98% sequence identity with the frame amino acid sequence of the VL domain of SEQ ID NO:38.

[0230] In a further aspect, the antibody binding to FolR1 comprises the CDR-H1, CDR-H2, and CDR-H3 amino acid sequences of the VH domain of SEQ ID NO:52 and the CDR-L1, CDR-L2, and CDR-L3 amino acid sequences of the VL domain of SEQ ID NO:26.

[0231] In one aspect, the antibody binding to FolR1 comprises: the three heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO:52; and a frame having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the frame amino acid sequence of the VH domain of SEQ ID NO:52. In one aspect, the antibody binding to FolR1 comprises: three heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO:52; and a frame having at least 95% sequence identity with the frame amino acid sequence of the VH domain of SEQ ID NO:52. In another aspect, the antibody binding to FolR1 comprises: three heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO:52; and a frame having at least 98% sequence identity with the frame amino acid sequence of the VH domain of SEQ ID NO:52.

[0232] In one aspect, the antibody binding to FolR1 comprises: three light chain CDR amino acid sequences of the VL domain of SEQ ID NO:26.An amino acid sequence; and a frame having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the frame amino acid sequence of the VL domain of SEQ ID NO:26. In one aspect, an antibody binding to FolR1 comprises: three light chain CDR amino acid sequences of the VL domain of SEQ ID NO:26; and a frame having at least 95% sequence identity with the frame amino acid sequence of the VL domain of SEQ ID NO:26. In another aspect, an antibody binding to FolR1 comprises: three light chain CDR amino acid sequences of the VL domain of SEQ ID NO:26; and a frame having at least 98% sequence identity with the frame amino acid sequence of the VL domain of SEQ ID NO:26.

[0233] In a further aspect, the antibody binding to FolR1 comprises the CDR-H1, CDR-H2, and CDR-H3 amino acid sequences of the VH domain of SEQ ID NO:47 and the CDR-L1, CDR-L2, and CDR-L3 amino acid sequences of the VL domain of SEQ ID NO:38.

[0234] In one aspect, the antibody binding to FolR1 comprises: the three heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO:47; and a frame having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, 98%, at least 99%, or 100% sequence identity with the frame amino acid sequence of the VH domain of SEQ ID NO:47. In one aspect, the antibody binding to FolR1 comprises: the three heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO:47; and a frame having at least 95% sequence identity with the frame amino acid sequence of the VH domain of SEQ ID NO:47. In another aspect, the antibody binding to FolR1 comprises: the three heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO:47; and a frame having at least 98% sequence identity with the frame amino acid sequence of the VH domain of SEQ ID NO:47.

[0235] In one aspect, withThe FolR1-binding antibody comprises: the three light chain CDR amino acid sequences of the VL domain of SEQ ID NO:38; and a frame having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the frame amino acid sequence of the VL domain of SEQ ID NO:38. In one aspect, the FolR1-binding antibody comprises: the three light chain CDR amino acid sequences of the VL domain of SEQ ID NO:38; and a frame having at least 95% sequence identity with the frame amino acid sequence of the VL domain of SEQ ID NO:38. On the other hand, the antibody binding to FolR1 comprises: the three light chain CDR amino acid sequences of the VL domain of SEQ ID NO:38; and a framework having at least 98% sequence identity with the framework amino acid sequence of the VL domain of SEQ ID NO:38.

[0236] In a further aspect, the antibody binding to FolR1 comprises the CDR-H1, CDR-H2 and CDR-H3 amino acid sequences of the VH domain of SEQ ID NO:56 and the CDR-L1, CDR-L2 and CDR-L3 amino acid sequences of the VL domain of SEQ ID NO:26.

[0237] In one aspect, the antibody binding to FolR1 comprises: three heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO:56; and a frame having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the frame amino acid sequence of the VH domain of SEQ ID NO:56. In another aspect, the antibody binding to FolR1 comprises: three heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO:56; and a frame having at least 95% sequence identity with the frame amino acid sequence of the VH domain of SEQ ID NO:56. In another aspect, the antibody binding to FolR1 comprises: three heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO:56.The CDR amino acid sequence; and a frame having at least 98% sequence identity with the frame amino acid sequence of the VH domain of SEQ ID NO:56.

[0238] In one aspect, the antibody binding to FolR1 comprises: three light chain CDR amino acid sequences of the VL domain of SEQ ID NO:26; and a frame having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the frame amino acid sequence of the VL domain of SEQ ID NO:26. In one aspect, the antibody binding to FolR1 comprises: three light chain CDR amino acid sequences of the VL domain of SEQ ID NO:26; and a frame having at least 95% sequence identity with the frame amino acid sequence of the VL domain of SEQ ID NO:26. In another aspect, the antibody binding to FolR1 comprises: three light chain CDR amino acid sequences of the VL domain of SEQ ID NO:26; and a frame having at least 98% sequence identity with the frame amino acid sequence of the VL domain of SEQ ID NO:26.

[0239] In a further aspect, the antibody binding to FolR1 comprises the CDR-H1, CDR-H2 and CDR-H3 amino acid sequences of the VH domain of SEQ ID NO:64 and the CDR-L1, CDR-L2 and CDR-L3 amino acid sequences of the VL domain of SEQ ID NO:26.

[0240] In one aspect, the antibody binding to FolR1 comprises: the three heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO:64; and a frame having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the frame amino acid sequence of the VH domain of SEQ ID NO:64. In one aspect, the antibody binding to FolR1 comprises: the three heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO:64; and a frame having at least 95% sequence identity with the frame amino acid sequence of the VH domain of SEQ ID NO:64.Sequence identity. In another aspect, the antibody binding to FolR1 comprises: the three heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO:64; and a frame having at least 98% sequence identity with the frame amino acid sequence of the VH domain of SEQ ID NO:64.

[0241] In one aspect, the antibody binding to FolR1 comprises: the three light chain CDR amino acid sequences of the VL domain of SEQ ID NO:26; and a frame having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the frame amino acid sequence of the VL domain of SEQ ID NO:26. In one aspect, the antibody binding to FolR1 comprises: three light chain CDR amino acid sequences of the VL domain of SEQ ID NO:26; and a frame having at least 95% sequence identity with the frame amino acid sequence of the VL domain of SEQ ID NO:26. In another aspect, the antibody binding to FolR1 comprises: three light chain CDR amino acid sequences of the VL domain of SEQ ID NO:26; and a frame having at least 98% sequence identity with the frame amino acid sequence of the VL domain of SEQ ID NO:26.

[0242] In a further aspect, the antibody binding to FolR1 comprises the CDR-H1, CDR-H2 and CDR-H3 amino acid sequences of the VH domain of SEQ ID NO:67 and the CDR-L1, CDR-L2 and CDR-L3 amino acid sequences of the VL domain of SEQ ID NO:26.

[0243] In one aspect, the antibody binding to FolR1 comprises: a three-chain CDR amino acid sequence of the VH domain of SEQ ID NO:67; and a framework having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the framework amino acid sequence of the VH domain of SEQ ID NO:67. In one aspect, the antibody binding to FolR1...The binding antibody comprises: the three heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO:67; and a frame having at least 95% sequence identity with the frame amino acid sequence of the VH domain of SEQ ID NO:67. Alternatively, the antibody binding to FolR1 comprises: the three heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO:67; and a frame having at least 98% sequence identity with the frame amino acid sequence of the VH domain of SEQ ID NO:67.

[0244] In one aspect, the antibody binding to FolR1 comprises: three light chain CDR amino acid sequences of the VL domain of SEQ ID NO:26; and a frame having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the frame amino acid sequence of the VL domain of SEQ ID NO:26. In one aspect, the antibody binding to FolR1 comprises: three light chain CDR amino acid sequences of the VL domain of SEQ ID NO:26; and a frame having at least 95% sequence identity with the frame amino acid sequence of the VL domain of SEQ ID NO:26. On the other hand, the antibody binding to FolR1 comprises: the three light chain CDR amino acid sequences of the VL domain of SEQ ID NO:26; and a framework having at least 98% sequence identity with the framework amino acid sequence of the VL domain of SEQ ID NO:26.

[0245] In a further aspect, the antibody binding to FolR1 comprises the CDR-H1, CDR-H2 and CDR-H3 amino acid sequences of the VH domain of SEQ ID NO:76 and the CDR-L1, CDR-L2 and CDR-L3 amino acid sequences of the VL domain of SEQ ID NO:38.

[0246] In one aspect, the antibody binding to FolR1 comprises: a three-chain CDR amino acid sequence of the VH domain of SEQ ID NO:76; and a framework having an amino acid sequence of at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity. In one aspect, the antibody binding to FolR1 comprises: the three heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO:76; and a frame having at least 95% sequence identity with the frame amino acid sequence of the VH domain of SEQ ID NO:76. In another aspect, the antibody binding to FolR1 comprises: the three heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO:76; and a frame having at least 98% sequence identity with the frame amino acid sequence of the VH domain of SEQ ID NO:76.

[0247] In one aspect, the antibody binding to FolR1 comprises: three light chain CDR amino acid sequences of the VL domain of SEQ ID NO:38; and a frame having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the frame amino acid sequence of the VL domain of SEQ ID NO:38. In one aspect, the antibody binding to FolR1 comprises: three light chain CDR amino acid sequences of the VL domain of SEQ ID NO:38; and a frame having at least 95% sequence identity with the frame amino acid sequence of the VL domain of SEQ ID NO:38. On the other hand, the antibody binding to FolR1 comprises: three light chain CDR amino acid sequences of the VL domain of SEQ ID NO:38; and a frame having at least 98% sequence identity with the frame amino acid sequence of the VL domain of SEQ ID NO:38.

[0248] In a further aspect, the antibody binding to FolR1 comprises the CDR-H1, CDR-H2 and CDR-H3 amino acid sequences of the VH domain of SEQ ID NO:82 and the CDR-L1, CDR-L2 and CDR-L3 amino acid sequences of the VL domain of SEQ ID NO:38.

[0249] In one aspect, the antibody binding to FolR1 comprises: three heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO:82; and a frame having at least 98% sequence identity with the frame amino acid sequence of the VH domain of SEQ ID NO:82.The antibody has at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity. In one aspect, the antibody binding to FolR1 comprises: the three heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO:82; and a frame having at least 95% sequence identity with the frame amino acid sequence of the VH domain of SEQ ID NO:82. In another aspect, the antibody binding to FolR1 comprises: the three heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO:82; and a frame having at least 98% sequence identity with the frame amino acid sequence of the VH domain of SEQ ID NO:82.

[0250] In one aspect, the antibody binding to FolR1 comprises: three light chain CDR amino acid sequences of the VL domain of SEQ ID NO:38; and a frame having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the frame amino acid sequence of the VL domain of SEQ ID NO:38. In one aspect, the antibody binding to FolR1 comprises: three light chain CDR amino acid sequences of the VL domain of SEQ ID NO:38; and a frame having at least 95% sequence identity with the frame amino acid sequence of the VL domain of SEQ ID NO:38. On the other hand, the antibody binding to FolR1 comprises: the three light chain CDR amino acid sequences of the VL domain of SEQ ID NO:38; and a framework having at least 98% sequence identity with the framework amino acid sequence of the VL domain of SEQ ID NO:38.

[0251] In a further aspect, the antibody binding to FolR1 comprises the CDR-H1, CDR-H2 and CDR-H3 amino acid sequences of the VH domain of SEQ ID NO:85 and the CDR-L1, CDR-L2 and CDR-L3 amino acid sequences of the VL domain of SEQ ID NO:38.

[0252] In one aspect, the antibody binding to FolR1 comprises: the three heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO:85.An amino acid sequence; and a frame having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the frame amino acid sequence of the VH domain of SEQ ID NO:85. In one aspect, the antibody binding to FolR1 comprises: the three heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO:85; and a frame having at least 95% sequence identity with the frame amino acid sequence of the VH domain of SEQ ID NO:85. On the other hand, the antibody binding to FolR1 comprises: three heavy chain CDR amino acid sequences of the VH domain of SEQ ID NO:85; and a frame having at least 98% sequence identity with the frame amino acid sequence of the VH domain of SEQ ID NO:85.

[0253] In one aspect, the antibody binding to FolR1 comprises: three light chain CDR amino acid sequences of the VL domain of SEQ ID NO:38; and a frame having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the frame amino acid sequence of the VL domain of SEQ ID NO:38. In one aspect, the antibody binding to FolR1 comprises: a three-light chain CDR amino acid sequence of the VL domain of SEQ ID NO:38; and a frame having at least 95% sequence identity with the frame amino acid sequence of the VL domain of SEQ ID NO:38. In another aspect, the antibody binding to FolR1 comprises: a three-light chain CDR amino acid sequence of the VL domain of SEQ ID NO:38; and a frame having at least 98% sequence identity with the frame amino acid sequence of the VL domain of SEQ ID NO:38.

[0254] In one aspect, the antibody binding to FolR1 comprises: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:19; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:20; (c) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:19.(d) CDR-H3 containing the amino acid sequence of SEQ ID NO: 21; (e) CDR-L2 containing the amino acid sequence of SEQ ID NO: 24; and (f) CDR-L3 containing the amino acid sequence of SEQ ID NO: 25; and a VH domain having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 22; and a VL domain having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 26; wherein the antibody specifically binds to FolR1. In one respect, the VH domain has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 22. In another respect, the VL domain has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 26.

[0255] In one aspect, the antibody binding to FolR1 comprises: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 44; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 45; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 46; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 23; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 24; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 25; and a VH domain having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 47; and a VL domain having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 47; and a VL domain having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 47; The amino acid sequence of 26 has at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity; wherein the antibody specifically binds to FolR1. In one aspect, VHThe VL domain shares at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 47. In one respect, the VL domain shares at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 26.

[0256] In one aspect, the antibody binding to FolR1 comprises: (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 19; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 58; (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 59; (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 23; (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 24; and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 25; and a VH domain having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% of the amino acid sequence of SEQ ID NO: 60. Or 100% sequence identity; and a VL domain having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 26; wherein the antibody specifically binds to FolR1. In one aspect, the VH domain has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 60. In one aspect, the VL domain has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 26.

[0257] In one aspect, the antibody binding to FolR1 comprises: (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:44; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:45; (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:78; (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:36; (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:24; and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:37; and a VH domain, which is associated with SEQ ID NO:79The amino acid sequence of the antibody has at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity; and a VL domain having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 38; wherein the antibody specifically binds to FolR1. In one aspect, the VH domain has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 79. In another aspect, the VL domain has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 38.

[0258] In one aspect, the antibody binding to FolR1 comprises: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 19; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 20; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 21; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 36; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 24; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 37; and a VH domain having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 22; and a VL domain having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 22; and a VL domain having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 22; The amino acid sequence of SEQ ID NO: 38 has at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity; wherein the antibody specifically binds to FolR1. In one aspect, the VH domain has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 22. In one aspect, the VL domain has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 38.

[0259] In one aspect, the antibody binding to FolR1 comprises: (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 49; (b)(c) CDR-H2 containing the amino acid sequence of SEQ ID NO: 50; (d) CDR-H3 containing the amino acid sequence of SEQ ID NO: 51; (e) CDR-L1 containing the amino acid sequence of SEQ ID NO: 23; (f) CDR-L2 containing the amino acid sequence of SEQ ID NO: 24; and (f) CDR-L3 containing the amino acid sequence of SEQ ID NO: 25; and a VH domain having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 52; and a VL domain having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 26. (See specification 33 / 112 pages 43 CN 122459340 A) The antibody exhibits 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity; wherein the antibody specifically binds to FolR1. In one aspect, the VH domain has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 52. In another aspect, the VL domain has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 26.

[0260] In one aspect, the antibody binding to FolR1 comprises: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 44; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 45; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 46; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 36; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 24; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 37; and a VH domain having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 47; and a VL domain having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 47; and a VL domain having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 45; The amino acid sequence of 38 has at least 90%, at least 91%, at least 92%, at least 93%, at least94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity; wherein the antibody specifically binds to FolR1. In one aspect, the VH domain has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 47. In one aspect, the VL domain has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 38.

[0261] In one aspect, the antibody binding to FolR1 comprises: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 54; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 55; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 21; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 23; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 24; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 25; and a VH domain having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 56; and a VL domain having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 56; and a VL domain having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 56; The amino acid sequence of SEQ ID NO: 26 has at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity; wherein the antibody specifically binds to FolR1. In one aspect, the VH domain has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 56. In one aspect, the VL domain has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 26.

[0262] In one aspect, the antibody binding to FolR1 comprises: (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 19; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 62; (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 63; (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 23; (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 24; and (f) comprising SEQ ID NO: 19.The antibody comprises: a CDR-L3 domain of the amino acid sequence of SEQ ID NO: 25; and a VH domain having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 64; and a VL domain having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 26; wherein the antibody specifically binds to FolR1. In one aspect, the VH domain has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 64. In another aspect, the VL domain has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 26.

[0263] In one aspect, the antibody binding to FolR1 comprises: (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 19; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 66; (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 21; (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 23; (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 24; and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 25; and a VH domain having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% of the amino acid sequence of SEQ ID NO: 67. Or 100% sequence identity; and a VL domain having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 26; wherein the antibody specifically binds to FolR1. In one aspect, the VH domain has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 67. In one aspect, the VL domain has at least 100% sequence identity with the amino acid sequence of SEQ ID NO: 26.95% sequence identity.

[0264] In one aspect, the antibody binding to FolR1 comprises: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 44; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 45; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 21; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 36; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 24; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 37; and a VH domain having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 76; and a VL domain having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 76; and a VL domain having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 76; The amino acid sequence of SEQ ID NO: 38 has at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity; wherein the antibody specifically binds to FolR1. In one aspect, the VH domain has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 76. In one aspect, the VL domain has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 38.

[0265] In one aspect, the antibody binding to FolR1 comprises: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 44; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 45; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 81; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 36; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 24; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 37; and a VH domain having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 82; and a VL domain having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 82; and a VL domain having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 82;The amino acid sequence of SEQ ID NO: 38 has at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity; wherein the antibody specifically binds to FolR1. In one aspect, the VH domain has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 82. In one aspect, the VL domain has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 38.

[0266] In one aspect, the antibody binding to FolR1 comprises: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 44; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 45; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 84; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 36; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 24; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 37; and a VH domain having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 85; and a VL domain having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 85; and a VL domain having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 85; The amino acid sequence of SEQ ID NO: 38 has at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity; wherein the antibody specifically binds to FolR1. In one aspect, the VH domain has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 85. In another aspect, the VL domain has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 38.

[0267] In another aspect, the antibody binding to FolR1 comprises a heavy chain variable domain (VH) sequence that has at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 22.Sequence identity. In one aspect, the FolR1-binding antibody comprises a heavy chain variable domain (VH) sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO:22. In some aspects, the VH sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity contains substitutions (e.g., conserved substitutions), insertions, or deletions relative to the reference sequence, but the FolR1-binding antibody containing this sequence retains its ability to bind to FolR1. In some aspects, in SEQ ID NO:22, a total of 1 to 10 amino acids have been substituted, inserted, and / or deleted. In some aspects, the substitution, insertion, or deletion occurs in a region outside the CDR (i.e., in the FR). Optionally, the FolR1-binding antibody comprises the VH sequence of SEQ ID NO:22, including post-translational modifications of that sequence. In one specific aspect, VH comprises one, two, or three CDRs selected from the following: (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 19, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 20, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 21. In another aspect, the antibody binding to FolR1 comprises a light chain variable domain (VL) sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 26. In one aspect, the antibody binding to FolR1 comprises a light chain variable domain (VL) sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 26. In some respects, VL sequences having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity with a reference sequence contain substitutions (e.g., conserved substitutions), insertions, or deletions, but antibodies containing such sequences that bind to FolR1 retain their ability to bind to FolR1. In some respects, in SEQ ID NO:26, a total of 1 to 10 amino acids have been substituted, inserted, and / or deleted. In some respects, substitutions, insertions, or deletions occur in regions outside the CDR (i.e., in the FR).Optionally, the antibody binding to FolR1 comprises the VL sequence of SEQ ID NO:26, including post-translational modifications of that sequence. In one specific aspect, the VL comprises one, two, or three CDRs selected from: (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:23, (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO:24, and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO:25.

[0268] In another aspect, the antibody binding to FolR1 comprises the VH sequence of any of the aspects provided above and the VL sequence of any of the aspects provided above. In one aspect, the antibody comprises the VH sequence and the VL sequence of SEQ ID NO:22 and SEQ ID NO:26, respectively, including post-translational modifications of those sequences.

[0269] In another aspect, the antibody binding to FolR1 comprises a heavy chain variable domain (VH) sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO:47. In some aspects, the VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conserved substitutions), insertions, or deletions relative to a reference sequence, but the antibody binding to FolR1 containing this sequence retains its ability to bind to FolR1. In some respects, in SEQ ID NO:47, page 36 / 112 of the specification, 1 to 10 amino acids have been substituted, inserted, and / or deleted. In some respects, the substitution, insertion, or deletion occurs in regions outside the CDR (i.e., in the FR). Optionally, the antibody binding to FolR1 comprises the VH sequence of SEQ ID NO:47, including post-translational modifications of that sequence. In one specific respect, VH comprises one, two, or three CDRs selected from: (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:44, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:45, and (c) CDR-H2 comprising the amino acid sequence of SEQ ID NO:46.The amino acid sequence of the CDR-H3. On the other hand, the antibody binding to FolR1 comprises a light chain variable domain (VL) sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO:26. In some aspects, the VL sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity contains substitutions (e.g., conserved substitutions), insertions, or deletions relative to the reference sequence, but the antibody binding to FolR1 containing this sequence retains its ability to bind to FolR1. In some aspects, in SEQ ID NO:26, a total of 1 to 10 amino acids have been substituted, inserted, and / or deleted. In some aspects, substitution, insertion, or deletion occurs in regions outside the CDR (i.e., in the FR). Optionally, the antibody binding to FolR1 comprises the VL sequence of SEQ ID NO:26, including post-translational modifications of that sequence. In one specific aspect, the VL comprises one, two, or three CDRs selected from the following: (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:23, (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO:24, and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO:25.

[0270] In another aspect, the antibody binding to FolR1 comprises the VH sequence of any of the aspects provided above and the VL sequence of any of the aspects provided above. On one hand, the antibody comprises the VH and VL sequences of SEQ ID NO: 47 and SEQ ID NO: 26, respectively, including post-translational modifications of those sequences.

[0271] On the other hand, the antibody binding to FolR1 comprises a heavy chain variable domain (VH) sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 60. In one aspect, the antibody binding to FolR1The binding antibody comprises a heavy chain variable domain (VH) sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO:60. In some aspects, VH sequences having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity with the reference sequence contain substitutions (e.g., conserved substitutions), insertions, or deletions, but antibodies containing this sequence that bind to FolR1 retain their ability to bind to FolR1. In some aspects, in SEQ ID NO:60, a total of 1 to 10 amino acids have been substituted, inserted, and / or deleted. In some aspects, substitutions, insertions, or deletions occur in regions outside the CDR (i.e., in the FR). Optionally, the FolR1-binding antibody comprises the VH sequence of SEQ ID NO:60, including post-translational modifications of that sequence. In one specific aspect, VH comprises one, two, or three CDRs selected from the following: (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 19, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 58, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 59. In another aspect, the antibody binding to FolR1 comprises a light chain variable domain (VL) sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 26. In one aspect, the antibody binding to FolR1 comprises a light chain variable domain (VL) sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 26. In some aspects, VL sequences having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity with the reference sequence contain substitutions (e.g., conserved substitutions), insertions, or deletions, but antibodies containing such sequences that bind to FolR1 retain their ability to bind to FolR1. In some aspects, in SEQ ID NO:26, a total of 1 to 10 amino acids have been substituted, inserted, and / or deleted. In some aspects, substitutions, insertions, or deletions occur in CDR.Outside the region (i.e., in FR). Optionally, the antibody binding to FolR1 comprises the VL sequence of SEQ ID NO:26, including post-translational modifications of that sequence. In one specific aspect, VL comprises one, two, or three CDRs selected from: (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:23, (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO:24, and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO:25.

[0272] In another aspect, the antibody binding to FolR1 comprises the VH sequence of any of the aspects provided above and the VL sequence of any of the aspects provided above. In one aspect, the antibody comprises the VH sequence and VL sequence of SEQ ID NO:60 and SEQ ID NO:26, respectively, including post-translational modifications of those sequences.

[0273] In another aspect, the antibody binding to FolR1 comprises a heavy chain variable domain (VH) sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO:79. In some aspects, the VH sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity contains substitutions (e.g., conserved substitutions), insertions, or deletions relative to a reference sequence, but the antibody binding to FolR1 containing this sequence retains its ability to bind to FolR1. In some respects, in SEQ ID NO:79, a total of 1 to 10 amino acids have been substituted, inserted, and / or deleted. In some respects, the substitution, insertion, or deletion occurs in a region outside the CDR (i.e., in the FR). Optionally, the antibody binding to FolR1 comprises the VH sequence of SEQ ID NO:79, including post-translational modifications of that sequence. In one specific respect, VH comprises one, two, or three CDRs selected from: (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:44, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:45, and (c) comprising...The CDR-H3 of the amino acid sequence of SEQ ID NO: 78. In another aspect, the antibody binding to FolR1 comprises a light chain variable domain (VL) sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 38. In one aspect, the antibody binding to FolR1 comprises a light chain variable domain (VL) sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 38. In some aspects, VL sequences having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity with a reference sequence contain substitutions (e.g., conserved substitutions), insertions, or deletions, but antibodies containing such sequences retain their ability to bind to FolR1. In some aspects, in SEQ ID NO:38, a total of 1 to 10 amino acids have been substituted, inserted, and / or deleted. In some aspects, substitutions, insertions, or deletions occur in regions outside the CDR (i.e., in the FR). Optionally, antibodies binding to FolR1 contain the VL sequence of SEQ ID NO:38, including post-translational modifications of that sequence. In one specific aspect, VL comprises one, two, or three CDRs selected from the following: (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 36, (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 24, and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 37.

[0274] In another aspect, the antibody binding to FolR1 comprises the VH sequence of any of the aspects provided above and the VL sequence of any of the aspects provided above. In one aspect, the antibody comprises the VH sequence and VL sequence of SEQ ID NO: 79 and SEQ ID NO: 38, respectively, including post-translational modifications of those sequences.

[0275] On the other hand, the antibody binding to FolR1 comprises a heavy chain variable domain (VH) sequence having an amino acid content of at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, and at least [missing information] compared to the amino acid sequence of SEQ ID NO:22.97%, at least 98%, at least 99%, or 100% sequence identity. In one aspect, the antibody binding to FolR1 comprises a heavy chain variable domain (VH) sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO:22. In some aspects, the VH sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity contains substitutions (e.g., conserved substitutions), insertions, or deletions relative to the reference sequence, but the antibody binding to FolR1 containing this sequence retains its ability to bind to FolR1. In some aspects, in SEQ ID NO:22, a total of 1 to 10 amino acids have been substituted, inserted, and / or deleted. In some aspects, the substitution, insertion, or deletion occurs in a region outside the CDR (i.e., in the FR). Optionally, the antibody binding to FolR1 comprises the VH sequence of SEQ ID NO:22, including post-translational modifications of that sequence. In one specific aspect, VH comprises one, two, or three CDRs selected from: (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:19, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:20, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:21. In another aspect, the antibody binding to FolR1 comprises a light chain variable domain (VL) sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO:38. In one aspect, the FolR1-binding antibody comprises a light chain variable domain (VL) sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO:38. In some aspects, VL sequences having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity contain substitutions (e.g., conserved substitutions), insertions, or deletions relative to a reference sequence, but the FolR1-binding antibody containing this sequence retains its ability to bind to FolR1. In some aspects, in SEQ ID NO:38, a total of 1 to 10 amino acids have been substituted, inserted, and / or deleted.In some respects, substitution, insertion, or deletion occurs in regions outside the CDR (i.e., in the FR). Optionally, the antibody binding to FolR1 comprises the VL sequence of SEQ ID NO:38, including post-translational modifications of that sequence. In one specific respect, the VL comprises one, two, or three CDRs selected from: (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:36, (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO:24, and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO:37.

[0276] In another respect, the antibody binding to FolR1 comprises the VH sequence of any of the aspects provided above and the VL sequence of any of the aspects provided above. In one respect, the antibody comprises the VH sequence and the VL sequence of SEQ ID NO:22 and SEQ ID NO:38, respectively, including post-translational modifications of those sequences.

[0277] In another aspect, the antibody binding to FolR1 comprises a heavy chain variable domain (VH) sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO:52. In some aspects, the VH sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity contains substitutions (e.g., conserved substitutions), insertions, or deletions relative to a reference sequence, but the antibody binding to FolR1 containing this sequence retains its ability to bind to FolR1. In some respects, in SEQ ID NO:52, a total of 1 to 10 amino acids have been substituted, inserted, and / or deleted. In some respects, the substitution, insertion, or deletion occurs outside the CDR (i.e., in FR). Optionally, the antibody binding to FolR1 comprises the VH sequence in SEQ ID NO:52, including post-translational modifications of that sequence. In one specific respect, VH comprises one, two, or three CDRs selected from: (a) comprising SEQ ID NO: 49The CDR-H1 comprising the amino acid sequence of SEQ ID NO: 50, (b) the CDR-H2 comprising the amino acid sequence of SEQ ID NO: 51, and (c) the CDR-H3 comprising the amino acid sequence of SEQ ID NO: 51. In another aspect, the antibody binding to FolR1 comprises a light chain variable domain (VL) sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 26. In one aspect, the antibody binding to FolR1 comprises a light chain variable domain (VL) sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 26. In some aspects, VL sequences having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity with a reference sequence contain substitutions (e.g., conserved substitutions), insertions, or deletions, but antibodies containing such sequences retain their ability to bind to FolR1. In some aspects, in SEQ ID NO:26, a total of 1 to 10 amino acids have been substituted, inserted, and / or deleted. In some aspects, substitutions, insertions, or deletions occur in regions outside the CDR (i.e., in the FR). Optionally, antibodies binding to FolR1 contain the VL sequence of SEQ ID NO:26, including post-translational modifications of that sequence. In one specific aspect, VL comprises one, two, or three CDRs selected from the following: (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 23, (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 24, and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 25.

[0278] In another aspect, the antibody binding to FolR1 comprises the VH sequence of any of the aspects provided above and the VL sequence of any of the aspects provided above. In one aspect, the antibody comprises the VH sequence and VL sequence of SEQ ID NO: 52 and SEQ ID NO: 26, respectively, including post-translational modifications of those sequences.

[0279] In another aspect, the antibody binding to FolR1 comprises a heavy chain variable domain (VH) sequence having at least 90%, at least 91%, at least 92%, at least 93%, and at least94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity. In one aspect, the antibody binding to FolR1 comprises a heavy chain variable domain (VH) sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO:47. In some aspects, the VH sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity contains substitutions (e.g., conserved substitutions), insertions, or deletions relative to the reference sequence, but the antibody binding to FolR1 containing this sequence retains its ability to bind to FolR1. In some aspects, in SEQ ID NO:47, a total of 1 to 10 amino acids have been substituted, inserted, and / or deleted. In some aspects, the substitution, insertion, or deletion occurs in a region outside the CDR (i.e., in the FR). Optionally, the antibody binding to FolR1 comprises the VH sequence of SEQ ID NO:47, including post-translational modifications of that sequence. In one specific aspect, VH comprises one, two, or three CDRs selected from: (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:44, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:45, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:46. In another aspect, the antibody binding to FolR1 comprises a light chain variable domain (VL) sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO:38. In one aspect, the antibody binding to FolR1 comprises a light chain variable domain (VL) sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO:38. In some aspects, the VL sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity contains substitutions (e.g., substitutions, insertions, or deletions) relative to the reference sequence, but the antibody binding to FolR1 containing this sequence retains its ability to bind to FolR1. In some aspects, inIn SEQ ID NO:38, a total of 1 to 10 amino acids have been substituted, inserted, and / or deleted. In some aspects, substitution, insertion, or deletion occurs in regions outside the CDR (i.e., in the FR). Optionally, the antibody binding to FolR1 comprises the VL sequence of SEQ ID NO:38, including post-translational modifications of that sequence. In one specific aspect, the VL comprises one, two, or three CDRs selected from the following: (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:36, (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO:24, and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO:37.

[0280] In another aspect, the antibody binding to FolR1 comprises the VH sequence of any of the aspects provided above and the VL sequence of any of the aspects provided above. On one hand, the antibody comprises the VH and VL sequences of SEQ ID NO: 47 and SEQ ID NO: 38, respectively, including post-translational modifications of those sequences.

[0281] On the other hand, the antibody binding to FolR1 comprises a heavy chain variable domain (VH) sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 56. In one aspect, the antibody binding to FolR1 comprises a heavy chain variable domain (VH) sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 56. In some aspects, a VH sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity with a reference sequence contains substitutions (e.g., conserved substitutions), insertions, or deletions relative to a reference sequence, but an antibody containing this sequence that binds to FolR1 retains its ability to bind to FolR1. In some aspects, in SEQ ID NO:56, a total of 1 to 10 amino acids have been substituted, inserted, and / or deleted. In some aspects, the substitution, insertion, or deletion occurs in a region outside the CDR (i.e., in the FR). Optionally, an antibody that binds to FolR1 contains the VH sequence of SEQ ID NO:56, including post-translational modifications of that sequence. In one specific aspect, the VH contains one, two, or three CDRs selected from: (a) containing SEQ ID NO:56.(a) CDR-H1 containing the amino acid sequence of SEQ ID NO: 54, (b) CDR-H2 containing the amino acid sequence of SEQ ID NO: 55, and (c) CDR-H3 containing the amino acid sequence of SEQ ID NO: 21. In another aspect, the antibody binding to FolR1 comprises a light chain variable domain (VL) sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 26. In one aspect, the antibody binding to FolR1 comprises a light chain variable domain (VL) sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 26. In some aspects, VL sequences having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity with a reference sequence contain substitutions (e.g., conserved substitutions), insertions, or deletions, but antibodies containing such sequences retain their ability to bind to FolR1. In some aspects, in SEQ ID NO:26, a total of 1 to 10 amino acids have been substituted, inserted, and / or deleted. In some aspects, substitutions, insertions, or deletions occur in regions outside the CDR (i.e., in the FR). Optionally, antibodies binding to FolR1 contain the VL sequence of SEQ ID NO:26, including post-translational modifications of that sequence. In one specific aspect, VL comprises one, two, or three CDRs selected from the following: (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 23, (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 24, and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 25.

[0282] In another aspect, the antibody binding to FolR1 comprises the VH sequence of any of the aspects provided above and the VL sequence of any of the aspects provided above. In one aspect, the antibody comprises the VH sequence and VL sequence of SEQ ID NO: 56 and SEQ ID NO: 26, respectively, including post-translational modifications of those sequences. Specification 41 / 112 pages 51 CN 122459340 A

[0283] In another aspect, the antibody binding to FolR1 comprises a heavy chain variable domain (VH) sequence, which is bound to the amino acid sequence of SEQ ID NO: 25.The amino acid sequence of SEQ ID NO:64 has at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity. In one aspect, the antibody binding to FolR1 comprises a heavy chain variable domain (VH) sequence that has at least 95% sequence identity with the amino acid sequence of SEQ ID NO:64. In some aspects, the VH sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity contains substitutions (e.g., conserved substitutions), insertions, or deletions relative to a reference sequence, but the antibody binding to FolR1 containing this sequence retains its ability to bind to FolR1. In some aspects, in SEQ ID NO:64, a total of 1 to 10 amino acids have been substituted, inserted, and / or deleted. In some respects, substitution, insertion, or deletion occurs in regions outside the CDR (i.e., in the FR). Optionally, the antibody binding to FolR1 comprises the VH sequence of SEQ ID NO:64, including post-translational modifications of that sequence. In one specific respect, the VH comprises one, two, or three CDRs selected from: (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:19, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:62, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:63. In another respect, the antibody binding to FolR1 comprises a light chain variable domain (VL) sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO:26. In one aspect, the antibody binding to FolR1 comprises a light chain variable domain (VL) sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO:26. In other aspects, the VL sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity contains substitutions (e.g., conserved substitutions), insertions, or deletions relative to a reference sequence, but the antibody binding to FolR1 containing this sequence retains its affinity for FolR1.Binding ability. In some aspects, in SEQ ID NO:26, a total of 1 to 10 amino acids have been substituted, inserted, and / or deleted. In some aspects, substitution, insertion, or deletion occurs in regions outside the CDR (i.e., in the FR). Optionally, the antibody binding to FolR1 comprises the VL sequence of SEQ ID NO:26, including post-translational modifications of that sequence. In one specific aspect, the VL comprises one, two, or three CDRs selected from the following: (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:23, (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO:24, and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO:25.

[0284] In another aspect, the antibody binding to FolR1 comprises the VH sequence of any of the aspects provided above and the VL sequence of any of the aspects provided above. On one hand, the antibody comprises the VH and VL sequences of SEQ ID NO: 64 and SEQ ID NO: 26, respectively, including post-translational modifications of those sequences.

[0285] On the other hand, the antibody binding to FolR1 comprises a heavy chain variable domain (VH) sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 67. In one aspect, the antibody binding to FolR1 comprises a heavy chain variable domain (VH) sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 67. In some respects, the VH sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity with the reference sequence contains substitutions (e.g., conserved substitutions), insertions, or deletions, but antibodies containing this sequence that bind to FolR1 retain their ability to bind to FolR1. In some respects, in SEQ ID NO:67, a total of 1 to 10 amino acids have been substituted, inserted, and / or deleted. In some respects, the substitutions, insertions, or deletions occur in regions outside the CDR (i.e., in the FR). Optionally, the antibody that binds to FolR1 comprises the VH sequence in SEQ ID NO:67, including this specification, page 42 / 112, 52 CN 122459340 A.Post-translational modifications of the sequence. In one specific aspect, VH comprises one, two, or three CDRs selected from: (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 19, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 66, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 21. In another aspect, the antibody binding to FolR1 comprises a light chain variable domain (VL) sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 26. In one aspect, the antibody binding to FolR1 comprises a light chain variable domain (VL) sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 26. In some aspects, VL sequences having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity with a reference sequence contain substitutions (e.g., conserved substitutions), insertions, or deletions, but antibodies containing such sequences retain their ability to bind to FolR1. In some aspects, in SEQ ID NO:26, a total of 1 to 10 amino acids have been substituted, inserted, and / or deleted. In some aspects, substitutions, insertions, or deletions occur in regions outside the CDR (i.e., in the FR). Optionally, antibodies binding to FolR1 contain the VL sequence of SEQ ID NO:26, including post-translational modifications of that sequence. In one specific aspect, VL comprises one, two, or three CDRs selected from the following: (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 23, (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 24, and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 25.

[0286] In another aspect, the antibody binding to FolR1 comprises the VH sequence of any of the aspects provided above and the VL sequence of any of the aspects provided above. In one aspect, the antibody comprises the VH sequence and VL sequence of SEQ ID NO: 67 and SEQ ID NO: 26, respectively, including post-translational modifications of those sequences.

[0287] In another aspect, the antibody binding to FolR1 comprises a heavy chain variable domain.The FolR1-binding antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO:76. In some aspects, the VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the reference sequence contains substitutions (e.g., conserved substitutions), insertions, or deletions relative to the reference sequence, but the FolR1-binding antibody containing this sequence retains its ability to bind to FolR1. In some respects, in SEQ ID NO:76, a total of 1 to 10 amino acids have been substituted, inserted, and / or deleted. In some respects, the substitution, insertion, or deletion occurs in regions outside the CDR (i.e., in the FR). Optionally, the antibody binding to FolR1 comprises the VH sequence of SEQ ID NO:76, including post-translational modifications of that sequence. In one specific respect, VH comprises one, two, or three CDRs selected from the following: (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:44, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:45, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:21. On the other hand, the antibody binding to FolR1 comprises a light chain variable domain (VL) sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO:38. In one aspect, the antibody binding to FolR1 comprises a light chain variable domain (VL) sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO:38. In some aspects, the VL sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity with the reference sequence contains substitutions (e.g., conserved substitutions), insertions, or deletions, but the antibody containing this sequence is compatible with FolR1.The bound antibody retains its ability to bind to FolR1. In some aspects, in SEQ ID NO:38, a total of 1 to 10 amino acids have been substituted, inserted, and / or deleted. In some aspects, the substitution, insertion, or deletion occurs in regions outside the CDR (i.e., in the FR). Optionally, the antibody binding to FolR1 comprises the VL sequence of SEQ ID NO:38, including post-translational modifications of that sequence. In one specific aspect, the VL comprises one, two, or three CDRs selected from: (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO:36, (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO:24, and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO:37.

[0288] In another aspect, the antibody binding to FolR1 comprises the VH sequence of any of the aspects provided above and the VL sequence of any of the aspects provided above. In one aspect, the antibody comprises the VH sequence and VL sequence of SEQ ID NO: 76 and SEQ ID NO: 38, respectively, including post-translational modifications of those sequences.

[0289] In another aspect, the antibody binding to FolR1 comprises a heavy chain variable domain (VH) sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 82. In one aspect, the antibody binding to FolR1 comprises a heavy chain variable domain (VH) sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 82. In some respects, the VH sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity with the reference sequence contains substitutions (e.g., conserved substitutions), insertions, or deletions, but antibodies containing this sequence that bind to FolR1 retain their ability to bind to FolR1. In some respects, in SEQ ID NO:82, a total of 1 to 10 amino acids have been substituted, inserted, and / or deleted. In some respects, the substitutions, insertions, or deletions occur in regions outside the CDR (i.e., in the FR). Optionally, the antibody that binds to FolR1 contains the sequence in SEQ ID NO:82.The VH sequence, including post-translational modifications thereof. In one specific aspect, the VH comprises one, two, or three CDRs selected from the following: (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 44, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 45, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 81. In another aspect, the antibody binding to FolR1 comprises a light chain variable domain (VL) sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 38. In one aspect, the antibody binding to FolR1 comprises a light chain variable domain (VL) sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 38. In some aspects, VL sequences having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity with a reference sequence contain substitutions (e.g., conserved substitutions), insertions, or deletions, but antibodies containing such sequences retain their ability to bind to FolR1. In some aspects, in SEQ ID NO:38, a total of 1 to 10 amino acids have been substituted, inserted, and / or deleted. In some aspects, substitutions, insertions, or deletions occur in regions outside the CDR (i.e., in the FR). Optionally, antibodies binding to FolR1 contain the VL sequence of SEQ ID NO:38, including post-translational modifications of that sequence. In one specific aspect, VL comprises one, two, or three CDRs selected from the following: (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 36, (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 24, and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 37.

[0290] In another aspect, the antibody binding to FolR1 comprises the VH sequence of any of the aspects provided above and the VL sequence of any of the aspects provided above. In one aspect, the antibody comprises the VH sequence and VL sequence of SEQ ID NO: 82 and SEQ ID NO: 38, respectively, including post-translational modifications of those sequences.

[0291] In another aspect, the antibody binding to FolR1The binding antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO:85 (page 44 / 112, CN 122459340 A). In one aspect, the antibody binding to FolR1 comprises a heavy chain variable domain (VH) sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO:85. In some aspects, the VH sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity with the reference sequence contains substitutions (e.g., conserved substitutions), insertions, or deletions, but antibodies containing this sequence that bind to FolR1 retain their ability to bind to FolR1. In some aspects, in SEQ ID NO:85, a total of 1 to 10 amino acids have been substituted, inserted, and / or deleted. In some aspects, the substitutions, insertions, or deletions occur in regions outside the CDR (i.e., in the FR). Optionally, the antibody that binds to FolR1 contains the VH sequence in SEQ ID NO:85, including post-translational modifications of that sequence. In one specific aspect, VH comprises one, two, or three CDRs selected from the following: (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 44, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 45, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 84. In another aspect, the antibody binding to FolR1 comprises a light chain variable domain (VL) sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 38. In another aspect, the antibody binding to FolR1 comprises a light chain variable domain (VL) sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 38. In some respects, it has at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity.The VL sequence contains substitutions (e.g., conserved substitutions), insertions, or deletions relative to the reference sequence, but antibodies containing this sequence that bind to FolR1 retain their ability to bind to FolR1. In some aspects, in SEQ ID NO:38, a total of 1 to 10 amino acids have been substituted, inserted, and / or deleted. In some aspects, substitutions, insertions, or deletions occur in regions outside the CDR (i.e., in the FR). Optionally, the antibody that binds to FolR1 contains the VL sequence of SEQ ID NO:38, including post-translational modifications of that sequence. In one specific aspect, the VL contains one, two, or three CDRs selected from: (a) CDR-L1 containing the amino acid sequence of SEQ ID NO:36, (b) CDR-L2 containing the amino acid sequence of SEQ ID NO:24, and (c) CDR-L3 containing the amino acid sequence of SEQ ID NO:37.

[0292] In another aspect, the antibody binding to FolR1 comprises the VH sequence of any of the aspects provided above and the VL sequence of any of the aspects provided above. In one aspect, the antibody comprises the VH sequence and VL sequence of SEQ ID NO: 85 and SEQ ID NO: 38, respectively, including post-translational modifications of those sequences.

[0293] In a further aspect of the invention, the antibody binding to FolR1 according to any of the above aspects is a monoclonal antibody, which includes human antibodies. In one aspect, the antibody binding to FolR1 is an antibody fragment, such as Fv, Fab, Fab', scFv, bisomatic antibody, or F(ab')2 fragment.

[0294] In another aspect, the antibody is a full-length antibody, IgG1 antibody, or other antibody class or isotype as defined herein.

[0295] In a further aspect, the antibody described herein is an IgG1 isotype / subtype and comprises a constant heavy chain domain of SEQ ID NO: 111 or a constant portion of the heavy chain amino acid sequence of SEQ ID NO: 111. In one aspect, an additional C-terminal glycine (Gly446) is present. In another aspect, C-terminal glycine (Gly446) and C-terminal lysine (Lys447) are also present.

[0296] In one aspect, the antibody binding FolR1 comprises the full light chain sequence (all L) of SEQ ID NO: 17 and the full heavy chain sequence (all H) of SEQ ID NO: 18. Specification 45 / 112 pages 55 CN 122459340 A

[0297] In one aspect, the antibody binding FolR1 comprises SEQ ID NO: 17The full light chain sequence (all L) of SEQ ID NO: 17 and the full heavy chain sequence (all H) of SEQ ID NO: 43.

[0298] In one aspect, the antibody binding to FolR1 comprises the full light chain sequence (all L) of SEQ ID NO: 17 and the full heavy chain sequence (all H) of SEQ ID NO: 57.

[0299] In one aspect, the antibody binding to FolR1 comprises the full light chain sequence (all L) of SEQ ID NO: 35 and the full heavy chain sequence (all H) of SEQ ID NO: 77.

[0300] In one aspect, the antibody binding to FolR1 comprises the full light chain sequence (all L) of SEQ ID NO: 35 and the full heavy chain sequence (all H) of SEQ ID NO: 34.

[0301] In one aspect, the antibody binding to FolR1 comprises the full light chain sequence (all L) of SEQ ID NO: 17 and the full heavy chain sequence (all H) of SEQ ID NO: 48.

[0302] In one aspect, the antibody binding to FolR1 comprises the all-light chain sequence (all-L) of SEQ ID NO: 35 and the all-heavy chain sequence (all-H) of SEQ ID NO: 43.

[0303] In one aspect, the antibody binding to FolR1 comprises the all-light chain sequence (all-L) of SEQ ID NO: 17 and the all-heavy chain sequence (all-H) of SEQ ID NO: 53.

[0304] In one aspect, the antibody binding to FolR1 comprises the all-light chain sequence (all-L) of SEQ ID NO: 17 and the all-heavy chain sequence (all-H) of SEQ ID NO: 61.

[0305] In one aspect, the antibody binding to FolR1 comprises the all-light chain sequence (all-L) of SEQ ID NO: 17 and the all-heavy chain sequence (all-H) of SEQ ID NO: 65.

[0306] In one aspect, the antibody binding to FolR1 comprises the all-light chain sequence (all-L) of SEQ ID NO: 35 and the all-heavy chain sequence (all-H) of SEQ ID NO: 75.

[0307] In one aspect, the antibody binding to FolR1 comprises the all-light chain sequence (all-L) of SEQ ID NO: 35 and the all-heavy chain sequence (all-H) of SEQ ID NO: 80.

[0308] In one aspect, the antibody binding to FolR1 comprises the all-light chain sequence (all-L) of SEQ ID NO: 35 and the all-heavy chain sequence (all-H) of SEQ ID NO: 83.

[0309] Table 10 shows an overview of the antibody sequences of the present invention. It also includes the all-H and all-L sequences of all IgG. Specification 46 / 112 pages 56 CN122459340 A

[0310]

[0311] In a further aspect, the antibody binding to FolR1 according to any of the foregoing aspects may, alone or in combination, combine any of the features described in sections 1-7 below:

[0312] 1. Antibody fragment

[0313] In some aspects, the antibodies provided herein are antibody fragments.

[0314] In one aspect, the antibody fragment is a Fab, Fab', Fab'-SH, or F(ab')2 fragment, particularly a Fab fragment. Papain digests the intact antibody to produce two identical antigen-binding fragments called "Fab" fragments, each "Fab" fragment containing a heavy chain variable domain and a light chain variable domain (VH and VL, respectively) as well as a constant domain (CL) of the light chain and a first constant domain (CH1) of the heavy chain. Therefore, the term "Fab fragment" refers to an antibody fragment comprising a light chain containing a VL domain and a CL domain, and a heavy chain containing a VH domain and a CH1 domain. A Fab' fragment differs from a Fab fragment in that a Fab' fragment has residues added to the carboxyl terminus of the CH1 domain, including one or more cysteine ​​residues from the antibody hinge region. Fab'-SH is a Fab' fragment in which the cysteine ​​residues of the constant domain are accompanied by free thiol groups. Pepsin treatment produces an F(ab')2 fragment having two antigen-binding sites (two Fab fragments) and a portion of the Fc region. For a discussion of Fab and F(ab')2 fragments containing salvage receptor-binding epitope residues and having an increased in vivo half-life, see U.S. Patent No. 5,869,046.

[0315] In another aspect, the antibody fragment is a bisomic antibody, a trisomic antibody, or a tetrasomic antibody. "Bisomatic antibodies" are antibody fragments having two antigen-binding sites, which can be bivalent or bispecific. See, for example, EP 404,097; WO 1993 / 01161; Hudson et al., Nat. Med. 9:129-134 (2003); and Hollinger et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993). Hudson et al. also described trisomatic and tetrasomatic antibodies in Nat. Med. 9:129-134 (2003).

[0316] In a further aspect, the antibody fragment is a single-chain Fab fragment. A "single-chain Fab fragment" or "scFab" is composed of a variable domain (VH) of the antibody heavy chain, a constant domain 1 (CH1) of the antibody heavy chain, and a variable domain of the antibody light chain.A polypeptide consisting of a VL, an antibody light chain constant domain (CL), and a linker, wherein the antibody domain and the linker have one of the following sequences in the N-terminal to C-terminal direction: a) VH-CH1-linker-VL-CL, b) VL-CL-linker-VH-CH1, c) VH-CL-linker-VL-CH1, or d) VL-CH1-linker-VH-CL. In particular, the linker is a polypeptide of at least 30 amino acids, preferably between 32 and 50 amino acids. The single-chain Fab fragment is stabilized via a native disulfide bond between the CL domain and the CH1 domain. Furthermore, these single-chain Fab fragments can be further stabilized by forming interchain disulfide bonds via the insertion of cysteine ​​residues (e.g., position 44 in the variable heavy chain and position 100 in the variable light chain according to Kabat numbering).

[0317] In another aspect, the antibody fragment is a single-chain variable fragment (scFv). A “single-chain variable fragment” or “scFv” is a fusion protein of the heavy chain variable domain (VH) and light chain variable domain (VL) of an antibody, linked by a linker. Specifically, the linker is a short polypeptide of 10 to 25 amino acids, typically rich in glycine for flexibility and serine or threonine for solubility, and can link the N-terminus of the VH to the C-terminus of the VL, or vice versa. Despite the removal of the constant region and the introduction of the linker, the protein retains the specificity of the original antibody. For a review of scFv fragments, see, for example, Plückthun, in The Pharmacology of Monoclonal Antibodies, Vol. 113, edited by Rosenburg and Moore, (Springer-Verlag, New York), pp. 269–315 (1994); see also WO 93 / 16185; and U.S. Patent Nos. 5,571,894 and 5,587,458.

[0318] In another aspect, the antibody fragment is a single-domain antibody. A “single-domain antibody” is an antibody fragment containing all or part of the variable heavy chain domain or all or part of the variable light chain domain of an antibody. In some aspects, a single-domain antibody is a human single-domain antibody (Domantis, Inc., Waltham, MA; see, for example, U.S. Patent No. 6,248,516 B1).

[0319] Antibody fragments can be prepared by various techniques, including but not limited to proteolytic digestion of intact antibodies and recombinant production from recombinant host cells (e.g., *E. coli*), as described herein.

[0320] 2. Human Antibodies

[0321] In some respects, the antibodies provided herein are human antibodies. Human antibodies can be produced using various techniques known in the art. Human antibodies are generally described in van Dijk and van de Winkel, Curr. Opin. Pharmacol. 5: 368-74 (2001) and Lonberg, Curr. Opin. Immunol. 20:450-459 (2008).

[0322] Human antibodies can be prepared by administering an immunogen to a transgenic animal, which has been modified to produce a complete human antibody or a complete antibody with a human variable region in response to antigen stimulation. Such animals typically contain all or part of a human immunoglobulin locus that replaces an endogenous immunoglobulin locus, or are present outside the animal's chromosome or randomly integrated into the animal's chromosome. In such transgenic mice, the endogenous immunoglobulin locus is typically inactivated. For a review of methods for obtaining human antibodies from transgenic animals, see Lonberg, Nat. Biotech. 23:1117-1125 (2005). See also, for example, U.S. Patent Nos. 6,075,181 and 6,150,584 describing XENOMOUSE™ technology; U.S. Patent No. 5,770,429 describing HuMab® technology; U.S. Patent No. 7,041,870 describing KM MOUSE® technology; and U.S. Patent Application Publication No. US 2007 / 0061900 describing VelociMouse® technology. The human variable region derived from the complete antibody produced from such animals can be further modified, for example, by combining it with different human constant regions.

[0323] Human antibodies can also be prepared by hybridoma-based methods. Human myeloma and mouse-human hybrid myeloma cell lines for producing human monoclonal antibodies have been described. (See, for example, Kozbor J. Immunol., 133: 3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987); and Boerner et al., J. Immunol., 147: 86 (1991).) Human antibodies produced via human B-cell hybridoma technology are also seen in Li et al., Proc. Natl. Acad. Sci. USA,103:3557-3562 (2006). Other methods include, for example, those described in U.S. Patent No. 7,189,826 (which describes the production of monoclonal human IgM antibodies from hybridoma cell lines) and Ni, Xiandai Mianyixue, 26(4):265-268 (2006) (which describes human-human hybridoma). Human hybridoma technology (Trioma technology) is also described in Vollmers and Brandlein, Histology and Histopathology, 20(3):927-937 (2005) and Vollmers and Brandlein, Methods and Findings in Experimental and Clinical Pharmacology, 27(3):185-91 (2005).

[0324] Human antibodies can also be produced by isolating variable domain sequences selected from human phage display libraries. Such variable domain sequences can then be bound to the desired human constant domain. The technique for selecting human antibodies from an antibody library is described below.

[0325] 3. Antibodies derived from a library

[0326] In some respects, the antibodies provided herein are derived from a library. The antibodies of the present invention can be isolated by screening a combinatorial library for antibodies having one or more desired activities. Methods for screening combinatorial libraries are reviewed, for example, in Lerner et al., Nature Reviews 16:498-508 (2016). For example, various methods are known in the art for generating phage display libraries and screening such libraries to obtain antibodies with the desired binding characteristics. Such methods are reviewed in, for example, Frenzel et al., mAbs 8:1177-1194 (2016); Bazan et al., Human Vaccines and Immunotherapeutics 8:1817-1828 (2012); and Zhao et al., Critical Reviews in Biotechnology 36:276-289 (2016), as well as Hoogenboom et al., Methods in Molecular Biology 178:1-37 (O'Brien et al., editors, Human Press, Totowa, NJ, 2001) and Marks and Bradbury, Methods in Molecular Biology 248:161-175 (Lo, editors, Human Press, 2001).In Totowa, NJ, 2003.

[0327] In some phage display methods, the entire set of VH and VL genes is cloned individually by polymerase chain reaction (PCR) and randomly recombined in a phage library, from which antigen-binding phages can then be screened, as described in Winter et al., Annual Review of Immunology 12: 433-455 (1994). Phages typically display antibody fragments as single-chain Fv (scFv) fragments or Fab fragments. Libraries from immunized sources provide high-affinity antibodies against immunogens without the need to construct hybridomas. Alternatively, all natural libraries (e.g., all natural libraries from humans) can be cloned (pages 49 / 112, 59 CN 122459340 A) to provide a single source of antibodies against a wide range of non-self and self antigens without any immunization, as described by Griffiths et al. in EMBO Journal 12: 725-734 (1993). Furthermore, natural libraries can be synthesized by cloning unrearranged V gene segments from stem cells and by using PCR primers containing random sequences to encode the highly variable CDR3 region and performing in vitro rearrangement, as described by Hoogenboom and Winter in Journal of Molecular Biology 227: 381-388 (1992). Patent publications describing human antibody phage libraries include, for example, U.S. Patent Nos. 5,750,373; 7,985,840; 7,785,903 and 8,679,490, and U.S. Patent Publications Nos. 2005 / 0079574, 2007 / 0117126, 2007 / 0237764 and 2007 / 0292936.

[0328] Other examples of methods known in the art for screening combinatorial libraries of antibodies having one or more desired activities include ribosome and mRNA display, and methods for displaying and selecting antibodies in bacterial, mammalian, insect, or yeast cells. Methods for yeast surface display are reviewed in, for example, Scholler et al., Methods in Molecular Biology 503:135-56 (2012), Cherf et al., Methods in Molecular Biology 1319:155-175 (2015), and Zhao et al., Methods in Molecular Biology 889:73-84.(2012). Methods for ribosome display are described, for example, in He et al., Nucleic Acids Research 25:5132-5134 (1997) and Hanes et al., PNAS 94:4937-4942 (1997).

[0329] Antibodies or antibody fragments isolated from human antibody libraries herein are considered human antibodies or human antibody fragments.

[0330] 4. Multispecific Antibodies

[0331] In some respects, the antibodies provided herein are multispecific antibodies, such as bispecific antibodies. A “multispecific antibody” is a monoclonal antibody that has binding specificity to at least two different sites (i.e., different epitopes on different antigens or different epitopes on the same antigen). In some respects, a multispecific antibody has three or more binding specificities. In some respects, one of the binding specificities is against FolR1, and another specificity is against any other antigen. In some respects, a bispecific antibody may bind to two (or more) different epitopes of FolR1. In one aspect of the invention, one binding specificity is against CD3, while the other specificity is against FolR1. Multispecific (e.g., bispecific) antibodies can also be used to target cytotoxic agents or cells to cells expressing FolR1. Multispecific antibodies can be prepared as full-length antibodies or antibody fragments.

[0332] Techniques for preparing multispecific antibodies include, but are not limited to, recombinant co-expression of two immunoglobulin heavy-light chain pairs with different specificities (see Milstein and Cuello, Nature 305: 537 (1983)) and engineered “mortar and pestle structures” (see, for example, U.S. Patent 5,731,168, and Atwell et al., J. Mol. Biol. 270:26 (1997)). Multispecific antibodies can also be prepared by: engineering electrostatic manipulation effects for preparing antibody Fc-heterodimer molecules (see, for example, WO 2009 / 089004); crosslinking two or more antibodies or fragments (see, for example, U.S. Patent No. 4,676,980, and Brennan et al., Science, 229: 81 (1985)); using leucine zippers to generate bispecific antibodies (see, for example, Kostelny et al., J. Immunol., 148(5): 1547-1553 (1992) and WO 2011 / 034605); using common light chain techniques to avoid light chain mismatch problems (see, for example, WO 98 / 50431); using “dimeric antibody” techniques for preparing bispecific antibody fragments (see, for example, Hollinger et al.,Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993)); and the use of single-chain Fv (sFv) dimers (see, for example, Gruber et al., J. Immunol., 152:5368 (1994)); and the preparation of trispecific antibodies as described in Tutt et al., J. Immunol. 147: 60 (1991).

[0333] This document also includes engineered antibodies having three or more antigen-binding sites, including, for example, “octopus antibodies” or DVD-Ig (see, for example, WO 2001 / 77342 and WO 2008 / 024715). Other examples of multispecific antibodies having three or more antigen binding sites can be found in WO 2010 / 115589, WO 2010 / 112193, WO 2010 / 136172, WO 2010 / 145792 and WO 2013 / 026831. Bispecific antibodies or their antigen-binding fragments also include “dual-acting FAb” or “DAF”, which contains antigen-binding sites that bind to FolR1 and another different antigen or to two different epitopes of FolR1 (see, for example, US 2008 / 0069820 and WO 2015 / 095539).

[0334] Multispecific antibodies may also be provided in an asymmetric form, wherein there are domain crossovers in one or more binding arms having the same antigen specificity, i.e., by exchanging VH / VL domains (see, for example, WO 2009 / 080252 and WO 2015 / 150447), CH1 / CL domains (see, for example, WO 2009 / 080253), or the complete Fab arm (see, for example, WO 2009 / 080251, WO 2016 / 016299, and also Schaefer et al., PNAS, 108 (2011) 1187-1191, and Klein et al., MAbs 8 (2016) 1010-20). In one aspect, multispecific antibodies contain crossover Fab fragments. The terms "cross-Fab fragment," "xFab fragment," or "crossover Fab fragment" refer to a Fab fragment in which the variable or constant regions of the heavy and light chains are exchanged. A cross-Fab fragment comprises a polypeptide chain consisting of a light chain variable region (VL) and a heavy chain constant region 1 (CH1), as well as a heavy chain variable region (VH).The polypeptide chain consists of a light chain constant region (CL). Asymmetric Fab arms can also be engineered by introducing charged or uncharged amino acid mutations into the domain interface to guide proper Fab pairing. See, for example, WO 2016 / 172485.

[0335] Various other molecular forms of multispecific antibodies are known in the art and are included herein (see, for example, Spiess et al., Mol Immunol 67 (2015) 95-106).

[0336] A particular type of multispecific antibody also included herein is a bispecific antibody designed to simultaneously bind a surface antigen on a target cell (e.g., tumor cells) and an activation-invariant component of the T cell receptor (TCR) complex (such as CD3) for retargeting T cells to kill the target cells. Thus, in some respects, the antibodies provided herein are multispecific antibodies, particularly bispecific antibodies, wherein one binding specificity is against FolR1 and the other against CD3.

[0337] Examples of bispecific antibody forms that can be used for this purpose include, but are not limited to, so-called “BiTE” (bispecific T cell conjugate) molecules, in which two scFv molecules are fused by a flexible linker (see, for example, WO 2004 / 106381, WO 2005 / 061547, WO 2007 / 042261 and WO 2008 / 119567; Nagorsen and Bäuerle, Exp Cell Res 317, 1255-1260 (2011)); bispecific antibodies (Holliger et al., Prot Eng 9, 299-305 (1996)) and their derivatives, such as tandem bispecific antibodies (“TandAb”; Kipriyanov et al., J Mol Biol 293, 41-56 (1999)); and “DART” (dual affinity retargeting) molecules, which are based on bispecific antibody forms but are characterized by having a C-type molecule for achieving additional stabilization. Terminal disulfide bridges (Johnson et al., J Mol Biol 399, 436-449 (2010)), and so-called triomab antibodies, which are fully hybridized mouse / rat IgG molecules (reviewed in Seimetz et al., Cancer Treat Rev 36, 458-467 (2010)). The specific T-cell bispecific antibody forms described in this article are described in the following references: WO 2013 / 026833; WO 2013 / 026839; WO 2016 / 020309; Bacac et al., Oncoimmunology 5(8) (2016).e1203498.

[0338] Certain aspects of the antibodies of the present invention are described below.

[0339] In one aspect, the present invention provides an antibody that binds to CD3 and FolR1, as described herein, the antibody comprising a CD3-binding domain and a first domain and an optional second domain that binds to FolR1.

[0340] According to certain aspects of the invention, the domains contained in the antibody are Fab molecules (i.e., domains composed of heavy and light chains that bind to an antigen (e.g., FolR1 or CD3), wherein each domain comprises a variable domain and a constant domain). In one aspect, the domains that bind to CD3 and FolR1 are Fab molecules. In one aspect, the Fab molecule described in CN 122459340 A on pages 51 / 112 of the specification is human. In another aspect, the Fab molecule is humanized. In yet another aspect, the Fab molecule comprises human heavy and light chain constant domains.

[0341] Preferably, at least one of the domains binding to CD3 or FolR1 is a cross-Fab molecule. Such modification reduces mismatches between heavy and light chains from different Fab molecules, thereby improving the yield and purity of recombinant production of multispecific antibodies according to the invention. In the preferred cross-Fab molecule used for the multispecific antibody according to the invention, variable domains of the Fab light chain and the Fab heavy chain (VL and VH, respectively) are exchanged. However, even with this domain exchange, the preparation of multispecific antibodies may still involve certain byproducts due to the so-called Bence Jones-type interaction between the mismatched heavy and light chains (see Schaefer et al., PNAS, 108 (2011) 11187-11191). To further reduce mismatches of heavy and light chains from different Fab molecules, thereby improving the purity and yield of the desired multispecific antibody, amino acids with opposite charges can be introduced at specific amino acid positions in the CH1 and CL domains of Fab molecules that bind to CD3 or Fab molecules that bind to FolR1, as further described herein. Charge modification is performed in conventional Fab molecules contained in multispecific antibodies (such as those shown, for example, A to C, G to J in Figure 15) or in VH / VL cross-Fab molecules contained in multispecific antibodies (such as those shown, for example, D to F, K to N in Figure 15) (but not both). In a preferred aspect, charge modification is performed in conventional Fab molecules contained in multispecific antibodies (preferably those that bind to FolR1).

[0342] In one aspect of the invention, the multispecific antibody is capable of binding to both CD3 and FolR1 simultaneously. In one aspect, the multispecific antibody is capable of crosslinking T cells and target cells by simultaneously binding to CD3 and FolR1. In an even more preferred aspect, such simultaneous binding causes the lysis of target cells, particularly target cells expressing FolR1, such as tumor cells. In one aspect, such simultaneous binding leads to the activation of T cells. In other aspects, such simultaneous binding leads to a cellular response of T lymphocytes, particularly cytotoxic T lymphocytes, selected from: proliferation, differentiation, cytokine secretion, release of cytotoxic effector molecules, cytotoxic activity, and expression of activation markers. In one aspect, the binding of the multispecific antibody to CD3 without simultaneously binding to FolR1 does not lead to T cell activation.

[0343] In one aspect, the multispecific antibody is capable of redirecting the cytotoxic activity of T cells to target cells. In a preferred aspect, the redirection is independent of MHC-mediated peptide antigen presentation of the target cells and / or T cell specificity.

[0344] Preferably, the T cells according to any aspect of the invention are cytotoxic T cells. In some aspects, the T cells are CD4+ or CD8+ T cells, particularly CD8+ T cells.

[0345] a) CD3 binding domain

[0346] In one aspect, the multispecific antibody according to the invention comprises at least one CD3-binding domain. In a preferred aspect, the CD3 is human CD3 (SEQ ID NO: 102) or cynomolgus monkey CD3 (SEQ ID NO: 101), most particularly human CD3. In one aspect, the CD3-binding domain has cross-reactivity with human and cynomolgus monkey CD3 (i.e., specific binding thereto). In some aspects, the CD3 is the ε subunit of CD3 (CD3ε).

[0347] In a preferred aspect, the multispecific antibody comprises no more than one CD3-binding domain. In one aspect, the multispecific antibody provides monovalent binding to CD3.

[0348] In one aspect, the CD3-binding domain comprises VH of SEQ ID NO: 115 and VL of SEQ ID NO: 116.

[0349] In one aspect, the CD3-binding domain is an antibody fragment selected from the group consisting of: Fv molecules, scFv molecules, Fab molecules, and F(ab')2 molecules. In a preferred aspect, the CD3-binding domain is a Fab molecule. Specification 52 / 112 pages 62 CN 122459340 A

[0350] In a preferred aspect, the CD3-binding domain is the cross-Fab molecule described herein.A Fab molecule, namely a Fab molecule in which the variable domains VH and VL of the Fab heavy chain and light chain exchange / replace each other or the constant domains CH1 and CL exchange / replace each other. In such respects, the domain binding to FolR1 is preferably a conventional Fab molecule. In the respect of having more than one domain binding to an antigen (e.g., CD3 and / or FolR1), particularly binding to FolR1 contained in a multispecific antibody, the domain binding to CD3 is preferably a cross-Fab molecule, and the domain binding to FolR1 is a conventional Fab molecule.

[0351] Alternatively, the domain binding to CD3 is a conventional Fab molecule. In such respects, the domain binding to FolR1 is a cross-Fab molecule as described herein, namely a Fab molecule in which the variable domains VH and VL of the Fab heavy chain and light chain exchange / replace each other or the constant domains CH1 and CL exchange / replace each other. In aspects where more than one domain binds to an antigen (e.g., FolR1 and / or CD3), particularly CD3-binding Fab molecules contained in multispecific antibodies, the FolR1-binding domain is preferably a cross-Fab molecule, and the CD3-binding domain is a conventional Fab molecule.

[0352] In some aspects, the CD3-binding domain is a Fab molecule in which the variable domains VL and VH of the Fab light chain and the Fab heavy chain are interchanged or the constant domains CL and CH1 are interchanged, particularly the variable domains VL and VH (i.e., according to such aspects, the CD3-binding domain is a cross-Fab molecule in which the variable or constant domains of the Fab light chain and the Fab heavy chain are exchanged). In one such aspect, the FolR1-binding antigen domain is a conventional Fab molecule.

[0353] In one aspect, no more than one CD3-binding domain is present in the multispecific antibody (i.e., the antibody provides monovalent binding to CD3).

[0354] b) FolR1 Binding Domain

[0355] The multispecific antibody according to the invention comprises at least one FolR1 binding domain, particularly a Fab molecule. The FolR1 binding domain enables the (multispecific) antibody to be directed to a target site, for example, to a specific type of cell expressing FolR1.

[0356] In one aspect, the FolR1 binding domain is an antibody fragment selected from the group consisting of: Fv molecules, scFv molecules, Fab molecules, and F(ab')2 molecules. In a preferred aspect, the FolR1 binding domain is...The binding domain is a Fab molecule.

[0357] In some aspects, the (multispecific) antibody comprises two domains that bind to FolR1, particularly Fab molecules. In a preferred aspect, all these domains are identical, i.e., they have the same molecular form (e.g., conventional or cross-Fab molecules) and contain the same amino acid sequence, which contains the same amino acid substitutions (if any) in the CH1 and CL domains as described herein. In one aspect, the (multispecific) antibody comprises no more than two domains that bind to FolR1, particularly Fab molecules.

[0358] In a preferred aspect, the domain that binds to FolR1 is a conventional Fab molecule. In such aspects, the domain that binds to CD3 is a cross-Fab molecule as described herein, i.e., a Fab molecule in which the variable domains VH and VL of the Fab heavy chain and light chain exchange / replace each other or the constant domains CH1 and CL exchange / replace each other.

[0359] In an alternative aspect, the domain binding to FolR1 is a cross-Fab molecule as described herein, i.e., a Fab molecule in which the variable domains VH and VL of the Fab heavy chain and light chain exchange / replace each other or the constant domains CH1 and CL exchange / replace each other. In such an aspect, the domain binding to CD3 is a conventional Fab molecule.

[0360] In one aspect, the domain binding to FolR1 contains a human constant region. In one aspect, the domain binding to FolR1 is a Fab molecule containing a human constant region, particularly the human CH1 and / or CL domains. Exemplary sequences of the constant domains are given in SEQ ID NO: 109 and SEQ ID NO: 110 (human κ and λ CL domains, respectively) and SEQ ID NO: 111 (human IgG1 heavy chain constant domain CH1-CH2-CH3). In one aspect, the domain binding to FolR1 includes a light chain constant region containing an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 109. Specifically, the light chain constant region may contain amino acid mutations under “charged modification” as described herein and / or if cross-FabThe molecule may contain deletions or substitutions of one or more (especially two) N-terminal amino acids. In some aspects, the FolR1-binding domain comprises a heavy chain constant region containing at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the same amino acid sequence as the CH1 domain sequence contained in the amino acid sequence of SEQ ID NO: 111. Specifically, the heavy chain constant region (especially the CH1 domain) may contain amino acid mutations under “charged modification” as described herein.

[0361] In one aspect, the FolR1-binding domain comprises any of the features of the FolR1-binding antibody described above.

[0362] c) Charge Modification

[0363] The (multispecific) antibody of the present invention may contain amino acid substitutions in the Fab molecule therein, which are particularly effective in reducing mismatches of light chains with mismatched heavy chains (Bence-Jones-type byproducts), which can occur in the generation of Fab-based multispecific antibodies having VH / VL exchanges in one of their binding arms (or multiple in the case of molecules containing more than two antigen-binding Fab molecules) (see also PCT Publication WO 2015 / 150447, in particular examples therein, the entire contents of which are incorporated herein by reference). The ratio of desired (multispecific) antibody to undesirable byproducts, particularly Bence-Jones-type byproducts appearing in multispecific antibodies having VH / VL domain exchanges in one of the binding arms of the (multispecific) antibody, can be improved by introducing charged amino acids with opposite charges at specific amino acid positions in the CH1 and CL domains (sometimes referred to herein as "charge modification").

[0364] Therefore, in some aspects, both the CD3-binding domain and the FolR1-binding domain of the multispecific antibody are Fab molecules, and in one of the domains (particularly the CD3-binding domain), the variable domains VL and VH of the Fab light chain and the Fab heavy chain are substituted for each other,

[0365] i) In the constant domain CL of the FolR1-binding domain, the amino acid at position 124 is replaced by a positively charged amino acid (according to Kabat numbering), and wherein, in the constant domain CH1 of the FolR1-binding domain, the amino acid at position 147 or the amino acid at position 213 is replaced by a negatively charged amino acid (according to Kabat numbering).EU index number) substitution; or

[0366] ii) In the constant domain CL of the CD3-binding domain, the amino acid at position 124 is substituted with a positively charged amino acid (according to the Kabat number), and wherein, in the constant domain CH1 of the CD3-binding domain, the amino acid at position 147 or the amino acid at position 213 is substituted with a negatively charged amino acid (according to the Kabat EU index number).

[0367] The (multispecific) antibody does not contain either of the modifications mentioned in i) and ii). The constant domains CL and CH1 of the domains with VH / VL exchange are not substituted for each other (i.e., remain unexchanged).

[0368] In a more specific aspect,

[0369] i) in the constant domain CL of the domain bound to FolR1, the amino acid at position 124 is independently substituted with lysine (K), arginine (R), or histidine (H) (according to Kabat number), and in the constant domain CH1 of the domain bound to FolR1, the amino acid at position 147 or the amino acid at position 213 is independently substituted with glutamic acid (E) or aspartic acid (D) (according to Kabat EU index number); or

[0370] ii) in the constant domain CL of the domain bound to CD3, the amino acid at position 124 is independently substituted with lysine (K), arginine (R), or histidine (H) (according to Kabat number), and in the constant domain CH1 of the domain bound to CD3, the amino acid at position 147 is independently substituted with lysine (K), arginine (R), or histidine (H) (according to Kabat number), and in the constant domain CH1 of the domain bound to CD3, the amino acid at position 147 is independently substituted with glutamic acid (E) or aspartic acid (D) (according to Kabat EU index number); The amino acid at position 124 or position 213 is independently substituted with glutamic acid (E) or aspartic acid (D) (according to Kabat EU index number).

[0371] In one such aspect, in the constant domain CL of the domain bound to FolR1, the amino acid at position 124 is independently substituted with lysine (K), arginine (R), or histidine (H) (according to Kabat number), and in the constant domain CH1 of the domain bound to FolR1, the amino acid at position 147 or position 213 is independently substituted with glutamic acid (E) or aspartic acid (D) (according to Kabat EU index number).

[0372] In a further aspect, in the constant domain CL of the domain bound to FolR1, the amino acid at position 124 is independently substituted with lysine (K), arginine (R), or histidine (H) (according to Kabat number), andIn the constant domain CH1 of the domain that binds to FolR1, the amino acid at position 147 is independently substituted with glutamic acid (E) or aspartic acid (D) (according to Kabat EU index number).

[0373] In a preferred aspect, in the constant domain CL of the domain that binds to FolR1, the amino acid at position 124 is independently substituted with lysine (K), arginine (R), or histidine (H) (according to Kabat number), and the amino acid at position 123 is independently substituted with lysine (K), arginine (R), or histidine (H) (according to Kabat number), and in the constant domain CH1 of the domain that binds to FolR1, the amino acid at position 147 is independently substituted with glutamic acid (E) or aspartic acid (D) (according to Kabat EU index number), and the amino acid at position 213 is independently substituted with glutamic acid (E) or aspartic acid (D) (according to Kabat EU index number).

[0374] In a more preferred aspect, in the constant domain CL of the domain that binds to FolR1, the amino acid at position 124 is replaced with lysine (K) (according to Kabat numbering), and the amino acid at position 123 is replaced with lysine (K) (according to Kabat numbering), and in the constant domain CH1 of the domain that binds to FolR1, the amino acid at position 147 is replaced with glutamic acid (E) (according to Kabat EU index numbering), and the amino acid at position 213 is replaced with glutamic acid (E) (according to Kabat EU index numbering).

[0375] In an even more preferred aspect, in the constant domain CL of the domain bound to FolR1, the amino acid at position 124 is substituted with lysine (K) (according to Kabat numbering), and the amino acid at position 123 is substituted with arginine (R) (according to Kabat numbering), and in the constant domain CH1 of the domain bound to FolR1, the amino acid at position 147 is substituted with glutamic acid (E) (according to Kabat EU index numbering), and the amino acid at position 213 is substituted with glutamic acid (E) (according to Kabat EU index numbering).

[0376] In a preferred aspect, if the amino acid substitutions according to the above aspects occur in the constant domain CL and the constant domain CH1 of the domain bound to FolR1, then the constant domain CL of the domain bound to FolR1 is a κ isotype.

[0377] Alternatively, the amino acid substitutions according to the above aspects may occur in the constant domain of the domain bound to CD3.In the constant domain CL and constant domain CH1, rather than in the constant domain CL and constant domain CH1 of the domain bound to FolR1. In a preferred aspect of this, the constant domain CL of the domain bound to CD3 is of the κ isotype.

[0378] Thus, in one aspect, in the constant domain CL of the domain bound to CD3, the amino acid at position 124 (page 55 / 112, CN 122459340 A) is independently substituted with lysine (K), arginine (R), or histidine (H) (according to Kabat number), and in the constant domain CH1 of the domain bound to CD3, the amino acid at position 147 or the amino acid at position 213 is independently substituted with glutamic acid (E) or aspartic acid (D) (according to Kabat EU index number).

[0379] In a further aspect, in the constant domain CL of the CD3-binding domain, the amino acid at position 124 is independently substituted with lysine (K), arginine (R), or histidine (H) (according to Kabat numbering), and in the constant domain CH1 of the CD3-binding domain, the amino acid at position 147 is independently substituted with glutamic acid (E) or aspartic acid (D) (according to Kabat EU index numbering).

[0380] In another aspect, in the constant domain CL of the CD3-binding domain, the amino acid at position 124 is independently substituted with lysine (K), arginine (R), or histidine (H) (according to Kabat numbering), and the amino acid at position 123 is independently substituted with lysine (K), arginine (R), or histidine (H) (according to Kabat numbering). In the constant domain CH1 of the CD3-binding domain, the amino acid at position 147 is independently substituted with glutamic acid (E) or aspartic acid (D) (according to Kabat EU indexing), and the amino acid at position 213 is independently substituted with glutamic acid (E) or aspartic acid (D) (according to Kabat EU indexing).

[0381] In one aspect, in the constant domain CL of the CD3-binding domain, the amino acid at position 124 is substituted with lysine (K) (according to Kabat numbering), and the amino acid at position 123 is substituted with lysine (K) (according to Kabat numbering), and in the constant domain CH1 of the CD3-binding domain, the amino acid at position 147 is substituted with glutamic acid (E) (according to Kabat EU index numbering), and the amino acid at position 213 is substituted with glutamic acid (E) (according to Kabat EU indexing).The amino acid at position 124 is replaced with glutamic acid (E) (according to Kabat EU index number).

[0382] On the other hand, in the constant domain CL of the CD3-binding domain, the amino acid at position 124 is replaced with lysine (K) (according to Kabat number), and the amino acid at position 123 is replaced with arginine (R) (according to Kabat number), and in the constant domain CH1 of the CD3-binding domain, the amino acid at position 147 is replaced with glutamic acid (E) (according to Kabat EU index number), and the amino acid at position 213 is replaced with glutamic acid (E) (according to Kabat EU index number).

[0383] d) Multispecific antibody form

[0384] The (multispecific) antibody according to the invention can have a variety of configurations. Exemplary configurations are described in FIG15.

[0385] In a preferred aspect, the CD3 and / or FolR1-binding domain contained in the (multispecific) antibody is a Fab molecule.

[0386] In one aspect, the FolR1 and CD3 binding domains of the (multispecific) antibody are fused together, optionally via peptide linkers. In a preferred aspect, the FolR1 and CD3 binding domains are each Fab molecules. In one such aspect, the CD3 binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the FolR1 binding domain. In another such aspect, the FolR1 binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the CD3 binding domain. Additionally, in which (i) the CD3-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the FolR1-binding domain, or (ii) the FolR1-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the CD3-binding domain, the Fab light chain of the CD3-binding domain and the Fab light chain of the FolR1-binding domain may be fused to each other, optionally via a peptide linker.

[0387] Multispecific antibodies having a single domain (such as a Fab molecule) that bind to FolR1 (e.g., as shown in Figures 15A, 15D, 15G, 15H, 15K, and 15L) are useful, especially when the FolR1 antigen is expected to be internalized after the domain binds to FolR1 with high affinity. In such cases, more than one [referring to] page 56 / 112 of the specification, 66 CNThe presence of a FolR1-binding domain can enhance the internalization of the FolR1 antigen, thereby reducing its availability.

[0388] However, in other cases, it would be advantageous to have (multispecific) antibodies (e.g., as shown in Figures 15B, 15C, 15E, 15F, 15I, 15J, 15M, or 15N) containing two or more FolR1-binding domains (such as Fab molecules), for example, to optimize targeting of the target site or to cross-link the target cell antigen.

[0389] Therefore, in some aspects, the (multispecific) antibody according to the invention contains a second domain that binds to FolR1.

[0390] In one aspect, the second domain that binds to FolR1 is a Fab molecule.

[0391] In one aspect, the second domain that binds to FolR1 is the same as another FolR1-binding domain, namely the first domain that binds to FolR1.

[0392] In some aspects, the first and second domains binding to FolR1 are each Fab molecules, and the second domain binding to FolR1 is identical to the first domain binding to FolR1. Therefore, in these aspects, the first and second domains binding to FolR1 contain the same heavy and light chain amino acid sequences and have the same arrangement of domains (i.e., conventional or crossed). Furthermore, in these aspects, the second domain binding to FolR1 contains the same amino acid substitutions (if any) as the first domain binding to FolR1. For example, amino acid substitutions described herein as “charge-modified” will be carried out in the constant domains CL and CH1 of each of the first and second domains binding to FolR1. Alternatively, the amino acid substitution may be carried out in constant domains CL and CH1 of the domain bound to CD3 (which is preferably also a Fab molecule), but not in the constant domains CL and CH1 of the first domain bound to FolR1 and the second domain bound to FolR1.

[0393] Similar to the first domain bound to FolR1, the second domain bound to FolR1 is preferably a conventional Fab molecule. However, it is also conceivable that the first and second domains bound to FolR1 are cross-Fab molecules (and the domain bound to CD3 is a conventional Fab molecule). Thus, in a preferred aspect, the first and second domains bound to FolR1 are each conventional Fab molecules, and the domain bound to CD3 is the cross-Fab molecule described herein.Fab molecules are those in which the variable domains VH and VL of the Fab heavy and light chains exchange / replace each other, or the constant domains CL and CH1 exchange / replace each other. In other aspects, the domains binding to FolR1 are each cross-Fab molecules, and the domain binding to CD3 is a conventional Fab molecule.

[0394] In a preferred aspect, the (multispecific) antibody of the present invention comprises an Fc domain consisting of a first subunit and a second subunit, particularly the human IgG1 Fc domain. The first and second subunits of the Fc domain are stably associated.

[0395] The (multispecific) antibody according to the present invention can have different conformations, i.e., the domain binding to CD3, the domain binding to FolR1 (and optionally the second domain binding to FolR1) can be fused to each other and fused to the Fc domain in different ways. The components can be fused directly to each other, or preferably fused via one or more suitable peptide linkers. When a Fab molecule fuses with the N-terminus of a subunit of the Fc domain, the fusion is typically via an immunoglobulin hinge region.

[0396] In some aspects, the domains binding to CD3 and FolR1 are each Fab molecules, and the domain binding to CD3 fuses with the N-terminus of either the first or second subunit of the Fc domain at the C-terminus of the Fab heavy chain. In such aspects, the domain binding to FolR1 may fuse with the N-terminus of either the Fab heavy chain of the CD3-binding domain or the N-terminus of the other subunit of the Fc domain at the C-terminus of the Fab heavy chain. In a preferred aspect of this type, the domain bound to FolR1 is a conventional Fab molecule, and the domain bound to CD3 is a cross-Fab molecule as described herein, i.e., a Fab molecule in which the variable domains VH and VL of the Fab heavy chain and light chain exchange / replace each other or the constant domains CL and CH1 exchange / replace each other. In other aspects of this type, the domain bound to FolR1 is a cross-Fab molecule, and the domain bound to CD3 is a conventional Fab molecule.

[0397] In one aspect, the domains bound to CD3 and FolR1 are each Fab molecules, the domain bound to CD3 is fused at the C-terminus of the first or second subunit of the Fc domain to the N-terminus of the Fab heavy chain, and the domain bound to FolR1 is fused at the C-terminus of the Fab heavy chain of the domain bound to CD3 to the N-terminus of the Fab heavy chain of the domain bound to CD3.Terminal fusion. In one specific aspect, the (multispecific) antibody essentially consists of a CD3-binding Fab molecule and a FolR1-binding Fab molecule, with an Fc domain consisting of a first subunit, a second subunit, and optionally one or more peptide linkers. The FolR1-binding Fab molecule is fused at the C-terminus of its Fab heavy chain to the N-terminus of the CD3-binding Fab molecule, and the CD3-binding Fab molecule is fused at the C-terminus of the first or second subunit of the Fc domain to the N-terminus. Such configurations are schematically depicted in Figures 15G and 15K (in these examples, the CD3-binding domain is a VH / VL cross-linked Fab molecule). Alternatively, the Fab light chain of the CD3-binding Fab molecule and the Fab light chain of the FolR1-binding Fab molecule may be fused to each other.

[0398] On the other hand, the CD3-binding domain and the FolR1-binding domain are each Fab molecules, and these domains are each fused at the C-terminus of the Fab heavy chain to the N-terminus of one of the subunits of the Fc domain. In one specific aspect, the (multispecific) antibody essentially consists of a CD3-binding Fab molecule and a FolR1-binding Fab molecule, the Fc domain being composed of a first subunit and a second subunit, and optionally one or more peptide linkers, wherein the Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of one of the subunits of the Fc domain. Such configurations are schematically depicted in Figures 15A and 15D (in these examples, the CD3-binding domain is a VH / VL cross-linked Fab molecule and the FolR1-binding domain is a conventional Fab molecule). The Fab molecule may be fused to the Fc domain directly or via a peptide linker. In a preferred aspect, each Fab molecule is fused to an Fc domain via an immunoglobulin hinge region. In a specific aspect, the immunoglobulin hinge region is a human IgG1 hinge region, particularly, wherein the Fc domain is an IgG1 Fc domain, and more particularly, wherein the Fc domain is a human IgG1 Fc domain.

[0399] In some aspects, the CD3-binding domain and the FolR1-binding domain are each Fab molecules, and the FolR1-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first or second subunit of the Fc domain. In such aspects, the CD3-binding domain may be fused at the C-terminus of the CD3-binding domain.The N-terminus of the Fab heavy chain or the N-terminus of another subunit of the Fc domain (as described above) is fused. In a preferred aspect of this type, the domain bound to FolR1 is a conventional Fab molecule, and the domain bound to CD3 is a cross-Fab molecule as described herein, i.e., a Fab molecule in which the variable domains VH and VL of the Fab heavy chain and light chain exchange / replace each other, or the constant domains CL and CH1 exchange / replace each other. In other aspects of this type, the domain bound to FolR1 is a cross-Fab molecule, and the domain bound to CD3 is a conventional Fab molecule.

[0400] In one aspect, the domain bound to CD3 and the domain bound to FolR1 are each Fab molecules, the domain bound to FolR1 is fused at the C-terminus of the first or second subunit of the Fc domain to the N-terminus of the Fab heavy chain, and the domain bound to CD3 is fused at the C-terminus of the Fab heavy chain of the domain bound to FolR1 to the N-terminus of the Fab heavy chain. In one specific aspect, the (multispecific) antibody essentially consists of a CD3-binding Fab molecule and a FolR1-binding Fab molecule. The Fc domain comprises a first subunit, a second subunit, and optionally one or more peptide linkers. The CD3-binding Fab molecule is fused at the C-terminus of the FolR1-binding Fab molecule to the N-terminus of the Fab heavy chain, and the FolR1-binding Fab molecule is fused at the C-terminus of the first or second subunit of the Fc domain. Such configurations are schematically depicted in Figures 15H and 15L (in these examples, the CD3-binding domain is a VH / VL crossover Fab molecule, and the FolR1-binding domain is a conventional Fab molecule). Alternatively, the Fab light chain of the Fab molecule bound to CD3 and the Fab light chain of the Fab molecule bound to FolR1 may be fused together.

[0401] In some aspects, the second domain bound to FolR1, particularly the second Fab molecule bound to FolR1, is fused at the C-terminus of the first or second subunit of the Fc domain to the N-terminus of the Fab heavy chain. In a preferred aspect of this, the domain bound to FolR1 and the domain bound to CD3 are each conventional Fab molecules, and the domain bound to CD3 is a cross-Fab molecule as described herein.A molecule, namely a Fab molecule in which the variable domains VH and VL of the Fab heavy chain and light chain exchange / replace each other or the constant domains CL and CH1 exchange / replace each other. In other such aspects, the domains (first and second) bound to FolR1 are each cross-Fab molecules, and the domain bound to CD3 is a conventional Fab molecule.

[0402] In one such aspect, the domain bound to CD3 and the second domain bound to FolR1 are each fused at the C-terminus of the Fab heavy chain to the N-terminus of one of the subunits of the Fc domain, and the first domain bound to FolR1 is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the CD3-bound Fab molecule. In one specific aspect, the (multispecific) antibody essentially consists of a CD3-binding Fab molecule and first and second Fab molecules binding to FolR1, the Fc domain being composed of a first and second subunit and optionally one or more peptide linkers, wherein the first Fab molecule binding to FolR1 is fused at the C-terminus of the Fab heavy chain of the CD3-binding Fab molecule to the N-terminus of the Fab heavy chain of the CD3-binding Fab molecule, and the CD3-binding Fab molecule is fused at the C-terminus of the C-terminus of the C-terminus of the C-terminus of the Fc domain to the N-terminus of the first subunit of the Fc domain, and wherein the second Fab molecule binding to FolR1 is fused at the C-terminus of the C-terminus of the C-terminus of the C-terminus of the Fc domain to the N-terminus of the second subunit of the Fc domain. This configuration is schematically depicted in Figures 15B and 15E (in these examples, the CD3-binding domain is a VH / VL cross-Fab molecule, and the first and second domains binding to FolR1 are conventional Fab molecules) and Figures 15J and 15N (in these examples, the CD3-binding domain is a conventional Fab molecule, and the FolR1-binding domain is a VH / VL cross-Fab molecule). The CD3-binding Fab molecule and the FolR1-binding second Fab molecule can be fused to the Fc domain directly or via a peptide linker. In a preferred aspect, the CD3-binding Fab molecule and the FolR1-binding Fab molecule are each fused to the Fc domain via an immunoglobulin hinge region. In a specific aspect, the immunoglobulin hinge region is the human IgG1 hinge region, particularly, wherein the Fc domain is the IgG1 Fc domain, and more particularly, the human IgG1 Fc domain. Additionally, optionally, the Fab light chain of the Fab molecule bound to CD3 and the Fab light chain bound to CD3...The Fab light chains of the Fab molecules bound by FolR1 can fuse with each other.

[0403] In another such aspect, the domains bound to Folr1 each fuse at the C-terminus of one of the subunits of the Fc domain, and the domain bound to CD3 fuses at the C-terminus of the Fab heavy chain with the N-terminus of the Fab heavy chain of the domain bound to FolR1. In one specific aspect, the (multispecific) antibody essentially consists of a CD3-binding Fab molecule and a FolR1-binding Fab molecule, the Fc domain being composed of a first subunit and a second subunit, and optionally one or more peptide linkers, wherein the CD3-binding Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first FolR1-binding Fab molecule, and the first FolR1-binding Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain, and wherein the FolR1-binding second Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second subunit of the Fc domain. This configuration is schematically depicted in Figures 15C and 15F (in these examples, the domain binding to CD3 is a VH / VL cross-Fab molecule, and the domain binding to FolR1 is a conventional Fab molecule), and Figure 15I (pages 59 / 112, CN 122459340 A and Figure 15M, in these examples, the domain binding to CD3 is a conventional Fab molecule, and the domain binding to FolR1 is a VH / VL cross-Fab molecule). The Fab molecule binding to FolR1 can be fused to the Fc domain directly or via a peptide linker. In a preferred aspect, each Fab molecule binding to FolR1 is fused to the Fc domain via an immunoglobulin hinge region. In a specific aspect, the immunoglobulin hinge region is a human IgG1 hinge region, particularly, wherein the Fc domain is an IgG1 Fc domain, and more particularly, wherein the Fc domain is a human IgG1 Fc domain. Alternatively, the Fab light chain of the Fab molecule binding to CD3 and the Fab light chain of the first Fab molecule binding to FolR1 may be fused together.

[0404] In the configuration of the (multispecific) antibody, wherein the Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of each subunit of the Fc domain via an immunoglobulin hinge region, the two Fab molecules, the hinge region, and the Fc domain are fused together.The domains essentially form the immunoglobulin molecule. In a preferred aspect, the immunoglobulin molecule is an IgG class immunoglobulin. In an even more preferred aspect, the immunoglobulin is an IgG1 subclass immunoglobulin. In another aspect, the immunoglobulin is an IgG4 subclass immunoglobulin. In yet another preferred aspect, the immunoglobulin is a human immunoglobulin. In other aspects, the immunoglobulin is a chimeric immunoglobulin or a humanized immunoglobulin. In one aspect, the immunoglobulin contains a human constant region, particularly a human Fc region.

[0405] In some of the (multispecific) antibodies of the present invention, the Fab light chain of a Fab molecule that binds to CD3 and the Fab light chain of a first Fab molecule that binds to FolR1 are fused together, optionally via a peptide linker. Depending on the configuration of the Fab molecule binding to CD3 and the first Fab molecule binding to FolR1, the Fab light chain of the CD3-binding Fab molecule may fuse at its C-terminus to the N-terminus of the Fab light chain of the first Fab molecule binding to FolR1, or the Fab light chain of the first Fab molecule binding to FolR1 may fuse at its C-terminus to the N-terminus of the Fab light chain of the CD3-binding Fab molecule. The fusion of the CD3-binding Fab molecule and the Fab light chain of the first Fab molecule binding to FolR1 further reduces mismatches between the Fab heavy chain and light chain, and also reduces the number of plasmids required to express some of the (multispecific) antibodies of the present invention.

[0406] The antigenic domains binding to FolR1 and CD3 may fuse directly to or with each other, or fuse with or with each other via a peptide linker containing one or more amino acids, typically about 2 to 20 amino acids. Peptide linkers are known in the art and described herein. Suitable non-immunogenic peptide linkers include, for example, (G4S)n, (SG4)n, (G4S)n, G4(SG4)n, or (G4S)nG5 peptide linkers. “n” is typically an integer from 1 to 10, and typically from 2 to 4. In one aspect, the peptide linker is at least 5 amino acids long; in another aspect, it is 5 to 100 amino acids long; and in a further aspect, it is 10 to 50 amino acids long. In one aspect, the peptide linker is (GxS)n or (GxS)nGm, where G = glycine, S = serine, and (x = 3, n = 3, 4, 5, or 6, and m = 0, 1, 2, or 3) or (x = 4, n = 1, 2, 3, 4, or 5, and m = 0, 1, 2, 3, 4, or 5). In one aspect, x= 4 and n = 2 or 3, on the other hand, x = 4 and n = 2, and on yet another side, x = 4, n = 1 and m = 5. In one aspect, the peptide linker is (G4S)2. In another aspect, the peptide linker is G4SG5. A particularly suitable peptide linker for fusing the Fab light chains of the first Fab molecule and the second Fab molecule to each other is (G4S)2. An exemplary peptide linker suitable for linking the Fab heavy chains of the first Fab fragment and the second Fab fragment comprises the sequence (D)-(G4S)2 (SEQ ID NO: 103 and SEQ ID NO: 104). Another suitable such linker comprises the sequence (D)-G4SG5 (SEQ ID NO 105 and SEQ ID NO 106). Additionally, the linker may comprise a portion of an immunoglobulin hinge region. In particular, in the case of fusion of the Fab molecule with the N-terminus of the Fc domain subunit, fusion can occur via the immunoglobulin hinge region or a portion thereof, with or without an additional peptide linker.

[0407] In some aspects, the (multispecific) antibody according to the invention comprises: a polypeptide wherein the variable region of the Fab light chain of the CD3-binding Fab molecule shares a carboxyl-terminal peptide bond with the constant region of the Fab heavy chain of the CD3-binding Fab molecule (i.e., the CD3-binding Fab molecule comprises a cross-linked Fab heavy chain, wherein the variable region of the heavy chain is replaced by the variable region of the light chain), which in turn shares a carboxyl-terminal peptide bond with the Fc domain subunit (VL(1)-CH1(1)-CH2-CH3(-CH4)); and a polypeptide wherein the Fab heavy chain of the second Fab molecule shares a carboxyl-terminal peptide bond with the Fc domain subunit (VH(2)-CH1(2)-CH2-CH3(-CH4)). In some aspects, the (multispecific) antibody further comprises: a polypeptide, wherein the variable region of the Fab heavy chain of the CD3-binding Fab molecule shares a carboxyl-terminal peptide bond (VH(1)-CL(1)) with the constant region of the Fab light chain of the CD3-binding Fab molecule, and shares a carboxyl-terminal peptide bond (VL(2)-CL(2)) with the Fab light chain polypeptide of a second Fab molecule. In some aspects, the polypeptide is covalently linked, for example, by a disulfide bond.

[0408] In some aspects, the (multispecific) antibody according to the invention comprises: a polypeptide, wherein the variable region of the Fab heavy chain of the CD3-binding Fab molecule shares a carboxyl-terminal peptide bond (VH(1)-CL(1)) with the constant region of the Fab light chain of the CD3-binding Fab molecule (i.e., the variable region of the Fab heavy chain of the CD3-binding Fab molecule) shares a carboxyl-terminal peptide bond (VH(1)-CL(1)) with the constant region of the Fab light chain of the CD3-binding Fab molecule.The Fab molecule comprises a cross-linked Fab heavy chain, wherein the heavy chain constant region is replaced by a light chain constant region, which then shares a carboxyl-terminal peptide bond with an Fc domain subunit (VH(1)-CL(1)-CH2-CH3(-CH4)); and a polypeptide, wherein the Fab heavy chain of the second Fab molecule shares a carboxyl-terminal peptide bond with an Fc domain subunit (VH(2)-CH1(2)-CH2-CH3(-CH4)). In some aspects, the (multispecific) antibody further comprises: a polypeptide, wherein the variable region of the Fab light chain of the CD3-binding Fab molecule shares a carboxyl-terminal peptide bond with the constant region of the Fab heavy chain of the CD3-binding Fab molecule (VL(1)-CH1(1)) and shares a carboxyl-terminal peptide bond with the Fab light chain polypeptide of the second Fab molecule (VL(2)-CL(2)). In some aspects, the polypeptide is covalently linked, for example, by a disulfide bond.

[0409] In some aspects, the (multispecific) antibody comprises: a polypeptide wherein the variable region of the Fab light chain of the CD3-binding Fab molecule shares a carboxyl-terminal peptide bond with the constant region of the Fab heavy chain of the CD3-binding Fab molecule (i.e., the CD3-binding Fab molecule comprises a cross-linked Fab heavy chain, wherein the variable region of the heavy chain is replaced by the variable region of the light chain), which in turn shares a carboxyl-terminal peptide bond with the Fab heavy chain of a second Fab molecule, which in turn shares a carboxyl-terminal peptide bond with an Fc domain subunit (VL(1)-CH1(1)-VH(2)-CH1(2)-CH2-CH3(-CH4)). In other respects, the (multispecific) antibody comprises: a polypeptide in which the Fab heavy chain of the second Fab molecule shares a C-terminal peptide bond with the variable region of the Fab light chain of the CD3-binding Fab molecule, and subsequently shares a C-terminal peptide bond with the constant region of the Fab heavy chain of the CD3-binding Fab molecule (i.e., the CD3-binding Fab molecule contains a cross-linked Fab heavy chain in which the variable region of the heavy chain is replaced by the variable region of the light chain), and subsequently shares a C-terminal peptide bond with an Fc domain subunit (VH(2)-CH1(2)-VL(1)-CH1(1)-CH2-CH3(-CH4)). In some aspects of these, the (multispecific) antibody further comprises: a cross-linked Fab light chain polypeptide of a CD3-binding Fab molecule, wherein the variable region of the Fab heavy chain of the CD3-binding Fab molecule shares a carboxyl-terminal peptide bond (VH(1)-CL(1)) with the constant region of the Fab light chain of the CD3-binding Fab molecule, and shares a carboxyl-terminal peptide bond with a Fab light chain polypeptide of a second Fab molecule.(VL(2)-CL(2)). In other aspects of these, the (multispecific) antibody further comprises: a polypeptide wherein the variable region of the Fab heavy chain of the CD3-binding Fab molecule shares a C-terminal peptide bond with the constant region of the Fab light chain of the CD3-binding Fab molecule, which in turn shares a C-terminal peptide bond with the Fab light chain polypeptide of the second Fab molecule (VH(1)-CL(1)-VL(2)-CL(2)); or a polypeptide wherein the Fab light chain polypeptide of the second Fab molecule shares a C-terminal peptide bond with the variable region of the Fab heavy chain of the CD3-binding Fab molecule, which in turn shares a C-terminal peptide bond with the constant region of the Fab light chain of the CD3-binding Fab molecule (VL(2)-CL(2)-VH(1)-CL(1)) (where appropriate). According to these aspects, (multispecific) antibodies may further comprise (i) an Fc domain subunit polypeptide (CH2-CH3(-CH4)), or (ii) a polypeptide wherein the Fab heavy chain of the second Fab molecule bound to FolR1 shares a carboxyl-terminal peptide bond with the Fc domain subunit (VH(3)-CH1(3)-CH2-CH3(-CH4)) and shares a carboxyl-terminal peptide bond with the Fab light chain polypeptide of the second Fab molecule bound to FolR1 (VL(3)-CL(3)). In some aspects, the polypeptide specification 61 / 112 pages 71 CN 122459340 A, for example, is covalently linked by a disulfide bond.

[0410] In some aspects, the (multispecific) antibody comprises: a polypeptide wherein the variable region of the Fab heavy chain of the CD3-binding Fab molecule shares a carboxyl-terminal peptide bond with the constant region of the Fab light chain of the CD3-binding Fab molecule (i.e., the CD3-binding Fab molecule comprises a cross-linked Fab heavy chain, wherein the heavy chain constant region is replaced by the light chain constant region), which in turn shares a carboxyl-terminal peptide bond with the Fab heavy chain of a second Fab molecule, which in turn shares a carboxyl-terminal peptide bond with an Fc domain subunit (VH(1)-CL(1)-VH(2)-CH1(2)-CH2-CH3(-CH4)). In other respects, the (multispecific) antibody comprises: a polypeptide, wherein the Fab heavy chain of the second Fab molecule shares a C-terminal peptide bond with the variable region of the Fab heavy chain of the CD3-binding Fab molecule, and subsequently shares a C-terminal peptide bond with the constant region of the Fab light chain of the CD3-binding Fab molecule (i.e., the CD3-binding Fab molecule comprises a cross-linked Fab heavy chain, wherein the heavy chain constant region is replaced by the light chain constant region), and subsequently shares a C-terminal peptide bond with an Fc domain subunit.(VH(2)-CH1(2)-VH(1)-CL(1)-CH2-CH3(-CH4)). In some aspects of these, the (multispecific) antibody further comprises: a cross-linked Fab light chain polypeptide of a CD3-binding Fab molecule, wherein the variable region of the Fab light chain of the CD3-binding Fab molecule shares a carboxyl-terminal peptide bond (VL(1)-CH1(1)) with the constant region of the Fab heavy chain of the CD3-binding Fab molecule, and shares a carboxyl-terminal peptide bond (VL(2)-CL(2)) with the Fab light chain polypeptide of a second Fab molecule. In other aspects of these, the (multispecific) antibody further comprises: a polypeptide wherein the variable region of the Fab light chain of the CD3-binding Fab molecule shares a C-terminal peptide bond with the constant region of the Fab heavy chain of the CD3-binding Fab molecule, which in turn shares a C-terminal peptide bond with the Fab light chain polypeptide of the second Fab molecule (VL(1)-CH1(1)-VL(2)-CL(2)); or a polypeptide wherein the Fab light chain polypeptide of the second Fab molecule shares a C-terminal peptide bond with the variable region of the Fab heavy chain of the CD3-binding Fab molecule, which in turn shares a C-terminal peptide bond with the constant region of the Fab light chain of the CD3-binding Fab molecule (VL(2)-CL(2)-VH(1)-CL(1)) (where appropriate). According to these aspects, (multispecific) antibodies may further comprise (i) an Fc domain subunit polypeptide (CH2-CH3(-CH4)), or (ii) a polypeptide wherein the Fab heavy chain of the second Fab molecule bound to FolR1 shares a carboxyl-terminal peptide bond (VH(3)-CH1(3)-CH2-CH3(-CH4)) with the Fc domain subunit, and shares a carboxyl-terminal peptide bond (VL(3)-CL(3)) with the Fab light chain polypeptide of the second Fab molecule bound to FolR1. In some aspects, the polypeptide is covalently linked, for example, by disulfide bonds.

[0411] In some aspects, (multispecific) antibodies do not comprise an Fc domain. In preferred embodiments of this kind, the (first) domain binding to FolR1 and (if present) the second domain binding to FolR1 are each conventional Fab molecules, and the domain binding to CD3 is a cr...

Claims

1. An antibody that binds to FolR1, wherein the antibody is reacted at a neutral pH with a first K D Binds to FolR1 and at acidic pH, via a second K D Combined with FolR1, wherein the first K D Greater than the second K D And the first K was measured at 25°C by surface plasmon resonance (SPR). D and the second K D .

2. The antibody according to claim 1, wherein the acidic pH is in the range of 6.0 to 6.6 and the neutral pH is in the range of 7.0 to 7.4, particularly wherein the acidic pH is 6.5 or 6.1 and the neutral pH is 7.0 or 7.4, more particularly wherein the acidic pH is 6.5 and the neutral pH is 7.

4.

3. The antibody according to claim 1 or 2, wherein the first K D For the second K D At least 2 times, at least 5 times, at least 8 times, at least 10 times, at least 11 times, at least 13 times, at least 16 times, at least 23 times, at least 31 times, at least 40 times, at least 60 times, at least 74 times, or at least 195 times or more.

4. The antibody according to claim 3, wherein the second K is present at pH 6.

5. D For a concentration equal to or lower than 47 nM, and at pH 7.4, the first K D It is equal to 46nM or higher.

5. The antibody according to any one of claims 1 to 4, wherein the first K D For the second K D 2 to 195 times or 5 to 195 times.

6. The antibody according to any one of claims 1 to 5, wherein the antibody is a monoclonal antibody.

7. The antibody according to any one of claims 1 to 6, wherein the antibody is a human antibody.

8. The antibody according to any one of claims 1 to 7, wherein the antibody comprises: a heavy chain variable domain (VH) comprising: (a) a CDR-H1 comprising the amino acid sequence X2YYX3H SEQ ID NO:88, (b) a CDR-H2 comprising the amino acid sequence X4INPX5X6GX7TX8YAQKFQG (SEQ ID NO:89), and (c) a CDR-H3 comprising the amino acid sequence GDX9X10X11LDY (SEQ ID NO:90); and a light chain variable domain (VL) comprising: (d) a CDR-L1 comprising the amino acid sequence RSSQSLLHX12NGYX13YLD (SEQ ID NO:86), (e) a CDR-L2 comprising the amino acid sequence LGSNRAS (SEQ ID NO:24), and (f) a CDR-L2 comprising the amino acid sequence MQALQGX14X15X16T (SEQ ID NO:88). The CDR-L3 of the amino acid sequence of NO:87, wherein X2 is S, T or E, X3 is M or I, X4 is I or V, X5 is S or R, X6 is D or G, X7 is R, S or N, X8 is S, R, N or T, X9 is F or Y, X10 is D or E, X11 is A, G or S, X12 is A or S, X13 is N or H, X14 is P or L, X15 is Y or A, and X16 is N or D, optionally wherein when X15 is Y, X16 is N, and when X15 is A, X16 is D.

9. The antibody according to any one of claims 1 to 8, wherein the antibody comprises: a heavy chain variable domain (VH) comprising: (a) a CDR-H1 comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 19, 44, 49, 54 and 58; (b) a CDR-H2 comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 20, 45, 50, 55, 59, 62 and 66; and (c) a CDR-H3 comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 21, 46, 51, 60, 63, 78, 81 and 84; and a light chain variable domain (VL) comprising: (d) a CDR-L1 comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 23, 36 and 40; (e) a CDR-L2 comprising an amino acid sequence of LGSNRAS (SEQ ID NO: 24); and (f) a CDR-L2 comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 23, 36 and 40; CDR-L3 of the amino acid sequence of the group consisting of 25, 37 and 41.

10. The antibody according to any one of claims 1 to 9, wherein the antibody comprises: A) A heavy chain variable domain (VH) comprising: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:19, (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:20, and (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:21; and a light chain variable domain (VL) comprising: (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:23, (e) a CDR-L2 comprising the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:25; B) A heavy chain variable domain (VH) comprising: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:44, (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:45, and (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:46; and a light chain variable domain (VL) comprising: (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:23, (e) a CDR-L2 comprising the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:25; C) A heavy chain variable domain (VH) comprising: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:19, (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:58, and (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:59; and a light chain variable domain (VL) comprising: (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:23, (e) a CDR-L2 comprising the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:25; D) Heavy chain variable domain (VH) comprising: (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:44, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:45, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:78; and light chain variable domain (VL) comprising: (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:36, (e) CDR-L2 comprising the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:37; E) Heavy chain variable domain (VH) comprising: (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:19, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:20, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:21; and light chain variable domain (VL) comprising: (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:36, (e) CDR-L2 comprising the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:37; G) Heavy chain variable domain (VH) comprising: (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:49, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:50, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:51; and light chain variable domain (VL) comprising: (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:23, (e) CDR-L2 comprising the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:25; H) A heavy chain variable domain (VH) comprising: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:44, (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:45, and (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:46; and a light chain variable domain (VL) comprising: (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:36, (e) a CDR-L2 comprising the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:37; I) A heavy chain variable domain (VH) comprising: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:54, (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:55, and (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:21; and a light chain variable domain (VL) comprising: (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:23, (e) a CDR-L2 comprising the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:25; J) A heavy chain variable domain (VH) comprising: (a) a CDR-H1 comprising the amino acid sequence of (SEQ ID NO:19), (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:62, and (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:63; and a light chain variable domain (VL) comprising: (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:23, (e) a CDR-L2 comprising the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:25; K) Heavy chain variable domain (VH) comprising: (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:19, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:66, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:21; and light chain variable domain (VL) comprising: (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:23, (e) CDR-L2 comprising the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:25; L) Heavy chain variable domain (VH) comprising: (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:44, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:45, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:21; and light chain variable domain (VL) comprising: (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:36, (e) CDR-L2 comprising the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:37; M) A heavy chain variable domain (VH) comprising: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:44, (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:45, and (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:81; and a light chain variable domain (VL) comprising: (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:36, (e) a CDR-L2 comprising the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:37; or N) Heavy chain variable domain (VH) comprising: (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:44, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:45, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:84; and light chain variable domain (VL) comprising: (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:36, (e) CDR-L2 comprising the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:

37.

11. An antibody that binds to FolR1, wherein the antibody comprises A) A heavy chain variable domain (VH) comprising: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:19, (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:20, and (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:21; and a light chain variable domain (VL) comprising: (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:23, (e) a CDR-L2 comprising the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:25; B) A heavy chain variable domain (VH) comprising: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:44, (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:45, and (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:46; and a light chain variable domain (VL) comprising: (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:23, (e) a CDR-L2 comprising the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:25; C) A heavy chain variable domain (VH) comprising: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:19, (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:58, and (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:59; and a light chain variable domain (VL) comprising: (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:23, (e) a CDR-L2 comprising the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:25; D) Heavy chain variable domain (VH) comprising: (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:44, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:45, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:78; and light chain variable domain (VL) comprising: (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:36, (e) CDR-L2 comprising the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:37; E) Heavy chain variable domain (VH) comprising: (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:19, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:20, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:21; and light chain variable domain (VL) comprising: (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:36, (e) CDR-L2 comprising the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:37; G) Heavy chain variable domain (VH) comprising: (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:49, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:50, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:51; and light chain variable domain (VL) comprising: (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:23, (e) CDR-L2 comprising the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:25; H) A heavy chain variable domain (VH) comprising: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:44, (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:45, and (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:46; and a light chain variable domain (VL) comprising: (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:36, (e) a CDR-L2 comprising the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:37; I) A heavy chain variable domain (VH) comprising: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:54, (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:55, and (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:21; and a light chain variable domain (VL) comprising: (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:23, (e) a CDR-L2 comprising the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:25; J) A heavy chain variable domain (VH) comprising: (a) a CDR-H1 comprising the amino acid sequence of (SEQ ID NO:19), (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:62, and (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:63; and a light chain variable domain (VL) comprising: (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:23, (e) a CDR-L2 comprising the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:25; K) Heavy chain variable domain (VH) comprising: (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:19, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:66, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:21; and light chain variable domain (VL) comprising: (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:23, (e) CDR-L2 comprising the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:25; L) Heavy chain variable domain (VH) comprising: (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:44, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:45, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:21; and light chain variable domain (VL) comprising: (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:36, (e) CDR-L2 comprising the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:37; M) A heavy chain variable domain (VH) comprising: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:44, (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:45, and (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:81; and a light chain variable domain (VL) comprising: (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:36, (e) a CDR-L2 comprising the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:37; or N) Heavy chain variable domain (VH) comprising: (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:44, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:45, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:84; and light chain variable domain (VL) comprising: (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:36, (e) CDR-L2 comprising the amino acid sequence of LGSNRAS (SEQ ID NO:24), and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:

37.

12. The antibody according to any one of claims 8 to 11, further comprising: the light chain variable domain framework FR1 sequence of SEQ ID NO:91, the light chain variable domain framework FR2 sequence of SEQ ID NO:92, the light chain variable domain framework FR3 sequence of SEQ ID NO:93, the light chain variable domain framework FR4 sequence of SEQ ID NO:94; and / or the heavy chain variable domain framework FR1 sequence of SEQ ID NO:95 or SEQ ID NO:96, the heavy chain variable domain framework FR2 sequence of SEQ ID NO:97, the heavy chain variable domain framework FR3 sequence of SEQ ID NO:98, and the heavy chain variable domain framework FR4 sequence of SEQ ID NO:

99.

13. The antibody according to any one of claims 1 to 12, wherein the antibody comprises a VH containing the amino acid sequence QVQLVQSGAEVKKPGASVKVSCKASGYTFX17X2YYX3HWVRQAPGQGLEWMGX4INPX5X6GX7TX8YAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGDX9X10X11LDYWGQGTLVTVSS (SEQ ID NO: 107), and / or a VL containing the amino acid sequence DIVMTQSPLSLPVTPGEPASISCRSSQSLLHX12NGYX13YLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQGX14X15X16TFGQGTKVEIK (SEQ ID NO: 108), wherein X2 is S, T X3 is M or I, X4 is I or V, X5 is S or R, X6 is D or G, X7 is R, S or N, X8 is S, R, N or T, X9 is F or Y, X10 is D or E, X11 is A, G or S, X12 is A or S, X13 is N or H, X14 is P or L, X15 is Y or A, X16 is N or D, and X17 is T or S, optionally where X15 is Y, X16 is N, and X15 is A, X16 is D.

14. The antibody according to any one of claims 1 to 13, wherein the antibody comprises: A) VH, which contains at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO: 22; and / or VL, which contains at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO: 26; B) VH, which contains at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO: 47; and / or VL, which contains at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO: 26; C) VH, which contains at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO: 60; and / or VL, which contains at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO: 26; D) VH, which contains at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO: 79; and / or VL, which contains at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO: 38; E) VH, which contains at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO: 22; and / or VL, which contains at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO: 38; G) VH, which contains at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO: 52; and / or VL, which contains at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO: 26; H) VH, which contains at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% of the amino acid sequence identical to that of SEQ ID NO: 47; and / or VL, which contains at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% of the amino acid sequence identical to that of SEQ ID NO: 38; I) VH, which contains at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO: 56; and / or VL, which contains at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO: 26; J) VH, which contains at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO: 64; and / or VL, which contains at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO: 26; K) VH, which contains at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% of the amino acid sequence identical to that of SEQ ID NO: 67; and / or VL, which contains at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% of the amino acid sequence identical to that of SEQ ID NO: 26; L) VH, which contains at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% of the amino acid sequence identical to that of SEQ ID NO: 76; and / or VL, which contains at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% of the amino acid sequence identical to that of SEQ ID NO: 38; M) VH, comprising at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical amino acid sequence to the amino acid sequence of SEQ ID NO: 82; and / or VL, comprising at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical amino acid sequence to the amino acid sequence of SEQ ID NO: 38; or N) VH, which contains at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% of the amino acid sequence identical to that of SEQ ID NO: 85; and / or VL, which contains at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% of the amino acid sequence identical to that of SEQ ID NO:

38.

15. The antibody according to any one of claims 1 to 14, wherein the antibody comprises: A) VH containing the amino acid sequence of SEQ ID NO: 22 and / or VL containing the amino acid sequence of SEQ ID NO: 26; B) VH containing the amino acid sequence of SEQ ID NO: 47 and / or VL containing the amino acid sequence of SEQ ID NO: 26; C) VH containing the amino acid sequence of SEQ ID NO: 60 and / or VL containing the amino acid sequence of SEQ ID NO: 26; D) VH containing the amino acid sequence of SEQ ID NO: 79 and / or VL containing the amino acid sequence of SEQ ID NO: 38; E) VH containing the amino acid sequence of SEQ ID NO: 22 and / or VL containing the amino acid sequence of SEQ ID NO: 38; G) VH containing the amino acid sequence of SEQ ID NO: 52 and / or VL containing the amino acid sequence of SEQ ID NO: 26; H) VH containing the amino acid sequence of SEQ ID NO: 47 and / or VL containing the amino acid sequence of SEQ ID NO: 38; I) VH containing the amino acid sequence of SEQ ID NO: 56 and / or VL containing the amino acid sequence of SEQ ID NO: 26; J) VH containing the amino acid sequence of SEQ ID NO: 64 and / or VL containing the amino acid sequence of SEQ ID NO: 26; K) VH containing the amino acid sequence of SEQ ID NO: 67 and / or VL containing the amino acid sequence of SEQ ID NO: 26; L) VH containing the amino acid sequence of SEQ ID NO: 76 and / or VL containing the amino acid sequence of SEQ ID NO: 38; M) VH containing the amino acid sequence of SEQ ID NO: 82 and / or VL containing the amino acid sequence of SEQ ID NO: 38; or N) VH containing the amino acid sequence of SEQ ID NO: 85 and / or VL containing the amino acid sequence of SEQ ID NO:

38.

16. An antibody that binds to FolR1, wherein the antibody comprises A) VH containing the amino acid sequence of SEQ ID NO: 22 and / or VL containing the amino acid sequence of SEQ ID NO: 26; B) VH containing the amino acid sequence of SEQ ID NO: 47 and / or VL containing the amino acid sequence of SEQ ID NO: 26; C) VH containing the amino acid sequence of SEQ ID NO: 60 and / or VL containing the amino acid sequence of SEQ ID NO: 26; D) VH containing the amino acid sequence of SEQ ID NO: 79 and / or VL containing the amino acid sequence of SEQ ID NO: 38; E) VH containing the amino acid sequence of SEQ ID NO: 22 and / or VL containing the amino acid sequence of SEQ ID NO: 38; G) VH containing the amino acid sequence of SEQ ID NO: 52 and / or VL containing the amino acid sequence of SEQ ID NO: 26; H) VH containing the amino acid sequence of SEQ ID NO: 47 and / or VL containing the amino acid sequence of SEQ ID NO: 38; I) VH containing the amino acid sequence of SEQ ID NO: 56 and / or VL containing the amino acid sequence of SEQ ID NO: 26; J) VH containing the amino acid sequence of SEQ ID NO: 64 and / or VL containing the amino acid sequence of SEQ ID NO: 26; K) VH containing the amino acid sequence of SEQ ID NO: 67 and / or VL containing the amino acid sequence of SEQ ID NO: 26; L) VH containing the amino acid sequence of SEQ ID NO: 76 and / or VL containing the amino acid sequence of SEQ ID NO: 38; M) VH containing the amino acid sequence of SEQ ID NO: 82 and / or VL containing the amino acid sequence of SEQ ID NO: 38; or N) VH containing the amino acid sequence of SEQ ID NO: 85 and / or VL containing the amino acid sequence of SEQ ID NO:

38.

17. The antibody according to any one of claims 1 to 16, wherein the antibody is an antibody fragment that binds to FolR1.

18. The antibody according to any one of claims 1 to 17, wherein the antibody fragment is a Fab molecule.

19. The antibody according to any one of claims 1 to 16, wherein the antibody is a full-length IgG1 antibody.

20. The antibody according to any one of claims 1 to 19, comprising an Fc domain consisting of a first subunit and a second subunit.

21. The antibody according to any one of claims 1 to 20, wherein the antibody is multispecific.

22. The antibody according to any one of claims 1 to 21, wherein the antibody is a bispecific antibody comprising at least one CD3-binding domain and at least one FolR1-binding domain.

23. The antibody of claim 22, wherein the CD3-binding domain is a Fab molecule, wherein the variable domains VL and VH of the Fab light chain and the Fab heavy chain or the constant domains CL and CH1, particularly the variable domains VL and VH are interchanged with each other.

24. The antibody according to claim 22 or 23, wherein the domain binding to FolR1 is a Fab molecule, wherein in the constant domain CL, the amino acid at position 124 is independently substituted with lysine (K), arginine (R), or histidine (H) (according to Kabat numbering), and the amino acid at position 123 is independently substituted with lysine (K), arginine (R), or histidine (H) (according to Kabat numbering); and in the constant domain CH1, the amino acid at position 147 is independently substituted with glutamic acid (E) or aspartic acid (D) (according to Kabat EU index numbering), and the amino acid at position 213 is independently substituted with glutamic acid (E) or aspartic acid (D) (according to Kabat EU index numbering).

25. The antibody according to any one of claims 18, 23 or 24, wherein the Fab molecule is a conventional Fab molecule.

26. The antibody according to any one of claims 22 to 25, wherein the CD3-binding domain and the FolR1-binding domain are fused together, optionally fused together via a peptide linker.

27. The antibody according to any one of claims 1 to 26, comprising a CD3-binding domain and a FolR1-binding domain, wherein the CD3-binding domain and the FolR1-binding domain are each Fab molecules, and (i) the FolR1-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the CD3-binding domain, or (ii) the CD3-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the FolR1-binding domain.

28. The antibody according to any one of claims 1 to 27, comprising a CD3-binding domain and a first domain binding to FolR1, optionally comprising a second domain binding to FolR1, wherein the CD3-binding domain and the FolR1-binding domain are each Fab molecules, and the antibody comprises an Fc domain composed of a first subunit and a second subunit; and wherein (i) the first domain binding to FolR1 is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the CD3-binding domain, and the CD3-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain, or (ii) the CD3-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first domain binding to FolR1, and the first domain binding to FolR1 is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fc domain. The N-terminus of the first subunit of the structural domain is fused; and the second structural domain, which is associated with FolR1, is fused with the N-terminus of the second subunit of the Fc structural domain at the C-terminus of the Fab heavy chain when present.

29. The antibody according to claim 20 or 28, wherein the Fc domain is an IgG Fc domain, particularly an IgG1 Fc domain, and more particularly a human IgG1 Fc domain.

30. The antibody according to any one of claims 20, 28 or 29, wherein the Fc domain is a human Fc domain.

31. The antibody according to any one of claims 20 or 28 to 30, wherein the Fc comprises a modification that promotes association between the first subunit and the second subunit of the Fc domain.

32. The antibody according to any one of claims 20 or 28 to 31, wherein the Fc domain comprises one or more amino acid substitutions that reduce binding to the Fc receptor and / or effector function.

33. The antibody according to any one of claims 20 or 28 to 32, wherein the antibody comprises an Fc region derived from human IgG1 and comprises an Fc region substituted for L234A, L235A and P329G (LALA-PG).

34. An immunoconjugate comprising: an antibody according to any one of claims 1 to 33, and a cytotoxic agent.

35. An isolated nucleic acid encoding an antibody according to any one of claims 1 to 34.

36. A host cell comprising the nucleic acid according to claim 35.

37. A method for producing an antibody that binds to FolR1, the method comprising culturing a host cell according to claim 36 under conditions suitable for the expression of the antibody.

38. The method of claim 37, further comprising recovering the antibody from the host cell.

39. An antibody produced by the method according to claim 37 or 38.

40. A pharmaceutical composition comprising: an antibody according to any one of claims 1 to 33; and a pharmaceutically acceptable carrier.

41. The antibody according to any one of claims 1 to 33 or 39, or the pharmaceutical composition according to claim 40, for use as a medicine.

42. The antibody according to any one of claims 1 to 33 or 39, or the pharmaceutical composition according to claim 40, for use in the treatment of cancer.

43. Use of the antibody according to any one of claims 1 to 33 or 39 or the pharmaceutical composition according to claim 40 in the manufacture of a medicament for treating cancer.

44. Use of the antibody of any one of claims 1 to 33 or 39 or the pharmaceutical composition of claim 40 in the manufacture of a medicament for pH-dependent T cell redirection and pH-dependent T cell-mediated killing of cancer cells.

45. A method of treating an individual suffering from cancer, the method comprising administering to the individual an effective amount of an antibody according to any one of claims 1 to 33 or 39 or a pharmaceutical composition according to claim 40.

46. ​​A method for pH-dependent T cell redirection and T cell-mediated killing of cancer cells in an individual, the method comprising administering to the individual an effective amount of an antibody according to any one of claims 1 to 33 or 39 or a pharmaceutical composition according to claim 40, to redirect T cells in a pH-dependent manner and mediate T cell killing of cancer cells.